-DOCSTART- -X- O O 

: - PUNCT O 
Evaluating - VERB O 
the - DET O 
Effects - NOUN O 
on - ADP O 
Lovastatin PROPN - B-MEDICINE 
Production PROPN - I-ORG 
and - CCONJ O 
Fungal PROPN - B-PERSON 
Morphology PROPN - I-PERSON 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
also - ADV O 
synergized - VERB O 
with - ADP O 
lapatinib - NOUN O 
to - PART O 
strongly - ADV O 
suppress - VERB O 
the - DET O 
in - ADP O 
vivo - NOUN O 
growth - NOUN O 
of - ADP O 
ErbB2-positive ADJ - B-NORP 
breast - NOUN O 
cancer - NOUN O 
xenografts - NOUN O 
. - PUNCT O 

Habit - PROPN O 
Modification - PROPN O 
of - ADP O 
the - DET O 
Active - PROPN O 
Pharmaceutical - PROPN O 
Ingredient - PROPN O 
Lovastatin PROPN - B-MEDICINE 
Through - ADP O 
a DET - B-ORG 
Predictive PROPN - I-ORG 
Solvent PROPN - I-ORG 
Selection PROPN - I-ORG 
Approach PROPN - I-ORG 
. - PUNCT O 

Use - PROPN O 
of - ADP O 
Topical - PROPN O 
Glycolic - PROPN O 
Acid - PROPN O 
Plus - CCONJ O 
a - DET O 
Lovastatin PROPN - B-MEDICINE 
- - PUNCT O 
Cholesterol - PROPN O 
Combination - PROPN O 
Cream - PROPN O 
for - ADP O 
the - DET O 
Treatment - PROPN O 
of - ADP O 
Autosomal - PROPN O 
Recessive - PROPN O 
Congenital - PROPN O 
Ichthyoses - PROPN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
natural - ADJ O 
competitive - ADJ O 
inhibitor - NOUN O 
of - ADP O 
3-hydroxy-3-methyl PROPN - B-CARDINAL 
glutaryl - ADJ O 
coenzyme - NOUN O 
- - PUNCT O 
A - NOUN O 
( - PUNCT O 
HMG - PROPN O 
- - PUNCT O 
CoA - PROPN O 
) - PUNCT O 
reductase - NOUN O 
and - CCONJ O 
inhibits - VERB O 
specifically - ADV O 
rate - NOUN O 
limiting - VERB O 
step - NOUN O 
in - ADP O 
cholesterol - NOUN O 
biosynthesis - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
statin - ADJ O 
drug - NOUN O 
, - PUNCT O 
which - ADJ O 
lowers - VERB O 
cholesterol - NOUN O 
level - NOUN O 
in - ADP O 
blood - NOUN O 
due - ADP O 
to - ADP O 
inhibition - NOUN O 
of - ADP O 
( - PUNCT O 
S)-3-hydroxy-3-methylglutaryl PROPN - B-PERSON 
- - PUNCT O 
CoA - NOUN O 
reductase - NOUN O 
. - PUNCT O 

Loading - VERB O 
Lovastatin PROPN - B-MEDICINE 
into - ADP O 
Camptothecin PROPN - B-ORG 
- PUNCT - I-ORG 
Floxuridine PROPN - I-ORG 
Conjugate PROPN - I-ORG 
Nanocapsules PROPN - I-ORG 
for - ADP O 
Enhancing - PROPN O 
Anti - PROPN O 
- - ADJ O 
metastatic - ADJ O 
Efficacy PROPN - B-ORG 
of - ADP O 
Cocktail PROPN - B-PERSON 
Chemotherapy PROPN - I-PERSON 
on - ADP O 
Triple - PROPN O 
- - PUNCT O 
negative - ADJ O 
Breast PROPN - B-LOC 
Cancer PROPN - I-LOC 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
has - VERB O 
been - VERB O 
shown - VERB O 
to - PART O 
protect - VERB O 
mice - NOUN O 
from - ADP O 
late - ADJ O 
radiation - NOUN O 
injury - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
( - PUNCT O 
20 NUM - B-CARDINAL 
to PART - I-CARDINAL 
80 NUM - I-CARDINAL 
mg - NOUN O 
/ - SYM O 
d - NOUN O 
) - PUNCT O 
was - VERB O 
started - VERB O 
on - ADP O 
day NOUN - B-DATE 
1 NUM - I-DATE 
of - ADP O 
radiation - NOUN O 
and - CCONJ O 
continued - VERB O 
for - ADP O 
12 NUM - B-DATE 
months NOUN - I-DATE 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
as - ADP O 
administered - VERB O 
in - ADP O 
this - DET O 
trial - NOUN O 
, - PUNCT O 
did - VERB O 
not - ADV O 
reduce - VERB O 
the - DET O 
incidence - NOUN O 
of - ADP O 
grade - NOUN O 
2 NUM - B-CARDINAL 
or - CCONJ O 
higher - ADJ O 
rectal - ADJ O 
toxicity - NOUN O 
compared - VERB O 
with - ADP O 
historical - ADJ O 
controls - NOUN O 
. - PUNCT O 

Prevent - PROPN O 
Radiation - NOUN O 
- - PUNCT O 
induced - VERB O 
Rectal PROPN - B-PERSON 
Injury PROPN - I-PERSON 
With - ADP O 
Lovastatin PROPN - B-MEDICINE 
. - PUNCT O 

Cerasomal - PROPN O 
Lovastatin PROPN - B-MEDICINE 
Nanohybrids - PROPN O 
for - ADP O 
Efficient - PROPN O 
Inhibition - PROPN O 
of - ADP O 
Triple - PROPN O 
- - PUNCT O 
Negative - PROPN O 
Breast - PROPN O 
Cancer - NOUN O 
Stem - VERB O 
Cells - NOUN O 
To - PART O 
Improve - VERB O 
Therapeutic - ADJ O 
Efficacy - NOUN O 
. - PUNCT O 

And - CCONJ O 
comparative - ADJ O 
gene - NOUN O 
expression - NOUN O 
analyses - NOUN O 
were - VERB O 
performed - VERB O 
in - ADP O 
buds - NOUN O 
of - ADP O 
decapitated - VERB O 
shoots - NOUN O 
and - CCONJ O 
buds - NOUN O 
of - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
biosynthetic - ADJ O 
inhibitor - NOUN O 
of - ADP O 
cytokinin - NOUN O 
( - PUNCT O 
Lovastatin PROPN - B-MEDICINE 
) - PUNCT O 
on - ADP O 
decapitated - VERB O 
shoots - NOUN O 
. - PUNCT O 

Results - NOUN O 
indicated - VERB O 
that - ADP O 
decapitation - NOUN O 
and - CCONJ O 
cytokinin - NOUN O 
increased - VERB O 
ZR PROPN - B-NORP 
content - NOUN O 
in - ADP O 
buds - NOUN O 
and - CCONJ O 
internodes - NOUN O 
at - ADP O 
4 NUM - B-CARDINAL 
- - SYM O 
8 - NUM O 
  - SPACE O 
h - NOUN O 
, - PUNCT O 
and - CCONJ O 
induced - VERB O 
bud - NOUN O 
elongation - NOUN O 
at - ADP O 
96 NUM - B-CARDINAL 
  - SPACE O 
h - ADV O 
after - ADP O 
treatment - NOUN O 
, - PUNCT O 
relative - ADJ O 
to - ADP O 
buds - NOUN O 
in - ADP O 
shoots - NOUN O 
receiving - VERB O 
the - DET O 
Lovastatin PROPN - B-MEDICINE 
treatment - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
we - PRON O 
investigated - VERB O 
the - DET O 
cell - NOUN O 
viability - NOUN O 
of - ADP O 
statins - NOUN O 
in - ADP O 
Cisplatin PROPN - B-ORG 
- - PUNCT O 
resistant - ADJ O 
HCP4 - PROPN O 
and - CCONJ O 
PCDP5 PROPN - B-PERSON 
cells - NOUN O 
compared - VERB O 
with - ADP O 
their - ADJ O 
parent - NOUN O 
Hela PROPN - B-PERSON 
and - CCONJ O 
PC3 PROPN - B-ORG 
cells - NOUN O 
, - PUNCT O 
respectively - ADV O 
, - PUNCT O 
and - CCONJ O 
found - VERB O 
that - ADP O 
HCP4 - PROPN O 
and - CCONJ O 
PCDP5 PROPN - B-PERSON 
cells - NOUN O 
were - VERB O 
37-fold NUM - B-CARDINAL 
and - CCONJ O 
18-fold NUM - B-CARDINAL 
more - ADV O 
resistant - ADJ O 
to - ADP O 
Cisplatin PROPN - B-ORG 
but - CCONJ O 
13-fold NUM - B-CARDINAL 
and - CCONJ O 
7-fold - NUM O 
more - ADV O 
sensitive - ADJ O 
to - ADP O 
Lovastatin PROPN - B-MEDICINE 
by - ADP O 
cell - NOUN O 
proliferation - NOUN O 
assay - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
induced - VERB O 
the - DET O 
apoptosis - NOUN O 
of - ADP O 
HCP4 - PROPN O 
cells - VERB O 
more - ADV O 
rapidly - ADV O 
and - CCONJ O 
to - ADP O 
greater - ADJ O 
extent - NOUN O 
than - ADP O 
in - ADP O 
Hela PROPN - B-GPE 
cells - NOUN O 
as - ADP O 
assessed - VERB O 
by - ADP O 
flow - NOUN O 
cytometry - NOUN O 
and - CCONJ O 
western - ADJ O 
blotting - VERB O 
analyses - NOUN O 
. - PUNCT O 

To - PART O 
elucidate - VERB O 
the - DET O 
mechanism - NOUN O 
underlying - VERB O 
the - DET O 
reduced - VERB O 
viability - NOUN O 
to - ADP O 
Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
we - PRON O 
performed - VERB O 
cDNA - PROPN O 
microarray - NOUN O 
analysis - NOUN O 
and - CCONJ O 
identified - VERB O 
65 NUM - B-CARDINAL 
and - CCONJ O 
54 NUM - B-CARDINAL 
genes - NOUN O 
that - ADJ O 
were - VERB O 
induced - VERB O 
more - ADJ O 
than - ADP O 
2-fold - NUM O 
by - ADP O 
Lovastatin PROPN - B-MEDICINE 
in - ADP O 
HCP4 - PROPN O 
and - CCONJ O 
PCDP5 PROPN - B-PERSON 
cells - NOUN O 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

These - DET O 
mRNAs - ADJ O 
were - VERB O 
strongly - ADV O 
induced - VERB O 
by - ADP O 
Lovastatin PROPN - B-MEDICINE 
with - ADP O 
transcriptional - ADJ O 
regulation - NOUN O 
in - ADP O 
HCP4 - PROPN O 
cells - NOUN O 
. - PUNCT O 

Consistent - ADJ O 
with - ADP O 
transcription - NOUN O 
, - PUNCT O 
the - DET O 
protein - NOUN O 
expression - NOUN O 
of - ADP O 
RHOB PROPN - B-ORG 
also - ADV O 
was - VERB O 
induced - VERB O 
by - ADP O 
Lovastatin PROPN - B-MEDICINE 
. - PUNCT O 

Combination - NOUN O 
treatment - NOUN O 
with - ADP O 
Cisplatin PROPN - B-ORG 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 
resulted - VERB O 
in - ADP O 
an - DET O 
agonistic - ADJ O 
effect - NOUN O 
in - ADP O 
Hela PROPN - B-GPE 
and - CCONJ O 
PC3 - PROPN O 
cells - NOUN O 
and - CCONJ O 
an - DET O 
antagonistic - ADJ O 
effect - NOUN O 
in - ADP O 
HCP4 - PROPN O 
and - CCONJ O 
PCDP5 PROPN - B-PERSON 
cells - NOUN O 
. - PUNCT O 

Effects - PROPN O 
of - ADP O 
Resveratrol PROPN - B-ORG 
, - PUNCT O 
Lovastatin PROPN - B-MEDICINE 
and - CCONJ O 
the - DET O 
mTOR - PROPN O 
- - PUNCT O 
Inhibitor - PROPN O 
RAD-001 - PROPN O 
on - ADP O 
Insulin PROPN - B-ORG 
- PUNCT - I-ORG 
Induced VERB - I-ORG 
Genomic ADJ - I-ORG 
Damage NOUN - I-ORG 
In ADP - I-ORG 
Vitro PROPN - I-ORG 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
attenuated - VERB O 
the - DET O 
neurotoxic - ADJ O 
effects - NOUN O 
of - ADP O 
β - DET O 
- - PUNCT O 
amyloid - NOUN O 
peptide - NOUN O 
( - PUNCT O 
Aβ - PROPN O 
) - PUNCT O 
and - CCONJ O 
affected - VERB O 
the - DET O 
metabolism - NOUN O 
of - ADP O 
APP - PROPN O 
, - PUNCT O 
reducing - VERB O 
levels - NOUN O 
of - ADP O 
Aβ1 - NOUN O 
to - ADP O 
Aβ42 - PROPN O 
and - CCONJ O 
β - ADJ O 
- - PUNCT O 
site - NOUN O 
amyloid - NOUN O 
precursor - NOUN O 
protein - NOUN O 
- - PUNCT O 
cleaving - VERB O 
enzyme - ADJ O 
1 NUM - B-CARDINAL 
; - PUNCT O 
enhancing - VERB O 
those - DET O 
of - ADP O 
αAPP - CCONJ O 
, - PUNCT O 
disintegrin - NOUN O 
metalloproteinase - NOUN O 
domain - NOUN O 
- - PUNCT O 
containing - VERB O 
protein - NOUN O 
10 NUM - B-CARDINAL 
, - PUNCT O 
and - CCONJ O 
β - DET O 
- - PUNCT O 
site - NOUN O 
amyloid - NOUN O 
precursor - NOUN O 
protein - NOUN O 
- - PUNCT O 
cleaving - VERB O 
enzyme - ADJ O 
2 NUM - B-CARDINAL 
; - PUNCT O 
and - CCONJ O 
up - ADV O 
- - PUNCT O 
regulating - VERB O 
expression - NOUN O 
of - ADP O 
α7 - NOUN O 
nAChR - NOUN O 
and - CCONJ O 
stimulating - VERB O 
phosphorylation - NOUN O 
of - ADP O 
extracellular - ADJ O 
signal - NOUN O 
- - PUNCT O 
regulated - VERB O 
kinase - NOUN O 
( - PUNCT O 
ERK)1/2 - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
also - ADV O 
blocked - VERB O 
the - DET O 
LPS- PROPN - B-ORG 
or - CCONJ O 
repeated - VERB O 
WAS - PROPN O 
- - PUNCT O 
induced - VERB O 
increased - VERB O 
gut - NOUN O 
permeability - NOUN O 
. - PUNCT O 

Development - NOUN O 
of - ADP O 
a - DET O 
Modified - PROPN O 
- - PUNCT O 
Release - PROPN O 
Formulation - PROPN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
Targeted VERB - I-ORG 
to - ADP O 
Intestinal - ADJ O 
Methanogens - PROPN O 

Lovastatin PROPN - B-MEDICINE 
analogues - NOUN O 
and - CCONJ O 
other - ADJ O 
metabolites - NOUN O 
from - ADP O 
soil - NOUN O 
- - PUNCT O 
derived - VERB O 
Aspergillus - PROPN O 
terreus - NOUN O 
YIM - PROPN O 
PH30711 - PROPN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
competitive - ADJ O 
inhibitor - NOUN O 
of - ADP O 
the - DET O 
enzyme - ADJ O 
hydroxymethyl - NOUN O 
glutaryl - NOUN O 
coenzyme - NOUN O 
A - DET O 
reductase - NOUN O 
( - PUNCT O 
HMGR - PROPN O 
) - PUNCT O 
in - ADP O 
cholesterol - NOUN O 
biosynthetic - ADJ O 
pathway - NOUN O 
and - CCONJ O 
hence - ADV O 
used - VERB O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
hyperlipidemia - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
gene - NOUN O 
cluster - NOUN O 
, - PUNCT O 
when - ADV O 
aligned - VERB O 
on - ADP O 
the - DET O 
consensus - NOUN O 
sequence - NOUN O 
of - ADP O 
both - DET O 
genomes - NOUN O 
, - PUNCT O 
the - DET O 
entire - ADJ O 
lovastatin ADJ - B-MEDICINE 
gene - NOUN O 
cluster - NOUN O 
was - VERB O 
detected - VERB O 
in - ADP O 
a - DET O 
single - ADJ O 
scaffold - NOUN O 
( - PUNCT O 
1.16 NUM - B-CARDINAL 
) - PUNCT O 
of - ADP O 
A.terreus - PROPN O 
genome - ADJ O 
. - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
the DET - B-LAW 
Combined PROPN - I-LAW 
Effect PROPN - I-LAW 
of ADP - I-LAW 
Recombinant PROPN - I-LAW 
High PROPN - I-LAW 
- PUNCT - I-LAW 
Density PROPN - I-LAW 
Lipoprotein PROPN - I-LAW 
Carrier PROPN - I-LAW 
and - CCONJ O 
the DET - B-ORG 
Encapsulated PROPN - I-ORG 
Lovastatin PROPN - I-MEDICINE 
in - ADP O 
RAW264.7 PROPN - B-GPE 
Macrophage NOUN - I-GPE 
Cells NOUN - I-GPE 
Based VERB - I-GPE 
on - ADP O 
the DET - B-FAC 
Median ADJ - I-FAC 
- PUNCT - I-FAC 
Effect PROPN - I-FAC 
Principle PROPN - I-FAC 
. - PUNCT O 

The - DET O 
contents - NOUN O 
of - ADP O 
MIAs - NOUN O 
were - VERB O 
qualified - VERB O 
by - ADP O 
High - PROPN O 
Performance - PROPN O 
Liquid - PROPN O 
Chromatography - PROPN O 
and - CCONJ O 
the - DET O 
transcript - NOUN O 
levels - NOUN O 
of - ADP O 
the - DET O 
relevant - ADJ O 
genes - NOUN O 
were - VERB O 
measured - VERB O 
by - ADP O 
qRT - NUM O 
- - PUNCT O 
PCR.Lovastatin - PROPN O 
improved - VERB O 
the - DET O 
accumulation - NOUN O 
of - ADP O 
MIAs - NOUN O 
via - ADP O 
increasing - VERB O 
the - DET O 
transcription - NOUN O 
of - ADP O 
their - ADJ O 
biosynthetic - ADJ O 
genes - NOUN O 
encoding - VERB O 
DXS1 - PROPN O 
, - PUNCT O 
tryptonphan - ADP O 
decarboxylase - NOUN O 
( - PUNCT O 
TDC PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
loganic - ADJ O 
acid - NOUN O 
methyltransferase - NOUN O 
( - PUNCT O 
LAMT - PROPN O 
) - PUNCT O 
, - PUNCT O 
strictosidine - NOUN O 
synthase - NOUN O 
( - PUNCT O 
STR PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
desacetoxyvindoline-4-hydroxylase - PROPN O 
( - PUNCT O 
D4H - PROPN O 
) - PUNCT O 
and - CCONJ O 
ORCA3 - PROPN O 
( - PUNCT O 
a - DET O 
jasmonate - ADJ O 
- - PUNCT O 
responsive - ADJ O 
transcriptional - ADJ O 
regulator - NOUN O 
) - PUNCT O 
, - PUNCT O 
whereas - ADP O 
clomazone - NOUN O 
reduced - VERB O 
the - DET O 
contents - NOUN O 
of - ADP O 
MIAs - NOUN O 
and - CCONJ O 
the - DET O 
mRNA - PROPN O 
levels - NOUN O 
of - ADP O 
the - DET O 
corresponding - ADJ O 
genes - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
commercially - ADV O 
important - ADJ O 
secondary - ADJ O 
metabolite - NOUN O 
produced - VERB O 
by - ADP O 
Aspergillus - PROPN O 
terreus - NOUN O 
, - PUNCT O 
either - CCONJ O 
by - ADP O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
or - CCONJ O 
by - ADP O 
submerged - VERB O 
fermentation - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
pravastatin - NOUN O 
, - PUNCT O 
fluvastatin - NOUN O 
, - PUNCT O 
and - CCONJ O 
pitavastatin - NOUN O 
were - VERB O 
not - ADV O 
associated - VERB O 
with - ADP O 
the - DET O 
risk - NOUN O 
of - ADP O 
developing - VERB O 
NOFs - NOUN O 
compared - VERB O 
with - ADP O 
simvastatin - ADJ O 
users - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
Alleviates VERB - I-ORG 
Endothelial - NOUN O 
- - PUNCT O 
to - ADP O 
- - PUNCT O 
Mesenchymal - PROPN O 
Transition - PROPN O 
in - ADP O 
Glomeruli PROPN - B-GPE 
via - ADP O 
Suppression - PROPN O 
of - ADP O 
Oxidative - PROPN O 
Stress - PROPN O 
and - CCONJ O 
TGF - PROPN O 
- - PUNCT O 
β1 - PROPN O 
Signaling - PROPN O 
. - PUNCT O 

We - PRON O 
investigated - VERB O 
the - DET O 
effects - NOUN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
against - ADP O 
sciatic - ADJ O 
nerve - NOUN O 
crush - NOUN O 
injury - NOUN O 
in - ADP O 
male - ADJ O 
Wistar PROPN - B-FAC 
Rats PROPN - I-FAC 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
or - CCONJ O 
vehicle - NOUN O 
was - VERB O 
given - VERB O 
parenteraly - NOUN O 
to - ADP O 
rats - NOUN O 
for - ADP O 
7 NUM - B-DATE 
days NOUN - I-DATE 
postoperative - ADJ O 
. - PUNCT O 

In - ADP O 
Lovastatin PROPN - B-MEDICINE 
treatment - NOUN O 
groups - NOUN O 
, - PUNCT O 
a - DET O 
single - ADJ O 
dose - NOUN O 
of - ADP O 
agent - NOUN O 
( - PUNCT O 
2 NUM - B-CARDINAL 
and - CCONJ O 
5mg NOUN - B-ORDINAL 
/ - SYM O 
kg - NOUN O 
) - PUNCT O 
was - VERB O 
administered - VERB O 
daily ADV - B-DATE 
. - PUNCT O 

Results - NOUN O 
showed - VERB O 
that - ADP O 
Lovastatin PROPN - B-MEDICINE 
in - ADP O 
a - DET O 
dose - NOUN O 
of - ADP O 
5mg NOUN - B-ORDINAL 
/ - SYM O 
kg - NOUN O 
could - VERB O 
significantly - ADV O 
( - PUNCT O 
P - NOUN O 
< - X O 
0.05 NUM - B-CARDINAL 
) - PUNCT O 
accelerate - VERB O 
regeneration - NOUN O 
process - NOUN O 
and - CCONJ O 
functional - ADJ O 
recovery - NOUN O 
. - PUNCT O 

Also - ADV O 
results - NOUN O 
demonstrated - VERB O 
that - ADP O 
morphometric - ADJ O 
parameters - NOUN O 
such - ADJ O 
as - ADP O 
mean - ADJ O 
axonal - ADJ O 
number - NOUN O 
and - CCONJ O 
myelin - NOUN O 
thickness - NOUN O 
were - VERB O 
significantly - ADV O 
higher - ADJ O 
in - ADP O 
Lovastatin PROPN - B-MEDICINE 
( - PUNCT O 
5mg NOUN - B-ORDINAL 
/ - SYM O 
kg - NOUN O 
) - PUNCT O 
treatment - NOUN O 
groups - NOUN O 
compared - VERB O 
to - ADP O 
controls - NOUN O 
( - PUNCT O 
P - NOUN O 
< - X O 
0.05 NUM - B-CARDINAL 
) - PUNCT O 
. - PUNCT O 

These - DET O 
findings - NOUN O 
suggest - VERB O 
that - ADP O 
a - DET O 
short - ADJ O 
- - PUNCT O 
term - NOUN O 
course - NOUN O 
treatment - NOUN O 
with - ADP O 
Lovastatin PROPN - B-MEDICINE 
can - VERB O 
protect - VERB O 
against - ADP O 
sciatic - ADJ O 
nerve - NOUN O 
injury - NOUN O 
. - PUNCT O 

Findings - NOUN O 
indicate - VERB O 
that - ADP O 
postoperative - ADJ O 
administration - NOUN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
led - VERB O 
to - PART O 
accelerate - VERB O 
regeneration - NOUN O 
process - NOUN O 
and - CCONJ O 
motor - NOUN O 
function - NOUN O 
recovery - NOUN O 
in - ADP O 
nerve - NOUN O 
crush - NOUN O 
model - NOUN O 
in - ADP O 
rats - NOUN O 
. - PUNCT O 

This - DET O 
effect - NOUN O 
might - VERB O 
be - VERB O 
due - ADP O 
to - ADP O 
the - DET O 
anti - ADJ O 
- - ADJ O 
inflammatory - ADJ O 
, - PUNCT O 
immunomodulatory - ADJ O 
or - CCONJ O 
anti - ADJ O 
- - ADJ O 
oxidative - ADJ O 
properties - NOUN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
. - PUNCT O 

Neuroprotective - ADJ O 
effect - NOUN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
on - ADP O 
motor - NOUN O 
deficit - NOUN O 
induced - VERB O 
by - ADP O 
sciatic - ADJ O 
nerve - NOUN O 
crush - NOUN O 
in - ADP O 
the - DET O 
rat - NOUN O 
. - PUNCT O 

Since - ADP O 
25-hydroxycholesterol NUM - B-CARDINAL 
( - PUNCT O 
25-HC NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
a - DET O 
metabolite - NOUN O 
of - ADP O 
cholesterol - NOUN O 
, - PUNCT O 
can - VERB O 
suppress - VERB O 
IL-1β - PROPN O 
production - NOUN O 
, - PUNCT O 
thus - ADV O 
reducing - VERB O 
inflammation - NOUN O 
, - PUNCT O 
we - PRON O 
evaluated - VERB O 
the - DET O 
effect - NOUN O 
of - ADP O 
25-HC NUM - B-CARDINAL 
in - ADP O 
an - DET O 
in - X O 
vitro - X O 
model - NOUN O 
of - ADP O 
mevalonate - NOUN O 
pathway - NOUN O 
alteration - NOUN O 
, - PUNCT O 
obtained - VERB O 
using - VERB O 
Lovastatin PROPN - B-MEDICINE 
. - PUNCT O 

Our - ADJ O 
results - NOUN O 
showed - VERB O 
that - ADP O 
25-HC NUM - B-PRODUCT 
is - VERB O 
able - ADJ O 
to - PART O 
reduce - VERB O 
inflammation - NOUN O 
but - CCONJ O 
it - PRON O 
is - VERB O 
ineffective - ADJ O 
to - PART O 
restore - VERB O 
autophagy - NOUN O 
flux - ADJ O 
and - CCONJ O 
to - PART O 
decrease - VERB O 
apoptosis - NOUN O 
levels - NOUN O 
, - PUNCT O 
both - DET O 
caused - VERB O 
by - ADP O 
lower - ADJ O 
protein - NOUN O 
prenylation - NOUN O 
; - PUNCT O 
so - CCONJ O 
, - PUNCT O 
in - ADP O 
spite - NOUN O 
of - ADP O 
its - ADJ O 
anti - ADJ O 
- - ADJ O 
inflammatory - ADJ O 
action - NOUN O 
it - PRON O 
is - VERB O 
not - ADV O 
useful - ADJ O 
to - PART O 
rescue - VERB O 
defective - ADJ O 
prenylation - NOUN O 
/ - SYM O 
autophagy - NOUN O 
impairment - NOUN O 
- - PUNCT O 
driven - VERB O 
apoptosis - NOUN O 
in - ADP O 
Lovastatin PROPN - B-MEDICINE 
impaired - VERB O 
mevalonate - NOUN O 
pathway - NOUN O 
. - PUNCT O 

25-Hydroxycholesterol NUM - B-CARDINAL 
and - CCONJ O 
inflammation - NOUN O 
in - ADP O 
Lovastatin PROPN - B-MEDICINE 
- - PUNCT O 
deregulated - VERB O 
mevalonate - NOUN O 
pathway - NOUN O 
. - PUNCT O 

Since - ADP O 
the - DET O 
parasite - NOUN O 
synthesizes - NOUN O 
ergosterol - VERB O 
instead - ADV O 
of - ADP O 
cholesterol - NOUN O 
, - PUNCT O 
using - VERB O 
the - DET O 
same - ADJ O 
biochemical - ADJ O 
pathway - NOUN O 
and - CCONJ O 
enzymes - NOUN O 
, - PUNCT O 
an - DET O 
inhibitor - NOUN O 
of - ADP O 
HMG PROPN - B-ORG 
- PUNCT - I-ORG 
CoA PROPN - I-ORG 
- PUNCT - I-ORG 
Reductase PROPN - I-ORG 
, - PUNCT O 
Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
has - VERB O 
been - VERB O 
tried - VERB O 
for - ADP O 
its - ADJ O 
anti - ADJ O 
- - ADJ O 
Leishmanial - ADJ O 
effect - NOUN O 
. - PUNCT O 

Lovastatin ADV - B-MEDICINE 
, - PUNCT O 
being - VERB O 
an - DET O 
inhibitor - NOUN O 
of - ADP O 
HMG PROPN - B-ORG 
- PUNCT - I-ORG 
CoA PROPN - I-ORG 
- PUNCT - I-ORG 
Reductase PROPN - I-ORG 
, - PUNCT O 
inhibits - VERB O 
infection - NOUN O 
by - ADP O 
cholesterol - NOUN O 
depletion - NOUN O 
, - PUNCT O 
while - ADP O 
chromium - NOUN O 
chloride - NOUN O 
complexes - NOUN O 
, - PUNCT O 
at - ADP O 
their - ADJ O 
higher - ADJ O 
concentrations - NOUN O 
, - PUNCT O 
are - VERB O 
reported - VERB O 
to - PART O 
exhibit - VERB O 
cytotoxicity - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
and - CCONJ O 
CrCl3.6H2O VERB - B-ORG 
in - ADP O 
combination - NOUN O 
has - VERB O 
appeared - VERB O 
to - PART O 
be - VERB O 
ineffective - ADJ O 
on - ADP O 
promastigotes - NOUN O 
but - CCONJ O 
has - VERB O 
induced - VERB O 
cytotoxic - ADJ O 
effect - NOUN O 
on - ADP O 
the - DET O 
intracellular - ADJ O 
amastigotes - NOUN O 
through - ADP O 
up - ADJ O 
- - PUNCT O 
regulation - NOUN O 
of - ADP O 
cellular - ADJ O 
signalling - NOUN O 
mechanisms - NOUN O 
. - PUNCT O 

3.6H2O NUM - B-ORG 
stimulates - VERB O 
generation - NOUN O 
of - ADP O 
NO - DET O 
, - PUNCT O 
leading - VERB O 
to - ADP O 
reduction - NOUN O 
of - ADP O 
the - DET O 
number - NOUN O 
of - ADP O 
intracellular - ADJ O 
amastigote - NOUN O 
, - PUNCT O 
while - ADP O 
Lovastatin PROPN - B-MEDICINE 
shows - VERB O 
HPO PROPN - B-ORG 
- - PUNCT O 
mediated - VERB O 
killing - NOUN O 
of - ADP O 
the - DET O 
same - ADJ O 
, - PUNCT O 
keeping - VERB O 
the - DET O 
host - NOUN O 
cell - NOUN O 
unaffected - ADJ O 
. - PUNCT O 

Conclusion - NOUN O 
: - PUNCT O 
Lovastatin PROPN - B-MEDICINE 
may - VERB O 
play - VERB O 
an - DET O 
important - ADJ O 
role - NOUN O 
in - ADP O 
antagonizing - VERB O 
the - DET O 
neurotoxicity - NOUN O 
of - ADP O 
Aβ - PROPN O 
through - ADP O 
a - DET O 
mechanism - NOUN O 
likely - ADV O 
related - VERB O 
to - ADP O 
the - DET O 
inhibition - NOUN O 
of - ADP O 
oxidative - ADJ O 
stress - NOUN O 
. - PUNCT O 

Molecular - PROPN O 
and - CCONJ O 
Vibrational PROPN - B-ORG 
Dynamics PROPN - I-ORG 
in - ADP O 
the DET - B-ORG 
Cholesterol PROPN - I-ORG 
- PUNCT - I-ORG 
Lowering VERB - I-ORG 
Agent PROPN - I-ORG 
Lovastatin PROPN - B-MEDICINE 
: - PUNCT O 
Solid PROPN - B-ORG 
- PUNCT - I-ORG 
State PROPN - I-ORG 
NMR PROPN - I-ORG 
, - PUNCT O 
Inelastic PROPN - B-PERSON 
Neutron PROPN - I-PERSON 
Scattering PROPN - I-PERSON 
, - PUNCT O 
and - CCONJ O 
Periodic PROPN - B-ORG 
DFT PROPN - I-ORG 
Study PROPN - I-ORG 
. - PUNCT O 

Inhibition - NOUN O 
of - ADP O 
NF - PROPN O 
- - PUNCT O 
κB - PROPN O 
Pathway - PROPN O 
and - CCONJ O 
Modulation - PROPN O 
of - ADP O 
MAPK - PROPN O 
Signaling - PROPN O 
Pathways - PROPN O 
in - ADP O 
Glioblastoma PROPN - B-GPE 
and - CCONJ O 
Implications - PROPN O 
for - ADP O 
Lovastatin PROPN - B-MEDICINE 
and - CCONJ O 
Tumor PROPN - B-ORG 
Necrosis PROPN - I-ORG 

Lovastatin ADJ - B-MEDICINE 
time - NOUN O 
/ - SYM O 
dose - NOUN O 
- - PUNCT O 
dependently - ADV O 
increased - VERB O 
miR-29b - NOUN O 
expression - NOUN O 
and - CCONJ O 
decreased - VERB O 
proteasome - ADJ O 
activity - NOUN O 
in - ADP O 
cultured - VERB O 
human - ADJ O 
umbilical - ADJ O 
vein - NOUN O 
endothelial - ADJ O 
cells - NOUN O 
( - PUNCT O 
HUVECs - PROPN O 
) - PUNCT O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
inhibited - VERB O 
oxidative - ADJ O 
stress - NOUN O 
induced - VERB O 
by - ADP O 
multiple - ADJ O 
oxidants - NOUN O 
including - VERB O 
ox - PROPN O 
- - PUNCT O 
LDL - PROPN O 
, - PUNCT O 
H2O2 NOUN - B-GPE 
, - PUNCT O 
TNFα - NOUN O 
, - PUNCT O 
homocysteine - NOUN O 
thiolactone - NOUN O 
( - PUNCT O 
HTL - PROPN O 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
high - ADJ O 
glucose - NOUN O 
( - PUNCT O 
HG PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
which - ADJ O 
were - VERB O 
reversed - VERB O 
by - ADP O 
inhibition - NOUN O 
of - ADP O 
miR-29b - NOUN O 
in - ADP O 
HUVECs - NUM O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
upregulates - VERB O 
microRNA-29b - VERB O 
to - PART O 
reduce - VERB O 
oxidative - ADJ O 
stress - NOUN O 
in - ADP O 
rats - NOUN O 
with - ADP O 
multiple - ADJ O 
cardiovascular - ADJ O 
risk - NOUN O 
factors - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
of ADP - I-ORG 
RYP PROPN - I-ORG 
is - VERB O 
a - DET O 
hypolipidemic - ADJ O 
commercial - ADJ O 
drug - NOUN O 
. - PUNCT O 

A - DET O 
Magnetic - PROPN O 
Resonance - PROPN O 
Spectroscopy - PROPN O 
Study - PROPN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
for - ADP O 
Treating - VERB O 
Bipolar - PROPN O 
Mood - PROPN O 
Disorder - NOUN O 
: - PUNCT O 
A - DET O 
4-Week - NUM O 
Randomized VERB - B-ORG 
Double PROPN - I-ORG 
- PUNCT - I-ORG 
Blind PROPN - I-ORG 
, PUNCT - I-ORG 
Placebo- - PROPN O 

Lovastatin PROPN - B-MEDICINE 
prevents - VERB O 
bleomycin - NOUN O 
- - PUNCT O 
induced - VERB O 
DNA - NOUN O 
damage - NOUN O 
to - ADP O 
HepG2 - PROPN O 
cells - NOUN O 
. - PUNCT O 

Berberine PROPN - B-PERSON 
( - PUNCT O 
PubChem - PROPN O 
CID - PROPN O 
: - PUNCT O 
2353 - NUM O 
) - PUNCT O 
; - PUNCT O 
Lovastatin PROPN - B-MEDICINE 
( - PUNCT O 
PubChem - PROPN O 
CID - PROPN O 
: - PUNCT O 
53232 NUM - B-CARDINAL 
) - PUNCT O 
. - PUNCT O 

Lovastatin ADJ - B-MEDICINE 
productivity - NOUN O 
was - VERB O 
increased - VERB O 
32-fold NUM - B-CARDINAL 
through - ADP O 
strain - NOUN O 
improvement - NOUN O 
methods - NOUN O 
, - PUNCT O 
including - VERB O 
mutations - NOUN O 
and - CCONJ O 
three NUM - B-CARDINAL 
successive - ADJ O 
rounds - NOUN O 
of - ADP O 
genome - DET O 
shuffling - NOUN O 
followed - VERB O 
by - ADP O 
optimizing - VERB O 
SSF NOUN - B-ORG 
factors - NOUN O 
. - PUNCT O 

Genome - DET O 
Shuffling - PROPN O 
of - ADP O 
Mangrove - PROPN O 
Endophytic - PROPN O 
Aspergillus - PROPN O 
luchuensis - NOUN O 
MERV10 - NOUN O 
for - ADP O 
Improving - VERB O 
the - DET O 
Cholesterol - PROPN O 
- - PUNCT O 
Lowering - VERB O 
Agent - PROPN O 
Lovastatin PROPN - B-MEDICINE 
under - ADP O 
Solid PROPN - B-GPE 
State PROPN - I-GPE 
Fermentation PROPN - I-GPE 
. - PUNCT O 

The - DET O 
present - ADJ O 
investigation - NOUN O 
, - PUNCT O 
focused - VERB O 
on - ADP O 
screening - NOUN O 
of - ADP O 
various - ADJ O 
fungal - ADJ O 
species - NOUN O 
for - ADP O 
Lovastatin PROPN - B-MEDICINE 
production - NOUN O 
using - VERB O 
different - ADJ O 
agro - NOUN O 
- - PUNCT O 
based - VERB O 
wastes - NOUN O 
, - PUNCT O 
also - ADV O 
, - PUNCT O 
for - ADP O 
maximizing - VERB O 
lovastatin ADJ - B-MEDICINE 
productivity - NOUN O 
by - ADP O 
isolated - VERB O 
Aspergillus PROPN - B-ORG 
fumigatus - NOUN O 
using - VERB O 
response - NOUN O 
surface - NOUN O 
methodology - NOUN O 
( - PUNCT O 
RSM PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

This - DET O 
Lovastatin PROPN - B-MEDICINE 
has - VERB O 
the - DET O 
possibility - NOUN O 
to - PART O 
use - VERB O 
in - ADP O 
different - ADJ O 
therapeutic - ADJ O 
applications - NOUN O 
. - PUNCT O 

Comparison - PROPN O 
of - ADP O 
Intrathecal - PROPN O 
Nalbuphine - PROPN O 
Hydrochloride - PROPN O 
and - CCONJ O 
Clonidine PROPN - B-PERSON 
Hydrochloride PROPN - I-PERSON 
as - ADP O 
an - DET O 
Adjuvant PROPN - B-ORG 
to ADP - I-ORG 
Hyperbaric PROPN - I-ORG 
Bupivacaine PROPN - I-ORG 
in - ADP O 
Abdominal - PROPN O 
Hysterectomy - PROPN O 
. - PUNCT O 

Validated PROPN - B-PERSON 
Colorimetric PROPN - I-PERSON 
Assay PROPN - I-PERSON 
of - ADP O 
Clonidine PROPN - B-ORG 
Hydrochloride PROPN - I-ORG 
from - ADP O 
Pharmaceutical PROPN - B-ORG 
Preparations PROPN - I-ORG 
. - PUNCT O 

Formulation - NOUN O 
of - ADP O 
a - DET O 
stable - ADJ O 
parenteral - ADJ O 
product - NOUN O 
; - PUNCT O 
Clonidine PROPN - B-ORG 
Hydrochloride PROPN - I-ORG 
Injection PROPN - I-ORG 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Aqueous - PROPN O 
Extract - PROPN O 
of - ADP O 
Azadirachta - PROPN O 
indica - VERB O 
Leaves - PROPN O 
on - ADP O 
Pharmacokinetics - PROPN O 
and - CCONJ O 
Pharmacodynamics - PROPN O 
of - ADP O 
Glipizide PROPN - B-MEDICINE 
. - PUNCT O 

The - DET O 
Study - PROPN O 
to - PART O 
Understand - VERB O 
the - DET O 
Genetics - PROPN O 
of - ADP O 
the - DET O 
Acute - PROPN O 
Response - PROPN O 
to - ADP O 
Metformin PROPN - B-PERSON 
and - CCONJ O 
Glipizide PROPN - B-MEDICINE 
in - ADP O 
Humans PROPN - B-GPE 
( - PUNCT O 
SUGAR - PROPN O 
- - PUNCT O 
MGH - PROPN O 
) - PUNCT O 
. - PUNCT O 

Diabetes - NOUN O 
mellitus - NOUN O 
is - VERB O 
a - DET O 
chronical - ADJ O 
disease - NOUN O 
nearly - ADV O 
related - VERB O 
to - ADP O 
oxidative - ADJ O 
stress - NOUN O 
, - PUNCT O 
whose - ADJ O 
treatment - NOUN O 
( - PUNCT O 
in - ADP O 
type - NOUN O 
II PROPN - B-ORG 
variant - NOUN O 
) - PUNCT O 
consists - VERB O 
in - ADP O 
the - DET O 
administration - NOUN O 
of - ADP O 
antidiabetic - ADJ O 
compounds - NOUN O 
( - PUNCT O 
Andb PROPN - B-ORG 
) - PUNCT O 
such - ADJ O 
as - ADP O 
Gliclazide PROPN - B-ORG 
( PUNCT - I-ORG 
Gli PROPN - I-ORG 
) - PUNCT O 
and - CCONJ O 
Glipizide PROPN - B-MEDICINE 
( - PUNCT O 
Glip - PROPN O 
) - PUNCT O 
. - PUNCT O 

Glipizide NOUN - B-MEDICINE 
tablets - NOUN O 
containing - VERB O 
different - ADJ O 
polymers - NOUN O 
from - ADP O 
3 NUM - B-CARDINAL 
categories - NOUN O 
( - PUNCT O 
immediate - ADJ O 
, - PUNCT O 
moderate - ADJ O 
, - PUNCT O 
and - CCONJ O 
extended - ADJ O 
release - NOUN O 
) - PUNCT O 
were - VERB O 
prepared - VERB O 
and - CCONJ O 
evaluated - VERB O 
. - PUNCT O 

Stable - ADJ O 
Co - NOUN O 
- - NOUN O 
crystals - NOUN O 
of - ADP O 
Glipizide PROPN - B-MEDICINE 
with - ADP O 
Enhanced - PROPN O 
Dissolution - PROPN O 
Profiles - PROPN O 
: - PUNCT O 
Preparation - NOUN O 
and - CCONJ O 
Characterization - PROPN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
treatment - NOUN O 
decreased - VERB O 
dilated - ADJ O 
renal - ADJ O 
tubule - NOUN O 
number - NOUN O 
, - PUNCT O 
improved - VERB O 
glomerulus - NOUN O 
integrity - NOUN O 
, - PUNCT O 
and - CCONJ O 
reduced - VERB O 
inflammatory - ADJ O 
infiltration - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
blocks - VERB O 
renal - ADJ O 
interstitial - ADJ O 
fibrosis - NOUN O 
by - ADP O 
inhibiting - VERB O 
AKT PROPN - B-ORG 
signaling - VERB O 
pathway - NOUN O 
. - PUNCT O 

We - PRON O 
performed - VERB O 
a - DET O 
network - NOUN O 
meta - ADJ O 
- - PUNCT O 
analysis - NOUN O 
to - PART O 
compare - VERB O 
the - DET O 
efficacy - NOUN O 
of - ADP O 
12 NUM - B-CARDINAL 
single - ADJ O 
- - PUNCT O 
drug - NOUN O 
regimens - NOUN O 
( - PUNCT O 
Glibenclamide PROPN - B-ORG 
, PUNCT - I-ORG 
Glimepiride PROPN - I-ORG 
, PUNCT - I-ORG 
Pioglitazone PROPN - I-ORG 
, PUNCT - I-ORG 
Rosiglitazone PROPN - I-ORG 
, PUNCT - I-ORG 
Repaglinide PROPN - I-ORG 
, - PUNCT O 
Metformin PROPN - B-GPE 
, - PUNCT O 
Sitaglitin PROPN - B-GPE 
, - PUNCT O 
Exenatide PROPN - B-GPE 
, - PUNCT O 
Liraglutide PROPN - B-GPE 
, - PUNCT O 
Acarbose PROPN - B-PERSON 
, - PUNCT O 
Benfluorex PROPN - B-PERSON 
, - PUNCT O 
and - CCONJ O 
Glipizide PROPN - B-MEDICINE 
) - PUNCT O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
type - NOUN O 
2 NUM - B-CARDINAL 
diabetes - NOUN O 
mellitus - NOUN O 
( - PUNCT O 
T2DM PROPN - B-GPE 
) - PUNCT O 
. - PUNCT O 

Liraglutide - PROPN O 
was - VERB O 
more - ADV O 
effective - ADJ O 
than - ADP O 
Glimepiride PROPN - B-ORG 
, PUNCT - I-ORG 
Pioglitazone PROPN - I-ORG 
, - PUNCT O 
Sitaglitin PROPN - B-GPE 
, - PUNCT O 
Exenatide PROPN - B-GPE 
, - PUNCT O 
and - CCONJ O 
Glipizide PROPN - B-MEDICINE 
at - ADP O 
reducing - VERB O 
glycated - VERB O 
hemoglobin - NOUN O 
( - PUNCT O 
HbA1c PROPN - B-PERSON 
) - PUNCT O 
levels - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
suppresses - VERB O 
prostate - NOUN O 
cancer - NOUN O 
progression - NOUN O 
in - ADP O 
the - DET O 
TRAMP - NOUN O 
model - NOUN O 
by - ADP O 
inhibiting - VERB O 
angiogenesis - NOUN O 
. - PUNCT O 

The - DET O 
authors - NOUN O 
present - VERB O 
a - DET O 
15-mo NUM - B-DATE 
- PUNCT - I-DATE 
old ADJ - I-DATE 
boy - NOUN O 
with - ADP O 
accidental - ADJ O 
ingestion - NOUN O 
of - ADP O 
Glipizide PROPN - B-MEDICINE 
who - NOUN O 
presented - VERB O 
with - ADP O 
encephalopathy - ADJ O 
, - PUNCT O 
seizure - NOUN O 
and - CCONJ O 
severe - ADJ O 
hypoglycemia - NOUN O 
. - PUNCT O 

Type NOUN - B-ORG 
II PROPN - I-ORG 
diabetes - NOUN O 
mellitus - NOUN O 
is - VERB O 
usually - ADV O 
treated - VERB O 
with - ADP O 
Glipizide PROPN - B-MEDICINE 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
belongs - VERB O 
to - ADP O 
sulfonylurea - NOUN O 
group - NOUN O 
. - PUNCT O 

Simultaneous - PROPN O 
Determination - PROPN O 
of - ADP O 
Metformin - PROPN O 
, - PUNCT O 
Glipizide PROPN - B-MEDICINE 
, - PUNCT O 
Repaglinide - PROPN O 
, - PUNCT O 
and - CCONJ O 
Glimepiride - PROPN O 
or - CCONJ O 
Metformin PROPN - B-PERSON 
and - CCONJ O 
Pioglitazone - PROPN O 
by - ADP O 
a - DET O 
Validated - PROPN O 
LC - PROPN O 
Method - PROPN O 
: - PUNCT O 
Application - NOUN O 
in - ADP O 
the DET - B-GPE 
Presence PROPN - I-GPE 
of ADP - I-GPE 
Metformin PROPN - I-GPE 
Impurity PROPN - I-GPE 
( - PUNCT O 
1-Cyanoguanidine - NUM O 
) - PUNCT O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
suppresses - VERB O 
embryonic - ADJ O 
vasculogenesis - NOUN O 
and - CCONJ O 
angiogenesis - NOUN O 
through - ADP O 
targeting - VERB O 
natriuretic - ADJ O 
peptide - NOUN O 
receptor - NOUN O 
A. - NOUN O 

A - DET O 
Post PROPN - B-ORG 
Hoc PROPN - I-ORG 
Analysis PROPN - I-ORG 
of ADP - I-ORG 
HbA1c PROPN - I-ORG 
, - PUNCT O 
Hypoglycemia PROPN - B-ORG 
, - PUNCT O 
and - CCONJ O 
Weight PROPN - B-ORG 
Change VERB - I-ORG 
Outcomes PROPN - I-ORG 
with - ADP O 
Alogliptin - PROPN O 
vs - ADP O 
Glipizide PROPN - B-MEDICINE 
in - ADP O 
Older - ADJ O 
Patients - NOUN O 
with - ADP O 
Type - PROPN O 
2 - PROPN O 
Diabetes - PROPN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
frequently - ADV O 
prescribed - VERB O 
second ADJ - B-ORDINAL 
generation - NOUN O 
sulfonylurea - NOUN O 
which - ADJ O 
lowers - VERB O 
the - DET O 
blood - NOUN O 
glucose - NOUN O 
in - ADP O 
type - NOUN O 
- - PUNCT O 
two NUM - B-CARDINAL 
diabetics - NOUN O 
. - PUNCT O 

PHARMACEUTICAL - NOUN O 
COMPOSITIONS - NOUN O 
OF - ADP O 
URSODIOL NOUN - B-MEDICINE 

The DET - B-ORG 
Inhibitory PROPN - I-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Essential PROPN - I-ORG 
Oils PROPN - I-ORG 
on ADP - I-ORG 
Rhizopus PROPN - I-MEDICINE 
stolonifer - NOUN O 
, - PUNCT O 
Trichophyton PROPN - B-NORP 
mentagrophytes - VERB O 
, - PUNCT O 
and - CCONJ O 
Microsporum - PROPN O 
gypseum - NOUN O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Photodynamic PROPN - B-ORG 
Inactivation PROPN - I-ORG 
on - ADP O 
the - DET O 
Growth - PROPN O 
and - CCONJ O 
Antifungal - PROPN O 
Susceptibility - PROPN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
. - PUNCT O 

Antifungal - ADJ O 
effects - NOUN O 
of - ADP O 
thymol - NOUN O 
and - CCONJ O 
salicylic - ADJ O 
acid - NOUN O 
on - ADP O 
cell - NOUN O 
membrane - NOUN O 
and - CCONJ O 
mitochondria - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
and - CCONJ O 
their - ADJ O 
application - NOUN O 
in - ADP O 
postharvest - NOUN O 
preservation - NOUN O 
of - ADP O 
tomatoes - NOUN O 
. - PUNCT O 

The - DET O 
influence - NOUN O 
of - ADP O 
polyols - NOUN O 
on - ADP O 
Rhizopus NOUN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
( - PUNCT O 
RCL PROPN - B-ORG 
) - PUNCT O 
was - VERB O 
investigated - VERB O 
under - ADP O 
high - ADJ O 
pressure - NOUN O 
. - PUNCT O 

Enhanced - PROPN O 
Performance - PROPN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
Lipase - PROPN O 
by - ADP O 
Reasonable - ADJ O 
Immobilization - NOUN O 
on - ADP O 
Magnetic - PROPN O 
Nanoparticles - PROPN O 
and - CCONJ O 
Its - ADJ O 
Application - PROPN O 
in - ADP O 
Synthesis - PROPN O 
1,3-Diacyglycerol - NUM O 
. - PUNCT O 

Enhanced - ADJ O 
application - NOUN O 
of - ADP O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
( - PUNCT O 
SSF PROPN - B-ORG 
) - PUNCT O 
in - ADP O 
industrial - ADJ O 
production - NOUN O 
and - CCONJ O 
the - DET O 
influence - NOUN O 
of - ADP O 
SSF PROPN - B-ORG 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
K1 - PROPN O 
on - ADP O 
glucoamylase - NOUN O 
productivity - NOUN O 
were - VERB O 
analyzed - VERB O 
using - VERB O 
the - DET O 
flat - ADJ O 
band - NOUN O 
method - NOUN O 
. - PUNCT O 

A - DET O 
growth - NOUN O 
model - NOUN O 
was - VERB O 
implemented - VERB O 
through - ADP O 
SSF PROPN - B-ORG 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
K1 - PROPN O 
in - ADP O 
this - DET O 
experiment - NOUN O 
, - PUNCT O 
and - CCONJ O 
spectrophotometric - ADJ O 
method - NOUN O 
was - VERB O 
used - VERB O 
to - PART O 
determine - VERB O 
glucoamylase - NOUN O 
activity - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
has - VERB O 
good - ADJ O 
utilization - NOUN O 
value - NOUN O 
for - ADP O 
glucoamylase - NOUN O 
production - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
in - ADP O 
SSF PROPN - B-ORG 
. - PUNCT O 

In - ADP O 
the - DET O 
present - ADJ O 
study - NOUN O 
, - PUNCT O 
the - DET O 
antifungal - ADJ O 
activity - NOUN O 
of - ADP O 
individual - ADJ O 
and - CCONJ O 
combined - VERB O 
monoterpenes - NOUN O 
against - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
and - CCONJ O 
Absidia PROPN - B-ORG 
coerulea - NOUN O 
was - VERB O 
evaluated - VERB O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
microsporus - NOUN O 
var - NOUN O 
. - PUNCT O 

An - DET O 
efficient - ADJ O 
biotransformation - NOUN O 
of - ADP O 
progesterone - NOUN O 
into - ADP O 
11α NOUN - B-DATE 
- - PUNCT O 
hydroxyprogesterone - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
var - NOUN O 
. - PUNCT O 

The - DET O 
antifungal - ADJ O 
activity - NOUN O 
of - ADP O 
the - DET O 
essential - ADJ O 
oils - NOUN O 
( - PUNCT O 
EOs - NOUN O 
) - PUNCT O 
of - ADP O 
Eucalyptus PROPN - B-ORG 
staigeriana - NOUN O 
, - PUNCT O 
Lippia PROPN - B-GPE 
sidoides - NOUN O 
and - CCONJ O 
Pimenta PROPN - B-GPE 
pseudocaryophyllus - NOUN O 
was - VERB O 
tested - VERB O 
in - ADP O 
vitro - NOUN O 
against - ADP O 
plant - NOUN O 
pathogen - NOUN O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
. - PUNCT O 

Control - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
in - ADP O 
strawberries - NOUN O 
by - ADP O 
the - DET O 
combination - NOUN O 
of - ADP O 
essential - ADJ O 
oil - NOUN O 
with - ADP O 
carboxymethylcellulose - NOUN O 
. - PUNCT O 

Morphological - ADJ O 
findings - NOUN O 
are - VERB O 
linked - VERB O 
to - ADP O 
Rhizopus NOUN - B-MEDICINE 
infection - NOUN O 
( - PUNCT O 
Mucormycosis)NECROTIZING PROPN - B-ORG 
MYOCTIC PROPN - I-ORG 
ACUTE PROPN - I-ORG 
OSTEOMYELITIS.Surgical PROPN - I-ORG 
treatment - NOUN O 
: - PUNCT O 
Radical - ADJ O 
debridement - ADJ O 
with - ADP O 
removal - NOUN O 
of - ADP O 
surgical - ADJ O 
material - NOUN O 
. - PUNCT O 

Mucormycosis NOUN - B-ORG 
is - VERB O 
a - DET O 
serious - ADJ O 
infection - NOUN O 
caused - VERB O 
by - ADP O 
fungi - NOUN O 
of - ADP O 
the - DET O 
order - NOUN O 
Mucorales PROPN - B-PERSON 
, - PUNCT O 
of - ADP O 
which - ADJ O 
the - DET O 
most - ADV O 
important - ADJ O 
family - NOUN O 
is - VERB O 
that - DET O 
of - ADP O 
the - DET O 
Mucoraceae PROPN - B-ORG 
, - PUNCT O 
which - ADJ O 
includes - VERB O 
the - DET O 
genera - NOUN O 
Rhizopus PROPN - B-MEDICINE 
, - PUNCT O 
Mucor PROPN - B-ORG 
and - CCONJ O 
Absidia PROPN - B-ORG 
. - PUNCT O 

The - DET O 
team - NOUN O 
is - VERB O 
using - VERB O 
the - DET O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
NRRL PROPN - B-ORG 
395 - NUM O 
bacteria - NOUN O 
for - ADP O 
the - DET O 
fermentation - NOUN O 
of - ADP O 
the - DET O 
glycerol - NOUN O 
. - PUNCT O 

Modeling - VERB O 
tool - NOUN O 
using - VERB O 
neural - ADJ O 
networks - NOUN O 
for - ADP O 
L(+)-lactic ADJ - B-ORG 
acid - NOUN O 
production - NOUN O 
by - ADP O 
pellet - NOUN O 
- - PUNCT O 
form - NOUN O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
NRRL PROPN - B-ORG 
395 - NUM O 
on - ADP O 
biodiesel - NOUN O 
crude - ADJ O 
glycerol - NOUN O 
. - PUNCT O 

Mucormycosis NOUN - B-ORG 
is - VERB O 
a - DET O 
life - NOUN O 
- - PUNCT O 
threatening - VERB O 
respiratory - ADJ O 
fungal - ADJ O 
infection - NOUN O 
predominantly - ADV O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

Here - ADV O 
we - PRON O 
show - VERB O 
how - ADV O 
, - PUNCT O 
as - ADP O 
opposed - VERB O 
to - ADP O 
other - ADJ O 
filamentous - ADJ O 
fungi - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

Mechanistically - ADV O 
, - PUNCT O 
lack - NOUN O 
of - ADP O 
intracellular - ADJ O 
swelling - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
conidia - NOUN O 
results - NOUN O 
in - ADP O 
surface - NOUN O 
retention - NOUN O 
of - ADP O 
melanin - NOUN O 
, - PUNCT O 
which - ADJ O 
induces - VERB O 
phagosome - ADJ O 
maturation - NOUN O 
arrest - VERB O 
through - ADP O 
inhibition - NOUN O 
of - ADP O 
LC3-associated - PROPN O 
phagocytosis - NOUN O 
. - PUNCT O 

Intracellular - ADJ O 
inhibition - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
important - ADJ O 
effector - NOUN O 
mechanism - NOUN O 
, - PUNCT O 
as - ADP O 
infection - NOUN O 
of - ADP O 
immunocompetent - ADJ O 
mice - NOUN O 
with - ADP O 
swollen - ADJ O 
conidia - NOUN O 
, - PUNCT O 
which - ADJ O 
evade - VERB O 
phagocytosis - NOUN O 
, - PUNCT O 
results - NOUN O 
in - ADP O 
acute - ADJ O 
lethality - NOUN O 
. - PUNCT O 

Host - NOUN O 
and - CCONJ O 
pathogen - NOUN O 
transcriptomics - NOUN O 
, - PUNCT O 
iron - NOUN O 
supplementation - NOUN O 
studies - NOUN O 
, - PUNCT O 
and - CCONJ O 
genetic - ADJ O 
manipulation - NOUN O 
of - ADP O 
iron - NOUN O 
assimilation - NOUN O 
of - ADP O 
fungal - ADJ O 
pathways - NOUN O 
demonstrate - VERB O 
that - ADP O 
iron - NOUN O 
restriction - NOUN O 
inside - ADP O 
macrophages - NOUN O 
regulates - VERB O 
immunity - NOUN O 
against - ADP O 
Rhizopus PROPN - B-MEDICINE 
. - PUNCT O 

Pyogranulomatous - ADJ O 
obliterative - ADJ O 
laryngotracheitis - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
( - PUNCT O 
syn - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
microsporus - NOUN O 
is - VERB O 
one - NUM O 
of - ADP O 
the - DET O 
main - ADJ O 
causative - ADJ O 
agents - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
the - DET O 
antifungal - ADJ O 
potential - NOUN O 
of - ADP O 
a - DET O 
phenolic - NOUN O 
extract - NOUN O 
obtained - VERB O 
from - ADP O 
rice - NOUN O 
bran - NOUN O 
fermented - VERB O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
CECT - PROPN O 
7560 - NUM O 
and - CCONJ O 
its - ADJ O 
application - NOUN O 
in - ADP O 
the - DET O 
elaboration - NOUN O 
of - ADP O 
bread - NOUN O 
was - VERB O 
assessed - VERB O 
. - PUNCT O 

Antifungal - ADJ O 
effect - NOUN O 
of - ADP O 
phenolic - NOUN O 
extract - NOUN O 
of - ADP O 
fermented - ADJ O 
rice - NOUN O 
bran - NOUN O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
and - CCONJ O 
its - ADJ O 
potential - ADJ O 
use - NOUN O 
in - ADP O 
loaf - ADJ O 
bread - NOUN O 
shelf - NOUN O 
life - NOUN O 
extension - NOUN O 

Fresh - ADJ O 
tofu - NOUN O 
was - VERB O 
fermented - VERB O 
by - ADP O 
Actinomucor PROPN - B-ORG 
elegans - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - NOUN O 
, - PUNCT O 
Mucor PROPN - B-ORG 
racemosus - NOUN O 
, - PUNCT O 
and - CCONJ O 
Rhizopus NOUN - B-MEDICINE 
chinensis - NOUN O 
, - PUNCT O 
either - CCONJ O 
alone - ADV O 
or - CCONJ O 
in - ADP O 
various - ADJ O 
combinations - NOUN O 
. - PUNCT O 

Oral - ADJ O 
mucormycosis - NOUN O 
due - ADP O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
manifested - VERB O 
as - ADP O 
localized - VERB O 
left - ADJ O 
buccal - ADJ O 
mucositis - NOUN O 
with - ADP O 
a - DET O 
1-cm NUM - B-NORP 
black - ADJ O 
focus - NOUN O 
before - ADP O 
neutrophil - NOUN O 
recovery - NOUN O 
. - PUNCT O 

Due - ADP O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
after - ADP O 
Allogeneic PROPN - B-ORG 
Stem PROPN - I-ORG 
Cell PROPN - I-ORG 
Transplantation PROPN - I-ORG 
. - PUNCT O 

Herein PROPN - B-ORG 
, - PUNCT O 
a - DET O 
facile - ADJ O 
one NUM - B-CARDINAL 
- - PUNCT O 
pot - NOUN O 
synthetic - ADJ O 
method - NOUN O 
was - VERB O 
explored - VERB O 
for - ADP O 
the - DET O 
fabrication - NOUN O 
of - ADP O 
glutathione - ADJ O 
capped - VERB O 
Mn2 - PROPN O 
+ - CCONJ O 
doped‑zinc - NOUN O 
sulphide - VERB O 
quantum - NOUN O 
dots - NOUN O 
( - PUNCT O 
GSH - PROPN O 
- - PUNCT O 
Mn2 - PROPN O 
+ - CCONJ O 
-ZnS - PROPN O 
QDs - PROPN O 
) - PUNCT O 
for - ADP O 
both - CCONJ O 
fluorescent - ADJ O 
detection - NOUN O 
of - ADP O 
Cu2 - NOUN O 
+ - CCONJ O 
and - CCONJ O 
Hg2 - PROPN O 
+ - CCONJ O 
ions - NOUN O 
and - CCONJ O 
for - ADP O 
fluorescence - NOUN O 
imaging - NOUN O 
of - ADP O 
two NUM - B-CARDINAL 
cancer - NOUN O 
( - PUNCT O 
RIN5F PROPN - B-GPE 
and - CCONJ O 
MDAMB231 - PROPN O 
) - PUNCT O 
and - CCONJ O 
fungal - ADJ O 
( - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
) - PUNCT O 
cells - NOUN O 
. - PUNCT O 

The - DET O 
GSH PROPN - B-ORG 
- - PUNCT O 
Mn2 - PROPN O 
+ - CCONJ O 
-ZnS - PUNCT O 
QDs - NOUN O 
exhibit - NOUN O 
least - ADJ O 
cytotoxicity - NOUN O 
against - ADP O 
RIN5F PROPN - B-GPE 
and - CCONJ O 
MDAMB231 - NOUN O 
cells - NOUN O 
, - PUNCT O 
demonstrating - VERB O 
the - DET O 
multifunctional - ADJ O 
applications - NOUN O 
in - ADP O 
sensing - NOUN O 
of - ADP O 
metal - NOUN O 
ions - NOUN O 
and - CCONJ O 
biocompatibility - NOUN O 
towards - ADP O 
cancer - NOUN O 
( - PUNCT O 
RIN5F VERB - B-GPE 
and - CCONJ O 
MDAMB231 - PROPN O 
) - PUNCT O 
and - CCONJ O 
fungal - ADJ O 
( - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
) - PUNCT O 
cells - NOUN O 
. - PUNCT O 

The - DET O 
rice - NOUN O 
seedling - NOUN O 
blight - ADJ O 
fungus - NOUN O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
weakens - VERB O 
or - CCONJ O 
kills - VERB O 
plants - NOUN O 
by - ADP O 
means - NOUN O 
of - ADP O 
a - DET O 
potent - ADJ O 
toxin - NOUN O 
produced - VERB O 
by - ADP O 
endobacteria - NOUN O 
( - PUNCT O 
Burkholderia PROPN - B-NORP 
rhizoxinica - NOUN O 
) - PUNCT O 
that - ADJ O 
live - VERB O 
within - ADP O 
the - DET O 
fungal - ADJ O 
hyphae - NOUN O 
. - PUNCT O 

cluster - NOUN O 
that - ADJ O 
is - VERB O 
conserved - VERB O 
among - ADP O 
all - DET O 
sequenced - VERB O 
Rhizopus PROPN - B-MEDICINE 
endosymbionts - NOUN O 
. - PUNCT O 

Through - ADP O 
in - ADP O 
vitro - X O 
and - CCONJ O 
in - ADP O 
vivo - NOUN O 
assays - NOUN O 
we - PRON O 
found - VERB O 
that - ADP O 
holrhizin - NOUN O 
acts - VERB O 
( - PUNCT O 
A - NOUN O 
) - PUNCT O 
as - ADP O 
a - DET O 
biosurfactant - NOUN O 
to - PART O 
reduce - VERB O 
surface - NOUN O 
tension - NOUN O 
, - PUNCT O 
( - PUNCT O 
B - NOUN O 
) - PUNCT O 
influences - VERB O 
the - DET O 
formation - NOUN O 
of - ADP O 
mature - ADJ O 
biofilms - NOUN O 
and - CCONJ O 
thus - ADV O 
cell - NOUN O 
motility - NOUN O 
behavior - NOUN O 
that - ADJ O 
ultimately - ADV O 
supports - VERB O 
the - DET O 
bacterial - ADJ O 
cells - NOUN O 
to - ADP O 
( - PUNCT O 
C - NOUN O 
) - PUNCT O 
colonize - VERB O 
and - CCONJ O 
invade - VERB O 
the - DET O 
fungal - ADJ O 
host - NOUN O 
, - PUNCT O 
consequently - ADV O 
supporting - VERB O 
the - DET O 
re - NOUN O 
- - NOUN O 
establishment - NOUN O 
of - ADP O 
the - DET O 
exceptional - ADJ O 
Burkholderia PROPN - B-GPE 
- - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
symbiosis - NOUN O 
. - PUNCT O 

There - ADV O 
was - VERB O 
concern - NOUN O 
that - ADP O 
excretion - NOUN O 
of - ADP O 
iron - NOUN O 
via - ADP O 
the - DET O 
peritoneal - ADJ O 
dialysate - NOUN O 
may - VERB O 
raise - VERB O 
the - DET O 
risk - NOUN O 
of - ADP O 
iron - NOUN O 
- - PUNCT O 
dependent - ADJ O 
infections - NOUN O 
( - PUNCT O 
Yersinia PROPN - B-PERSON 
and - CCONJ O 
Rhizopus).Whilst PROPN - B-PERSON 
receiving - VERB O 
Exjade - PROPN O 
1000 NUM - B-CARDINAL 
mg - NOUN O 
/day - NUM O 
, - PUNCT O 
a - DET O 
total - ADJ O 
collection - NOUN O 
of - ADP O 
12.7L NUM - B-DATE 
of - ADP O 
peritoneal - ADJ O 
dialysate - NOUN O 
was - VERB O 
collected - VERB O 
over - ADP O 
a - DET O 
24 NUM - B-TIME 
hour NOUN - I-TIME 
period - NOUN O 
by - ADP O 
the - DET O 
patient - NOUN O 
. - PUNCT O 

Whilst - ADP O 
only - ADV O 
moderately - ADV O 
effective - ADJ O 
at - ADP O 
a - DET O 
dosage - NOUN O 
of - ADP O 
1000mg NUM - B-DATE 
/ SYM - I-DATE 
day NOUN - I-DATE 
, - PUNCT O 
deferasirox - NOUN O 
may - VERB O 
be - VERB O 
a - DET O 
safe - ADJ O 
agent - NOUN O 
for - ADP O 
iron - NOUN O 
removal - NOUN O 
in - ADP O 
iron - NOUN O 
overloaded - VERB O 
peritoneal - ADJ O 
dialysis - NOUN O 
patients - NOUN O 
, - PUNCT O 
as - ADP O 
relatively - ADV O 
low - ADJ O 
dialysate - NOUN O 
iron - NOUN O 
levels - NOUN O 
reduces - VERB O 
the - DET O 
risk - NOUN O 
of - ADP O 
Yersinia PROPN - B-GPE 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
infection - NOUN O 
. - PUNCT O 

The - DET O 
effect - NOUN O 
of - ADP O 
β - ADJ O 
- - PUNCT O 
aminobutyric - NOUN O 
acid - NOUN O 
( - PUNCT O 
BABA - PROPN O 
) - PUNCT O 
on - ADP O 
Rhizopus PROPN - B-MEDICINE 
rot - PROPN O 
produced - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
in - ADP O 
harvested - VERB O 
peaches - NOUN O 
and - CCONJ O 
the - DET O 
possible - ADJ O 
action - NOUN O 
modes - NOUN O 
were - VERB O 
investigated - VERB O 
. - PUNCT O 

Thus - ADV O 
, - PUNCT O 
our - ADJ O 
results - NOUN O 
demonstrated - VERB O 
that - ADP O 
BABA - PROPN O 
was - VERB O 
effective - ADJ O 
on - ADP O 
controlling - VERB O 
Rhizopus PROPN - B-MEDICINE 
rot - VERB O 
by - ADP O 
inducing - VERB O 
disease - NOUN O 
resistance - NOUN O 
, - PUNCT O 
which - ADJ O 
includes - VERB O 
the - DET O 
increase - NOUN O 
in - ADP O 
gene - NOUN O 
transcription - NOUN O 
and - CCONJ O 
activity - NOUN O 
of - ADP O 
defense - NOUN O 
- - PUNCT O 
related - VERB O 
enzymes - NOUN O 
, - PUNCT O 
the - DET O 
enhancement - NOUN O 
of - ADP O 
cell - NOUN O 
wall - NOUN O 
strength - NOUN O 
, - PUNCT O 
and - CCONJ O 
the - DET O 
maintenance - NOUN O 
of - ADP O 
high - ADJ O 
energy - NOUN O 
status - NOUN O 
in - ADP O 
Prunus PROPN - B-GPE 
persica NOUN - I-GPE 
fruit - NOUN O 
. - PUNCT O 

In - ADP O 
the - DET O 
fungal - ADJ O 
microbiome - NOUN O 
, - PUNCT O 
a - DET O 
decrease - NOUN O 
in - ADP O 
the - DET O 
abundance - NOUN O 
of - ADP O 
Mortierella PROPN - B-ORG 
, PUNCT - I-ORG 
Rhizopus PROPN - I-MEDICINE 
, - PUNCT O 
Kluyveromyces PROPN - B-ORG 
, - PUNCT O 
Embellisia PROPN - B-ORG 
and - CCONJ O 
Haematonectria PROPN - B-GPE 
and - CCONJ O 
an - DET O 
increase - NOUN O 
in - ADP O 
the - DET O 
abundance - NOUN O 
of - ADP O 
pathogenic - ADJ O 
fungi - NOUN O 
Aspergillus PROPN - B-PERSON 
and - CCONJ O 
Malassezia PROPN - B-NORP 
were - VERB O 
observed - VERB O 
in - ADP O 
BK PROPN - B-ORG 
patients - NOUN O 
compared - VERB O 
to - ADP O 
HC PROPN - B-ORG 
. - PUNCT O 

[ - PUNCT O 
Clinical - ADJ O 
features - NOUN O 
of - ADP O 
cutaneous - ADJ O 
infection - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
with - ADP O 
childhood - NOUN O 
acute - ADJ O 
lymphoblastic - ADJ O 
leukemia - NOUN O 
: - PUNCT O 
a - DET O 
case - NOUN O 
report]. - VERB O 

First ADJ - B-ORG 
Report PROPN - I-ORG 
of ADP - I-ORG 
Rhizopus PROPN - I-MEDICINE 
Head PROPN - I-ORG 
Rot PROPN - I-ORG 
of ADP - I-ORG 
Sunflower PROPN - I-ORG 
Caused VERB - I-ORG 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
( - PUNCT O 
syn - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
oligosporus - NOUN O 
, - PUNCT O 
a - DET O 
fungus - NOUN O 
in - ADP O 
the - DET O 
family - NOUN O 
Mucoraceae PROPN - B-ORG 
, - PUNCT O 
is - VERB O 
widely - ADV O 
used - VERB O 
as - ADP O 
a - DET O 
starter - NOUN O 
for - ADP O 
homemade - ADJ O 
tempeh - NOUN O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Tempeh - PROPN O 
Fermentation - PROPN O 
with - ADP O 
Lactobacillus - PROPN O 
Plantarum - PROPN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
Oligosporus - PROPN O 
on - ADP O 
Streptozotocin - PROPN O 
- - PUNCT O 
Induced - PROPN O 
Type - PROPN O 
II - PROPN O 
Diabetes - NOUN O 
Mellitus - PROPN O 
in - ADP O 
Rats - PROPN O 

The - DET O 
ability - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
to - PART O 
produce - VERB O 
fumaric - ADJ O 
acid - NOUN O 
in - ADP O 
the - DET O 
presence - NOUN O 
of - ADP O 
glycerol - NOUN O 
and/or - CCONJ O 
various - ADJ O 
monosaccharides - NOUN O 
as - ADP O 
carbon - NOUN O 
sources - NOUN O 
was - VERB O 
examined - VERB O 
for - ADP O 
seventeen NUM - B-CARDINAL 
different - ADJ O 
strains - NOUN O 
of - ADP O 
this - DET O 
fungi - NOUN O 
. - PUNCT O 

The - DET O 
production - NOUN O 
of - ADP O 
fumaric - ADJ O 
acid - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
was - VERB O 
also - ADV O 
increased - VERB O 
in - ADP O 
the - DET O 
dual - ADJ O 
presence - NOUN O 
of - ADP O 
glycerol - NOUN O 
and - CCONJ O 
monosaccharides - NOUN O 
like - ADP O 
fructose - NOUN O 
, - PUNCT O 
galactose - ADJ O 
, - PUNCT O 
and - CCONJ O 
mannose - NOUN O 
. - PUNCT O 

Understanding - VERB O 
how - ADV O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
utilize - VERB O 
various - ADJ O 
carbon - NOUN O 
sources - NOUN O 
may - VERB O 
provide - VERB O 
alternative - ADJ O 
avenues - NOUN O 
of - ADP O 
fumaric - ADJ O 
acid - NOUN O 
fermentation - NOUN O 
. - PUNCT O 

A - DET O 
co - NOUN O 
- - NOUN O 
utilization - NOUN O 
strategy - NOUN O 
to - PART O 
consume - VERB O 
glycerol - NOUN O 
and - CCONJ O 
monosaccharides - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
strains - NOUN O 
for - ADP O 
fumaric - ADJ O 
acid - NOUN O 
production - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
delemar - NOUN O 
is - VERB O 
an - DET O 
invasive - ADJ O 
fungal - ADJ O 
pathogen - NOUN O 
responsible - ADJ O 
for - ADP O 
the - DET O 
frequently - ADV O 
fatal - ADJ O 
disease - NOUN O 
mucormycosis - NOUN O 
. - PUNCT O 

Germination - PROPN O 
, - PUNCT O 
a - DET O 
crucial - ADJ O 
mechanism - NOUN O 
by - ADP O 
which - ADJ O 
infectious - ADJ O 
spores - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
cause - NOUN O 
disease - NOUN O 
, - PUNCT O 
is - VERB O 
a - DET O 
key - ADJ O 
developmental - ADJ O 
process - NOUN O 
that - ADJ O 
transforms - VERB O 
the - DET O 
dormant - ADJ O 
spore - ADJ O 
state - NOUN O 
into - ADP O 
a - DET O 
vegetative - ADJ O 
one - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
provides - VERB O 
a - DET O 
greater - ADJ O 
understanding - NOUN O 
of - ADP O 
the - DET O 
regulation - NOUN O 
of - ADP O 
germination - NOUN O 
and - CCONJ O 
highlights - NOUN O 
processes - NOUN O 
involved - VERB O 
in - ADP O 
transforming - VERB O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
from - ADP O 
a - DET O 
single - ADJ O 
- - PUNCT O 
cellular - ADJ O 
to - ADP O 
multicellular - ADJ O 
organism - NOUN O 
. - PUNCT O 

Silkworm - NOUN O 
infection - NOUN O 
models - NOUN O 
have - VERB O 
been - VERB O 
established - VERB O 
for - ADP O 
Candida PROPN - B-GPE 
albicans - NOUN O 
, - PUNCT O 
Candida - PROPN O 
tropicalis - NOUN O 
, - PUNCT O 
Candida - PROPN O 
glabrata - NOUN O 
and - CCONJ O 
Cryptococcus PROPN - B-ORG 
neoformans - NOUN O 
, - PUNCT O 
which - ADJ O 
are - VERB O 
yeast - NOUN O 
type - NOUN O 
fungi - NOUN O 
, - PUNCT O 
and - CCONJ O 
Aspergillus PROPN - B-ORG 
fumigatus - NOUN O 
, - PUNCT O 
Arthroderma PROPN - B-ORG 
vanbreuseghemii - NOUN O 
, - PUNCT O 
Arthroderma - PROPN O 
benhamiae - VERB O 
, - PUNCT O 
Microsporum PROPN - B-PERSON 
canis - NOUN O 
, - PUNCT O 
Trichophyton PROPN - B-GPE 
rubrum - NOUN O 
, - PUNCT O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
which - ADJ O 
are - VERB O 
filamentous - ADJ O 
fungi - NOUN O 
. - PUNCT O 

Improvement - NOUN O 
of - ADP O 
enzymatic - ADJ O 
properties - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
α - PUNCT O 
- - PUNCT O 
amylase - NOUN O 
by - ADP O 
site - NOUN O 
- - PUNCT O 
saturation - NOUN O 
mutagenesis - NOUN O 
of - ADP O 
histidine - NOUN O 
286 NUM - B-CARDINAL 
. - PUNCT O 

The - DET O 
strains - NOUN O 
were - VERB O 
identified - VERB O 
as - ADP O 
Aspergillus - PROPN O 
fumigatus - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
sp - PART O 
. - PUNCT O 

The DET - B-WORK_OF_ART 
Rhizopus PROPN - I-MEDICINE 
Sp PROPN - I-WORK_OF_ART 
. - PUNCT O 

Beneficial - ADJ O 
effects - NOUN O 
of - ADP O 
extracellular - ADJ O 
polysaccharide - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
on - ADP O 
the - DET O 
intestinal - ADJ O 
immunity - NOUN O 
of - ADP O 
colorectal - ADJ O 
cancer - NOUN O 
mice - NOUN O 
. - PUNCT O 

Cutaneous - ADJ O 
mucormycosis - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
in - ADP O 
an - DET O 
immunocompetent - ADJ O 
patient - NOUN O 
: - PUNCT O 
A - DET O 
case - NOUN O 
report - NOUN O 
and - CCONJ O 
review - NOUN O 
of - ADP O 
literature - NOUN O 
. - PUNCT O 

Mucorales - ADJ O 
species - NOUN O 
were - VERB O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - VERB O 
in - ADP O 
16 NUM - B-CARDINAL 
( - PUNCT O 
84 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
cases - NOUN O 
, - PUNCT O 
R. PROPN - B-PERSON 
  SPACE - I-PERSON 
arrhizus - NOUN O 
/ - SYM O 

Amylomyces - PROPN O 
rouxii - VERB O 
in - ADP O 
2 NUM - B-CARDINAL 
( - PUNCT O 
10.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
cases - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
in - ADP O 
one NUM - B-CARDINAL 
case - NOUN O 
( - PUNCT O 
5.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Anti - ADJ O 
- - ADJ O 
Rhizopus ADJ - B-MEDICINE 
activity - NOUN O 
of - ADP O 
tanzawaic - NOUN O 
acids - NOUN O 
produced - VERB O 
by - ADP O 
the - DET O 
hot - ADJ O 
spring - NOUN O 
- - PUNCT O 
derived - VERB O 
fungus - NOUN O 
Penicillium - PROPN O 
sp - VERB O 
. - PUNCT O 

Continuous - ADJ O 
ethyl - ADV O 
oleate - ADJ O 
synthesis - NOUN O 
by - ADP O 
lipases - NOUN O 
produced - VERB O 
by - ADP O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
. - PUNCT O 

Bioconversion - NOUN O 
of - ADP O 
waste - NOUN O 
cooking - NOUN O 
oil - NOUN O 
glycerol - NOUN O 
from - ADP O 
cabbage - NOUN O 
extract - NOUN O 
to - ADP O 
lactic - ADJ O 
acid - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
. - PUNCT O 

Improved - VERB O 
continuous - ADJ O 
fumaric - ADJ O 
acid - NOUN O 
production - NOUN O 
with - ADP O 
immobilised - ADJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
by - ADP O 
implementation - NOUN O 
of - ADP O 
a - DET O 
revised - VERB O 
nitrogen - NOUN O 
control - NOUN O 
strategy - NOUN O 
. - PUNCT O 

Monohexosylceramides - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
Species - PROPN O 
Isolated - VERB O 
from - ADP O 
Brazilian ADJ - B-NORP 
Caatinga PROPN - B-PERSON 
: - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
oligosporus - NOUN O 
and - CCONJ O 
Lactobacillus PROPN - B-ORG 
plantarum - NOUN O 
were - VERB O 
the - DET O 
probiotic - ADJ O 
FDA PROPN - B-ORG 
- - PUNCT O 
approved - VERB O 
food - NOUN O 
- - PUNCT O 
grade - NOUN O 
cultures - NOUN O 
used - VERB O 
in - ADP O 
this - DET O 
study - NOUN O 
. - PUNCT O 

( - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
the - DET O 
biocatalysis - NOUN O 
of - ADP O 
18β NOUN - B-DATE 
- - PUNCT O 
glycyrrhetinic - NOUN O 
acid - NOUN O 
by - ADP O 
two NUM - B-CARDINAL 
strains - NOUN O 
of - ADP O 
filamentous - ADJ O 
fungi - NOUN O 
, - PUNCT O 
namely - ADV O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - VERB O 
AS ADP - B-ORG 
3.2893 NUM - B-PRODUCT 
and - CCONJ O 
Circinella PROPN - B-PERSON 
muscae - NOUN O 
AS - ADP O 
3.2695 - NUM O 
, - PUNCT O 
was - VERB O 
investigated - VERB O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
arrhizus - VERB O 
RH - PROPN O 

Phylogenetic - ADJ O 
analysis - NOUN O 
of - ADP O 
the - DET O 
sequences - NOUN O 
confirmed - VERB O 
the - DET O 
presence - NOUN O 
of - ADP O 
the - DET O 
species - NOUN O 
Gilbertella - PROPN O 
persicaria - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
, - PUNCT O 
Mucor PROPN - B-ORG 
circinelloides - NOUN O 
and - CCONJ O 
Mucor PROPN - B-ORG 
hiemalis - NOUN O 
, - PUNCT O 
which - ADJ O 
cause - VERB O 
soft - ADJ O 
rot - NOUN O 
in - ADP O 
papaya - ADJ O 
fruits - NOUN O 
, - PUNCT O 
therefore - ADV O 
, - PUNCT O 
spores - NOUN O 
of - ADP O 
these - DET O 
fungi - NOUN O 
found - VERB O 
in - ADP O 
the - DET O 
orchard - NOUN O 
soils - NOUN O 
can - VERB O 
be - VERB O 
considered - VERB O 
as - ADP O 
a - DET O 
constant - ADJ O 
source - NOUN O 
of - ADP O 
contamination - NOUN O 
that - ADJ O 
affects - VERB O 
healthy - ADJ O 
fruits - NOUN O 
. - PUNCT O 

Additionally - ADV O 
, - PUNCT O 
Choanephora PROPN - B-PERSON 
cucurbitarum - NOUN O 
, - PUNCT O 
Mucor PROPN - B-ORG 
ellipsoideus - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
homothallicus - PROPN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
schipperae - NOUN O 
, - PUNCT O 
Lichteimia PROPN - B-PERSON 
ramosa - NOUN O 
, - PUNCT O 
Gongronella PROPN - B-PERSON 
butleri - NOUN O 
, - PUNCT O 

In - ADP O 
this - DET O 
work - NOUN O 
, - PUNCT O 
a - DET O 
dual - ADV O 
- - PUNCT O 
limited - VERB O 
growth - NOUN O 
model - NOUN O 
of - ADP O 
P. PROPN - B-ORG 
pastoris - NOUN O 
considering - VERB O 
an - DET O 
interactive - ADJ O 
kinetic - ADJ O 
effect - NOUN O 
was - VERB O 
applied - VERB O 
to - ADP O 
an - DET O 
optimised - VERB O 
fed - VERB O 
- - PUNCT O 
batch - NOUN O 
process - NOUN O 
production - NOUN O 
of - ADP O 
heterologous - ADJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
lipase - NOUN O 
( - PUNCT O 
ROL PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

To - PART O 
investigate - VERB O 
the - DET O 
transcriptional - ADJ O 
regulation - NOUN O 
of - ADP O 
cellobiose - NOUN O 
synthase - NOUN O 
( - PUNCT O 
CBS PROPN - B-ORG 
) - PUNCT O 
in - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
. - PUNCT O 

Emerging - PROPN O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
Infections - PROPN O 
in - ADP O 
India PROPN - B-GPE 
. - PUNCT O 

Eluates - NOUN O 
from - ADP O 
DNA - NOUN O 
extraction - NOUN O 
were - VERB O 
tested - VERB O 
by - ADP O 
MUC PROPN - B-ORG 
PCR PROPN - I-ORG 
, - PUNCT O 
which - ADJ O 
detects - VERB O 
known - ADJ O 
pathogens - NOUN O 
from - ADP O 
seven NUM - B-CARDINAL 
Mucorales - PROPN O 
genera - NOUN O 
( - PUNCT O 
Apophysomyces - PROPN O 
, - PUNCT O 
Cunninghamella PROPN - B-ORG 
, - PUNCT O 
Lichtheimia PROPN - B-NORP 
[ - PUNCT O 
previously - ADV O 
Absidia PROPN - B-ORG 
] - PUNCT O 
, - PUNCT O 
Mucor PROPN - B-ORG 
, - PUNCT O 
Rhizomucor PROPN - B-ORG 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
and - CCONJ O 
Saksenaea).ResultsThe - ADP O 
proportions - NOUN O 
of - ADP O 
MUC PROPN - B-PRODUCT 
PCR PROPN - I-PRODUCT 
and - CCONJ O 
ASP PROPN - B-ORG 
PCR - PROPN O 
positive - ADJ O 
BAL - PROPN O 
specimens - NOUN O 
were - VERB O 
1.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
16 NUM - B-CARDINAL 
) - PUNCT O 
and - CCONJ O 
6.9 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
74 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

The - DET O 
effect - NOUN O 
of - ADP O 
temperature - NOUN O 
on - ADP O 
the - DET O 
mycelium - NOUN O 
growth - NOUN O 
kinetics - NOUN O 
of - ADP O 
four NUM - B-CARDINAL 
postharvest - ADJ O 
fungal - ADJ O 
isolates - NOUN O 
( - PUNCT O 
i.e. - X O 
, - PUNCT O 
Penicillium - PROPN O 
expansum - NOUN O 
, - PUNCT O 
Alternaria PROPN - B-PERSON 
alternata - NOUN O 
, - PUNCT O 
Botrytis PROPN - B-ORG 
cinerea - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - PROPN O 
) - PUNCT O 
was - VERB O 
assessed - VERB O 
. - PUNCT O 

Solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
and - CCONJ O 
Yarrowia PROPN - B-GPE 
lipolytica - NOUN O 
improved - VERB O 
nutritional - ADJ O 
and - CCONJ O 
flavour - ADJ O 
properties - NOUN O 
of - ADP O 
okara - NOUN O 

Furthermore - ADV O 
, - PUNCT O 
DKxanthenes PROPN - B-ORG 
showed - VERB O 
growth - NOUN O 
inhibitory - NOUN O 
activity - NOUN O 
against - ADP O 
the - DET O 
fungi - NOUN O 
Aspergillus ADV - B-ORG 
niger - ADV O 
, - PUNCT O 
Candida PROPN - B-GPE 
albicans - NOUN O 
, - PUNCT O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
. - PUNCT O 

Filamentous - ADJ O 
fungi - NOUN O 
are - VERB O 
the - DET O 
predominant - NOUN O 
microorganisms - NOUN O 
used - VERB O 
to - PART O 
produce - VERB O 
organic - ADJ O 
acids - NOUN O 
, - PUNCT O 
including - VERB O 
fumaric - ADJ O 
acid - NOUN O 
, - PUNCT O 
and - CCONJ O 
most - ADJ O 
studies - NOUN O 
to - ADP O 
date - NOUN O 
have - VERB O 
focused - VERB O 
on - ADP O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

While - ADP O 
10 NUM - B-CARDINAL 
diseases - NOUN O 
are - VERB O 
surveyed - VERB O 
annually ADV - B-DATE 
, - PUNCT O 
we - PRON O 
focus - VERB O 
this - DET O 
article - NOUN O 
on - ADP O 
the - DET O 
importance - NOUN O 
, - PUNCT O 
findings - NOUN O 
, - PUNCT O 
implications - NOUN O 
, - PUNCT O 
and - CCONJ O 
impacts - NOUN O 
of - ADP O 
the - DET O 
five NUM - B-CARDINAL 
most - ADV O 
important - ADJ O 
: - PUNCT O 
downy - NOUN O 
mildew - NOUN O 
, - PUNCT O 
Phomopsis - NOUN O 
stem - NOUN O 
canker - NOUN O 
, - PUNCT O 
rust - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
head - NOUN O 
rot - PROPN O 
, - PUNCT O 
and - CCONJ O 
Sclerotinia PROPN - B-GPE 
head - NOUN O 
rot - VERB O 
. - PUNCT O 

Here - ADV O 
, - PUNCT O 
sterol - ADJ O 
patterns - NOUN O 
of - ADP O 
six NUM - B-CARDINAL 
clinically - ADV O 
relevant - ADJ O 
Mucorales PROPN - B-PERSON 
( - PUNCT O 
Lichtheimia - PROPN O 
corymbifera - NOUN O 
, - PUNCT O 
Lichtheimia PROPN - B-NORP 
ramosa - NOUN O 
, - PUNCT O 
Mucor PROPN - B-ORG 
circinelloides - VERB O 
, - PUNCT O 
Rhizomucor PROPN - B-ORG 
pusillus - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - NOUN O 
, - PUNCT O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
) - PUNCT O 
were - VERB O 
analysed - VERB O 
in - ADP O 
a - DET O 
targeted - VERB O 
metabolomics - NOUN O 
fashion - NOUN O 
after - ADP O 
derivatization - NOUN O 
by - ADP O 
gas - NOUN O 
chromatography - NOUN O 
- - PUNCT O 
mass - NOUN O 
spectrometry - NOUN O 
. - PUNCT O 

Piper - NOUN O 
Essential - ADJ O 
Oils - PROPN O 
Inhibit - PROPN O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
Growth - PROPN O 
, - PUNCT O 
Biofilm - PROPN O 
Formation - PROPN O 
, - PUNCT O 
and - CCONJ O 
Rhizopuspepsin PROPN - B-ORG 
Activity PROPN - I-ORG 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
quinoa - NOUN O 
was - VERB O 
fermented - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
( - PUNCT O 
R. PROPN - B-NORP 
oligosporus - NOUN O 
) - PUNCT O 
up - ADP O 
to - PART O 
5 NUM - B-CARDINAL 
  - SPACE O 
days NOUN - B-DATE 
and - CCONJ O 
the - DET O 
functional - ADJ O 
compounds - NOUN O 
( - PUNCT O 
L - NOUN O 
- - PUNCT O 
carnitine - NOUN O 
, - PUNCT O 
GABA PROPN - B-ORG 
, - PUNCT O 
vanillic - ADJ O 
acid - NOUN O 
and - CCONJ O 
gallic - ADJ O 
acid - NOUN O 
) - PUNCT O 
were - VERB O 
analyzed - VERB O 
by - ADP O 
LC PROPN - B-ORG 
/ SYM - I-ORG 
MS PROPN - I-ORG 
. - PUNCT O 

Tempeh - PROPN O 
products - NOUN O 
included - VERB O 
soybean - NOUN O 
fermented - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
, - PUNCT O 
soybean - NOUN O 
fermented - VERB O 
through - ADP O 
cocultivation - NOUN O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
and CCONJ - I-ORG 
Lactobacillus - PROPN O 
, - PUNCT O 
and - CCONJ O 
red - ADJ O 
bean - NOUN O 
fermented - VERB O 
through - ADP O 
cocultivation - NOUN O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
and - CCONJ O 
Lactobacillus - PROPN O 
( - PUNCT O 
RT - PROPN O 
- - PUNCT O 
C - PROPN O 
) - PUNCT O 
. - PUNCT O 

Spatiotemporal - ADJ O 
analyses - NOUN O 
of - ADP O 
rhizopus NOUN - B-MEDICINE 
rot - VERB O 
progress - NOUN O 
in - ADP O 
peach - NOUN O 
fruit - NOUN O 
inoculated - VERB O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 

In - ADP O 
this - DET O 
review - NOUN O 
we - PRON O 
summarize - VERB O 
recent - ADJ O 
advances - NOUN O 
in - ADP O 
genetic - ADJ O 
tools - NOUN O 
to - PART O 
study - VERB O 
the - DET O 
two NUM - B-CARDINAL 
most - ADV O 
prevalent - ADJ O 
and - CCONJ O 
genetically - ADV O 
amenable - ADJ O 
Mucoralean PROPN - B-NORP 
fungi - NOUN O 
, - PUNCT O 
Mucor PROPN - B-ORG 
circinelloides - VERB O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
. - PUNCT O 

However - ADV O 
, - PUNCT O 
only - ADV O 
a - DET O 
small - ADJ O 
amount - NOUN O 
of - ADP O 
lactic - ADJ O 
acid - NOUN O 
is - VERB O 
produced - VERB O 
even - ADV O 
though - ADP O 
Rhizopus NOUN - B-MEDICINE 
oryzae - NOUN O 
can - VERB O 
consume - VERB O 
glucose - NOUN O 
in - ADP O 
rice - NOUN O 
straw - NOUN O 
- - PUNCT O 
derived - VERB O 
hydrolysates - NOUN O 
. - PUNCT O 

PCggmt1 PROPN - B-PERSON 
was - VERB O 
further - ADV O 
used - VERB O 
to - PART O 
control - VERB O 
the - DET O 
expression - NOUN O 
of - ADP O 
lactate - ADJ O 
dehydrogenase - NOUN O 
gene - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
in - ADP O 
C. PROPN - B-GPE 
  SPACE - I-GPE 
glycerinogenes - NOUN O 
. - PUNCT O 

Mono - NOUN O 
- - PUNCT O 
culture - NOUN O 
fermentation - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
could - VERB O 
promote - VERB O 
the - DET O 
healthiness - NOUN O 
of - ADP O 
immune - ADJ O 
systems - NOUN O 
and - CCONJ O 
cholesterol - NOUN O 
levels - NOUN O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
dietary - ADJ O 
supplement - NOUN O 
from - ADP O 
mono - ADJ O 
- - PUNCT O 
culture - NOUN O 
fermentation - NOUN O 
of - ADP O 
Moringa PROPN - B-GPE 
oleifera - NOUN O 
seeds - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
on - ADP O 
hematology - NOUN O 
and - CCONJ O 
markers - NOUN O 
linked - VERB O 
to - PART O 
hypercholesterolemia - NOUN O 
in - ADP O 
rat - NOUN O 
model - NOUN O 
. - PUNCT O 

High - ADJ O 
- - PUNCT O 
level - NOUN O 
extracellular - ADJ O 
production - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
lipase - NOUN O 
in - ADP O 
Pichia PROPN - B-GPE 
pastoris - PROPN O 
via - ADP O 
a - DET O 
strategy - NOUN O 
combining - VERB O 
optimization - NOUN O 
of - ADP O 
gene - NOUN O 
- - PUNCT O 
copy - NOUN O 
number - NOUN O 
with - ADP O 
co - NOUN O 
- - NOUN O 
expression - NOUN O 
of - ADP O 
ERAD - PROPN O 
- - PUNCT O 
related - VERB O 
proteins - NOUN O 
. - PUNCT O 

A - DET O 
Noninvasive - PROPN O 
Rhizopus PROPN - B-MEDICINE 
Infection - PROPN O 
With - ADP O 
a - DET O 
Bladder - NOUN O 
Fungal - PROPN O 
Ball - PROPN O 
in - ADP O 
a - DET O 
Patient - PROPN O 
With - ADP O 
Poorly - ADV O 
Controlled - VERB O 
Diabetes - PROPN O 
Mellitus - PROPN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
oligosporus - NOUN O 
, - PUNCT O 
a - DET O 
fungus - NOUN O 
in - ADP O 
the - DET O 
family - NOUN O 
Mucoraceae PROPN - B-ORG 
, - PUNCT O 
is - VERB O 
widely - ADV O 
used - VERB O 
as - ADP O 
a - DET O 
starter - NOUN O 
for - ADP O 
homemade - ADJ O 
tempeh - NOUN O 
. - PUNCT O 

( - PUNCT O 
6.3 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

A - DET O 
metabolite - NOUN O 
screening - NOUN O 
was - VERB O 
conducted - VERB O 
by - ADP O 
adding - VERB O 
ZEN PROPN - B-ORG 
to - ADP O 
liquid - NOUN O 
fungi - ADJ O 
cultures - NOUN O 
of - ADP O 
known - ADJ O 
ZEN - PROPN O 
conjugating - VERB O 
Aspergillus PROPN - B-PERSON 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
strains - NOUN O 
. - PUNCT O 

In - ADP O 
addition - NOUN O 
, - PUNCT O 
a - DET O 
consecutive - ADJ O 
biosynthesis - NOUN O 
was - VERB O 
developed - VERB O 
by - ADP O 
using - VERB O 
Fusarium PROPN - B-ORG 
graminearum - NOUN O 
for - ADP O 
ZEN - PROPN O 
biosynthesis - NOUN O 
with - ADP O 
subsequent - ADJ O 
conjugation - NOUN O 
of - ADP O 
the - DET O 
toxin - NOUN O 
by - ADP O 
utilizing - VERB O 
Aspergillus PROPN - B-PERSON 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

( - PUNCT O 
yield - NOUN O 
: - PUNCT O 
67 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
and - CCONJ O 
ZEN-16-glucoside PROPN - B-PERSON 
( - PUNCT O 
yield - NOUN O 
: - PUNCT O 
39 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
are - VERB O 
formed - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
and - CCONJ O 
Rhizopusoligosporus PROPN - B-ORG 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
species - NOUN O 
are - VERB O 
the - DET O 
most - ADV O 
common - ADJ O 
cause - NOUN O 
of - ADP O 
the - DET O 
disease - NOUN O 
, - PUNCT O 
responsible - ADJ O 
for - ADP O 
approximately ADV - B-PERCENT 
70 NUM - I-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
all - DET O 
cases - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
. - PUNCT O 

During - ADP O 
pulmonary - ADJ O 
mucormycosis - NOUN O 
, - PUNCT O 
inhaled - VERB O 
Rhizopus PROPN - B-MEDICINE 
spores - NOUN O 
must - VERB O 
adhere - VERB O 
to - PART O 
and - CCONJ O 
invade - VERB O 
airway - ADJ O 
epithelial - ADJ O 
cells - NOUN O 
in - ADP O 
order - NOUN O 
to - PART O 
establish - VERB O 
infection - NOUN O 
. - PUNCT O 

We - PRON O 
performed - VERB O 
an - DET O 
unbiased - ADJ O 
survey - NOUN O 
of - ADP O 
the - DET O 
host - NOUN O 
transcriptional - ADJ O 
response - NOUN O 
during - ADP O 
early - ADJ O 
stages - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
var - NOUN O 
. - PUNCT O 

g - ADP O 
total - ADJ O 
weight - NOUN O 
basis - NOUN O 
) - PUNCT O 
showed - VERB O 
antimicrobial - ADJ O 
effects - NOUN O 
against - ADP O 
Bacillus - PROPN O 
cereus - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
sp - PROPN O 
. - PUNCT O 

Interestingly - ADV O 
, - PUNCT O 
the - DET O 
bread - NOUN O 
containing - VERB O 
chitooligosaccharides - NOUN O 
showed - VERB O 
a - DET O 
stronger - ADJ O 
inhibitory - ADJ O 
effect - NOUN O 
against - ADP O 
B. PROPN - B-PERSON 
cereus - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
sp - PROPN O 
. - PUNCT O 

compared - VERB O 
to - ADP O 
bread - NOUN O 
containing - VERB O 
chitosan - NOUN O 
and - CCONJ O 
control - NOUN O 
, - PUNCT O 
where - ADV O 
B. PROPN - B-PERSON 
cereus - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 

Here - ADV O 
, - PUNCT O 
an - DET O 
endo - NOUN O 
- - PUNCT O 
β - NOUN O 
- - PUNCT O 
mannanase - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
( - PUNCT O 
RmMan134A - PROPN O 
) - PUNCT O 
was - VERB O 
cloned - VERB O 
and - CCONJ O 
expressed - VERB O 
. - PUNCT O 

The - DET O 
majority - NOUN O 
of - ADP O 
fungal - ADJ O 
isolates - NOUN O 
belonged - VERB O 
to - ADP O 
Aspergillus - PROPN O 
flavus - NOUN O 
( - PUNCT O 
35 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
followed - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
( - PUNCT O 
13 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
and - CCONJ O 
Eurotium - PROPN O 
amstelodami - NOUN O 
( - PUNCT O 
9 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Using - VERB O 
the - DET O 
agar - NOUN O 
plate - NOUN O 
method - NOUN O 
, - PUNCT O 
Alternaria PROPN - B-PERSON 
alternata - NOUN O 
was - VERB O 
isolated - VERB O 
from - ADP O 
coriander - NOUN O 
seed - NOUN O 
lots - NOUN O 
together - ADV O 
with - ADP O 
four NUM - B-CARDINAL 
other - ADJ O 
fungal - ADJ O 
genera - NOUN O 
, - PUNCT O 
which - ADJ O 
included - VERB O 
Aspergillus PROPN - B-ORG 
, PUNCT - I-ORG 
Fusarium PROPN - I-ORG 
, PUNCT - I-ORG 
Penicillium PROPN - I-ORG 
and CCONJ - I-ORG 
Rhizopus PROPN - I-MEDICINE 
. - PUNCT O 

Under - ADP O 
optimal - ADJ O 
fermentation - NOUN O 
conditions - NOUN O 
, - PUNCT O 
the - DET O 
extractability - NOUN O 
of - ADP O 
β - ADJ O 
- - PUNCT O 
glucan - PROPN O 
in - ADP O 
oat - NOUN O 
bran - NOUN O 
increased - VERB O 
to - ADP O 
45.57 NUM - B-CARDINAL 
  - SPACE O 
± - X O 
  - SPACE O 
1.82 NUM - B-PERCENT 
% NOUN - I-PERCENT 
and - CCONJ O 
51.10 NUM - B-CARDINAL 
  - SPACE O 
± - PUNCT O 
  - SPACE O 
2.32 NUM - B-PERCENT 
% NOUN - I-PERCENT 
by - ADP O 
Aspergillus - NOUN O 
niger - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

niger - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
reduced - VERB O 
the - DET O 
molecular - ADJ O 
weight - NOUN O 
of - ADP O 
the - DET O 
extracted - VERB O 
β - DET O 
- - PUNCT O 
glucan - PROPN O 
from - ADP O 
6.74 NUM - B-MONEY 
  SPACE - I-MONEY 
× PROPN - I-MONEY 
  - SPACE O 
105 NUM - B-CARDINAL 
to - ADP O 
2.84 NUM - B-CARDINAL 
  - SPACE O 
× - PROPN O 
  - SPACE O 
105 NUM - B-CARDINAL 
and - CCONJ O 
2.20 NUM - B-CARDINAL 
  - SPACE O 
× - PROPN O 
  - SPACE O 

Peaches - NOUN O 
were - VERB O 
inoculated - VERB O 
with - ADP O 
three NUM - B-CARDINAL 
common - ADJ O 
spoilage - NOUN O 
fungi - NOUN O 
, - PUNCT O 
Botrytis PROPN - B-ORG 
cinerea - NOUN O 
, - PUNCT O 
Monilinia PROPN - B-GPE 
fructicola - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
and - CCONJ O 
then - ADV O 
stored - VERB O 
for - ADP O 
various - ADJ O 
periods - NOUN O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
high - ADJ O 
hydrostatic - ADJ O 
pressure - NOUN O 
on - ADP O 
Rhizopus PROPN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
: - PUNCT O 
II PROPN - B-ORG 
. - PUNCT O 

The - DET O 
species - NOUN O 
isolated - VERB O 
in - ADP O 
the - DET O 
mycological - ADJ O 
culture - NOUN O 
was - VERB O 
Rhizopus PROPN - B-MEDICINE 
sp - PART O 
. - PUNCT O 

We - PRON O 
report - VERB O 
a - DET O 
case - NOUN O 
of - ADP O 
rhinocerebral - ADJ O 
mucormycosis - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
var - NOUN O 
. - PUNCT O 

Most - ADJ O 
common - ADJ O 
fungus - NOUN O 
was - VERB O 
Aspergillus PROPN - B-ORG 
species - NOUN O 
( - PUNCT O 
31.1 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
followed - VERB O 
by - ADP O 
Fusarium PROPN - B-ORG 
species - NOUN O 
( - PUNCT O 
24.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Alternaria PROPN - B-ORG 
( - PUNCT O 
10.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Curvularia PROPN - B-PERSON 
( - PUNCT O 
10.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Helminthosporium - PROPN O 
( - PUNCT O 
5.7 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Bipolaris PROPN - B-PERSON 
( - PUNCT O 
5.4 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Penicillium - PROPN O 
( - PUNCT O 
4.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Candida PROPN - B-GPE 
( - PUNCT O 
4.4 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Acremonium - PROPN O 
( - PUNCT O 
1.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
( - PUNCT O 
1.0 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Paecilomyces - NOUN O 
( - PUNCT O 
0.8 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Rhodotorula PROPN - B-ORG 
( - PUNCT O 
0.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
and - CCONJ O 
Mucor PROPN - B-ORG 
( - PUNCT O 
0.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

The - DET O 
genus - ADJ O 
Rhizopus PROPN - B-MEDICINE 
is - VERB O 
the - DET O 
main - ADJ O 
cause - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
, - PUNCT O 
a - DET O 
life - NOUN O 
- - PUNCT O 
threatening - VERB O 
infection - NOUN O 
that - ADJ O 
affects - VERB O 
predominantly - ADV O 
hosts - NOUN O 
with - ADP O 
an - DET O 
impaired - VERB O 
immune - ADJ O 
system - NOUN O 
. - PUNCT O 

Genetic - ADJ O 
manipulation - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
is - VERB O 
critical - ADJ O 
for - ADP O 
identifying - VERB O 
fungal - ADJ O 
targets - NOUN O 
to - PART O 
develop - VERB O 
more - ADV O 
effective - ADJ O 
therapies - NOUN O 
. - PUNCT O 

However - ADV O 
, - PUNCT O 
Rhizopus NOUN - B-MEDICINE 
genetics - NOUN O 
are - VERB O 
challenging - VERB O 
because - ADP O 
of - ADP O 
lack - NOUN O 
of - ADP O 
dominant - ADJ O 
selection - NOUN O 
markers - NOUN O 
, - PUNCT O 
low - ADJ O 
efficiency - NOUN O 
of - ADP O 
transformation - NOUN O 
, - PUNCT O 
and - CCONJ O 
rarity - NOUN O 
of - ADP O 
chromosomal - ADJ O 
integration - NOUN O 
. - PUNCT O 

Optimization - NOUN O 
of - ADP O 
the - DET O 
CRISPR - PROPN O 
/ - SYM O 
Cas9 - PROPN O 
System - PROPN O 
to - PART O 
Manipulate - PROPN O 
Gene - PROPN O 
Function - PROPN O 
in - ADP O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
. - PUNCT O 

Disseminated - VERB O 
Infection - PROPN O 
with - ADP O 
Multiple - PROPN O 
Cold - PROPN O 
Abscesses - NOUN O 
Caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
Arrhizusin - PROPN O 
an - DET O 
Immunocompetent - PROPN O 
Girl - PROPN O 
. - PUNCT O 

In - ADP O 
this - DET O 
work - NOUN O 
, - PUNCT O 
we - PRON O 
investigated - VERB O 
the - DET O 
possibility - NOUN O 
of - ADP O 
producing - VERB O 
a - DET O 
tempeh - ADJ O 
analogue - NOUN O 
containing - VERB O 
high - ADJ O 
amounts - NOUN O 
of - ADP O 
vitamin - NOUN O 
B12 - PROPN O 
using - VERB O 
seeds - NOUN O 
of - ADP O 
three NUM - B-CARDINAL 
different - ADJ O 
species - NOUN O 
of - ADP O 
the - DET O 
legume - NOUN O 
lupin - NOUN O 
, - PUNCT O 
namely - ADV O 
Lupinus PROPN - B-NORP 
albus - NOUN O 
, - PUNCT O 
L. PROPN - B-PERSON 
angustifolius - NOUN O 
and - CCONJ O 
L. PROPN - B-PERSON 
mutabilis - NOUN O 
, - PUNCT O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
and - CCONJ O 
Propionibacterium - NOUN O 
freudenreichii - ADJ O 
cofermentation - NOUN O 
. - PUNCT O 

Synergic - ADJ O 
effects - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
and CCONJ - I-ORG 
Propionibacterium PROPN - I-ORG 
in - ADP O 
increasing - VERB O 
vitamin - NOUN O 
B12 PROPN - B-CARDINAL 
up - ADP O 
to - ADP O 
1230 NUM - B-DATE 
  - SPACE O 

Antimicrobial - ADJ O 
assays - NOUN O 
showed - VERB O 
that - ADP O 
all - DET O 
three NUM - B-CARDINAL 
peptides - NOUN O 
exhibited - VERB O 
strong - ADJ O 
antifungal - ADJ O 
activity - NOUN O 
against - ADP O 
Trichoderma PROPN - B-NORP 
koningii - VERB O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
sp - PART O 
. - PUNCT O 
, - PUNCT O 
and - CCONJ O 
Fusarium NOUN - B-ORG 
oxysporum - NOUN O 
. - PUNCT O 

Mucormycosis - NOUN O 
pathogenesis - NOUN O 
: - PUNCT O 
Beyond - ADP O 
Rhizopus PROPN - B-MEDICINE 
. - PUNCT O 

Eight NUM - B-CARDINAL 
genera - NOUN O 
( - PUNCT O 
24 NUM - B-CARDINAL 
species - NOUN O 
) - PUNCT O 
of - ADP O 
Mucorales PROPN - B-GPE 
organisms - NOUN O 
were - VERB O 
identified - VERB O 
in - ADP O 
447/851 PROPN - B-DATE 
( - PUNCT O 
53 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
cases - NOUN O 
, - PUNCT O 
of - ADP O 
which - ADJ O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

Compared - VERB O 
with - ADP O 
other - ADJ O 
genera - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 
was - VERB O 
predominantly - ADV O 
observed - VERB O 
in - ADP O 
patients - NOUN O 
with - ADP O 
rhino - NOUN O 
- - PUNCT O 
orbital - ADJ O 
- - PUNCT O 
cerebral - ADJ O 
mucormycosis - NOUN O 
( - PUNCT O 
75/213 NOUN - B-ORDINAL 
, - PUNCT O 
35 NUM - B-PERCENT 
% NOUN - I-PERCENT 
versus - ADP O 
34/234 - PROPN O 
, - PUNCT O 
15 NUM - B-PERCENT 
% NOUN - I-PERCENT 
; - PUNCT O 
p - DET O 
  - SPACE O 
< - X O 
  - SPACE O 
0.001 NUM - B-DATE 
) - PUNCT O 
. - PUNCT O 

This - DET O 
work - NOUN O 
investigated - VERB O 
coupled - VERB O 
effects - NOUN O 
of - ADP O 
pressure - NOUN O 
and - CCONJ O 
salts - NOUN O 
on - ADP O 
Rhizopus NOUN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
( - PUNCT O 
RCL PROPN - B-ORG 
) - PUNCT O 
to - PART O 
provide - VERB O 
significant - ADJ O 
information - NOUN O 
for - ADP O 
its - ADJ O 
further - ADJ O 
applications - NOUN O 
. - PUNCT O 

Identification - NOUN O 
of - ADP O 
a - DET O 
Novel - PROPN O 
Rhizopus PROPN - B-MEDICINE 
- - PUNCT O 
specific - PROPN O 
Antigen - PROPN O 
by - ADP O 
Screening - VERB O 
with - ADP O 
a DET - B-ORG 
Signal PROPN - I-ORG 
Sequence PROPN - I-ORG 
Trap PROPN - I-ORG 
and CCONJ - I-ORG 
Evaluation PROPN - I-ORG 
as - ADP O 
a - DET O 
Possible - PROPN O 
Diagnostic - PROPN O 
Marker - PROPN O 
of - ADP O 
Mucormycosis PROPN - B-ORG 
. - PUNCT O 

The - DET O 
six NUM - B-CARDINAL 
isolates - NOUN O 
( - PUNCT O 
Pseudomonas PROPN - B-GPE 
hibiscicola - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
, - PUNCT O 
Fusarium - PROPN O 
solani - NOUN O 
, - PUNCT O 
Actinomucor PROPN - B-ORG 
elegans - NOUN O 
, - PUNCT O 
Enterobacter - NOUN O 
aerogenes - NOUN O 
and - CCONJ O 
Aspergillus PROPN - B-PRODUCT 
tubingensis - NOUN O 
) - PUNCT O 
from - ADP O 
rotten - ADJ O 
roots - NOUN O 
were - VERB O 
confirmed - VERB O 
to - PART O 
be - VERB O 
pathogens - NOUN O 
for - ADP O 
root - NOUN O 
decay - NOUN O 
of - ADP O 
R. PROPN - B-NORP 
glutinosa - NOUN O 
in - ADP O 
pot - NOUN O 
experiments - NOUN O 
with - ADP O 
different - ADJ O 
pathogenicities - NOUN O 
of - ADP O 
33.33%–100 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
suggesting - VERB O 
the - DET O 
potential - ADJ O 
synergy - NOUN O 
of - ADP O 
several - ADJ O 
pathogens - NOUN O 
in - ADP O 
causing - VERB O 
root - NOUN O 
rot - NOUN O 
in - ADP O 
R. PROPN - B-NORP 
glutinosa - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
was - VERB O 
conducted - VERB O 
to - PART O 
determine - VERB O 
if - ADP O 
topical - ADJ O 
application - NOUN O 
of - ADP O 
Moringa PROPN - B-GPE 
oleifera - NOUN O 
extracts - NOUN O 
and - CCONJ O 
its - ADJ O 
bioconversion - NOUN O 
product - NOUN O 
fermented - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
has - VERB O 
therapeutic - ADJ O 
properties - NOUN O 
enhancement - NOUN O 
for - ADP O 
treatment - NOUN O 
of - ADP O 
atopic - ADJ O 
dermatitis - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
oligosporus - NOUN O 
( - PUNCT O 
KCCM PROPN - B-ORG 
11232P - PROPN O 
) - PUNCT O 
was - VERB O 
used - VERB O 
to - PART O 
ferment - VERB O 
Moringa PROPN - B-GPE 
leaves - NOUN O 
' - PART O 
extracts - NOUN O 
in - ADP O 
this - DET O 
study - NOUN O 
. - PUNCT O 

Cutaneous - ADJ O 
granuloma - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
with - ADP O 
a - DET O 
novel - ADJ O 
mutation - NOUN O 
in - ADP O 
the - DET O 
CYBB PROPN - B-ORG 
gene - NOUN O 
in - ADP O 
a - DET O 
monozygotic - ADJ O 
male - NOUN O 
twin - NOUN O 
. - PUNCT O 

The - DET O 
fungi - NOUN O 
isolated - VERB O 
were - VERB O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
( - PUNCT O 
17 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
Apophysomyces - PROPN O 
variabilis - NOUN O 
( - PUNCT O 
12 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
R. PROPN - B-NORP 
microsporus - NOUN O 
( - PUNCT O 
9 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
Lichtheimia - PROPN O 
ramosa - NOUN O 
( - PUNCT O 
8) - NUM O 
, - PUNCT O 
Saksenaea NOUN - B-GPE 
erythrospora - NOUN O 
( - PUNCT O 
5 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 

Furthermore - ADV O 
, - PUNCT O 
in - ADP O 
the - DET O 
antibacterial - ADJ O 
test - NOUN O 
, - PUNCT O 
the - DET O 
selective - ADJ O 
encapsulation - NOUN O 
of - ADP O 
HPCD PROPN - B-ORG 
improved - VERB O 
the - DET O 
inhibition - NOUN O 
effect - NOUN O 
of - ADP O 
SAEO PROPN - B-ORG 
on - ADP O 
Rhizopus NOUN - B-MEDICINE 
stolonoifer - NOUN O 
, - PUNCT O 
Saccharomyces - NOUN O 
cerevisiae - VERB O 
, - PUNCT O 
and - CCONJ O 
E. - PROPN O 
coli - NOUN O 
and - CCONJ O 
its - ADJ O 
antibacterial - ADJ O 
stability - NOUN O 
in - ADP O 
24 NUM - B-CARDINAL 
h. - NOUN O 

The - DET O 
rice - NOUN O 
seedling - NOUN O 
blight - ADJ O 
fungus - NOUN O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
harbors - NOUN O 
endosymbiotic - ADJ O 
bacteria - NOUN O 
( - PUNCT O 
Burkholderia PROPN - B-NORP 
rhizoxinica - NOUN O 
) - PUNCT O 
that - ADJ O 
produce - VERB O 
the - DET O 
virulence - NOUN O 
factor - NOUN O 
rhizoxin - NOUN O 
and - CCONJ O 
control - VERB O 
host - NOUN O 
development - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
Propionibacterium - NOUN O 
freudenreichii - VERB O 
, - PUNCT O 
a - DET O 
food - NOUN O 
- - PUNCT O 
grade - NOUN O 
, - PUNCT O 
vitamin - NOUN O 
B12 - PROPN O 
producing - VERB O 
bacterium - NOUN O 
, - PUNCT O 
was - VERB O 
used - VERB O 
in - ADP O 
co - NOUN O 
- - NOUN O 
culture - NOUN O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
to - PART O 
produce - VERB O 
B12-enriched - PROPN O 
lupin - NOUN O 
tempeh - NOUN O 
. - PUNCT O 

[ - PUNCT O 
Hepatic - ADJ O 
mucormycosis - NOUN O 
due - ADP O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
: - PUNCT O 

Backbone - PROPN O 
and - CCONJ O 
Ile - PROPN O 
- - PUNCT O 
δ1 - PROPN O 
, - PUNCT O 
Leu PROPN - B-ORG 
, - PUNCT O 
Val - PROPN O 
methyl - NOUN O 
1H PROPN - B-DATE 
, - PUNCT O 
15N NUM - B-CARDINAL 
, - PUNCT O 
and - CCONJ O 
13C NUM - B-CARDINAL 
, - PUNCT O 
chemical - NOUN O 
shift - NOUN O 
assignments - NOUN O 
for - ADP O 
Rhizopus NOUN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
. - PUNCT O 

The - DET O 
potential - NOUN O 
of - ADP O 
six NUM - B-CARDINAL 
microorganisms - NOUN O 
( - PUNCT O 
Pseudomonas PROPN - B-GPE 
aeruginosa - NOUN O 
, - PUNCT O 
Micrococcus PROPN - B-PERSON 
sp - X O 
, - PUNCT O 
Flavobacterium PROPN - B-LOC 
sp - X O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
sp - PROPN O 
, - PUNCT O 
Penicillium - PROPN O 
sp - PROPN O 
and - CCONJ O 
Fusarium PROPN - B-ORG 
sp - X O 
) - PUNCT O 
isolated - VERB O 
from - ADP O 
hydrocarbon - NOUN O 
contaminated - VERB O 
site - NOUN O 
were - VERB O 
evaluated - VERB O 
for - ADP O 
their - ADJ O 
biodegradation - NOUN O 
ability - NOUN O 
. - PUNCT O 

P. - PROPN O 
aeruginosa - NOUN O 
had - VERB O 
the - DET O 
highest - ADJ O 
level - NOUN O 
of - ADP O 
degradation - NOUN O 
( - PUNCT O 
89.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
while - ADP O 
Micrococcus PROPN - B-PERSON 
sp - PART O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
sp - PROPN O 
had - VERB O 
the - DET O 
least - ADJ O 
degradation - NOUN O 
at - ADP O 
79.9 NUM - B-PERCENT 
% NOUN - I-PERCENT 
. - PUNCT O 

The - DET O 
residues - NOUN O 
located - VERB O 
at - ADP O 
the - DET O 
crevice - NOUN O 
- - PUNCT O 
like - ADJ O 
binding - NOUN O 
site - NOUN O 
of - ADP O 
four NUM - B-CARDINAL 
representative - ADJ O 
lipases - NOUN O 
including - VERB O 
Thermomyces PROPN - B-NORP 
lanuginosus - NOUN O 
lipases - NOUN O 
( - PUNCT O 
TLL PROPN - B-ORG 
and - CCONJ O 
Lip PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
lipase - NOUN O 
( - PUNCT O 
ROL PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
Rhizomucor PROPN - B-ORG 
miehei - NOUN O 
lipase - NOUN O 
( - PUNCT O 
RML PROPN - B-ORG 
) - PUNCT O 
were - VERB O 
identified - VERB O 
through - ADP O 
structural - ADJ O 
analysis - NOUN O 
. - PUNCT O 

N PROPN - B-ORG 
- PUNCT - I-ORG 
Glycosylation PROPN - I-ORG 
Engineering PROPN - I-ORG 
to PART - I-ORG 
Improve - VERB O 
the - DET O 
Constitutive - PROPN O 
Expression - PROPN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
Lipase - PROPN O 
in - ADP O 
Komagataella PROPN - B-ORG 
phaffii - NOUN O 
. - PUNCT O 

To - PART O 
efficiently - ADV O 
produce - VERB O 
xylitol - NOUN O 
from - ADP O 
xylose - NOUN O 
by - ADP O 
xylose - ADJ O 
reductase - NOUN O 
in - ADP O 
a - DET O 
single - ADJ O 
step - NOUN O 
, - PUNCT O 
the - DET O 
coupled - ADJ O 
system - NOUN O 
and - CCONJ O 
the - DET O 
coexpression - NOUN O 
system - NOUN O 
using - VERB O 
xylose - NOUN O 
reductase - NOUN O 
( - PUNCT O 
XR - PROPN O 
) - PUNCT O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
and - CCONJ O 
glucose - NOUN O 
dehydrogenase - NOUN O 
( - PUNCT O 
GDH - PROPN O 
) - PUNCT O 
from - ADP O 
Exiguobacterium PROPN - B-GPE 
sibiricum - NOUN O 
were - VERB O 
constructed - VERB O 
, - PUNCT O 
the - DET O 
latter - ADJ O 
of - ADP O 
which - ADJ O 
was - VERB O 
used - VERB O 
for - ADP O 
cofactor - NOUN O 
regeneration - NOUN O 
. - PUNCT O 

Rhino NOUN - B-NORP 
- - PUNCT O 
orbital - ADJ O 
skin - NOUN O 
necrosis - NOUN O 
with - ADP O 
positive - ADJ O 
samples - NOUN O 
for - ADP O 
the - DET O 
organism - NOUN O 
Rhizopus PROPN - B-MEDICINE 
on - ADP O 
eventual - ADJ O 
orbital - ADJ O 
exenteration - NOUN O 
revealed - VERB O 
angioinvasive - ADJ O 
fungal - ADJ O 
infection - NOUN O 
, - PUNCT O 
mucormycosis - NOUN O 
, - PUNCT O 
to - PART O 
be - VERB O 
the - DET O 
cause - NOUN O 
. - PUNCT O 

Use - PROPN O 
of - ADP O 
inductors - NOUN O 
in - ADP O 
the - DET O 
control - NOUN O 
of - ADP O 
Colletotrichum PROPN - B-NORP 
gloeosporioides - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
isolated - VERB O 
from - ADP O 
soursop - NOUN O 
fruits - NOUN O 
: - PUNCT O 
in - ADP O 
vitro - NOUN O 
tests - NOUN O 
. - PUNCT O 

The - DET O 
goals - NOUN O 
get - VERB O 
on - ADP O 
heterologous - ADJ O 
Candida PROPN - B-GPE 
antarctica - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
and - CCONJ O 
Candida PROPN - B-GPE 
rugosa - NOUN O 
lipases - VERB O 
, - PUNCT O 
three NUM - B-CARDINAL 
of - ADP O 
the - DET O 
most - ADV O 
common - ADJ O 
lipases - NOUN O 
used - VERB O 
in - ADP O 
biocatalysis - NOUN O 
, - PUNCT O 
are - VERB O 
showed - VERB O 
. - PUNCT O 

The - DET O 
alcoholysis - NOUN O 
of - ADP O 
triolein - NOUN O 
was - VERB O 
used - VERB O 
to - PART O 
explore - VERB O 
the - DET O 
specific - ADJ O 
features - NOUN O 
of - ADP O 
a - DET O 
recombinant - ADJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
lipase - NOUN O 
( - PUNCT O 
rROL - PROPN O 
) - PUNCT O 
for - ADP O 
biodiesel - NOUN O 
synthesis - NOUN O 
. - PUNCT O 

Exploring - VERB O 
substrate - NOUN O 
specificities - NOUN O 
of - ADP O 
a - DET O 
recombinant - ADJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
lipase - NOUN O 
in - ADP O 
biodiesel - NOUN O 
synthesis - NOUN O 
. - PUNCT O 

The - DET O 
aim - NOUN O 
of - ADP O 
this - DET O 
study - NOUN O 
was - VERB O 
to - PART O 
evaluate - VERB O 
the - DET O 
antifungal - ADJ O 
activity - NOUN O 
( - PUNCT O 
in - ADP O 
vitro - X O 
) - PUNCT O 
of - ADP O 
thymol - NOUN O 
and - CCONJ O 
carvacrol - NOUN O 
alone - ADV O 
or - CCONJ O 
in - ADP O 
mixtures - NOUN O 
against - ADP O 
Fusarium PROPN - B-ORG 
verticillioides - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
, - PUNCT O 
and - CCONJ O 
to - PART O 
obtain - VERB O 
primary - ADJ O 
growth - NOUN O 
models - NOUN O 
. - PUNCT O 

Fusarium - NOUN O 
verticillioides - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
with - ADP O 
thymol - NOUN O 
and - CCONJ O 
carvacrol - NOUN O 
. - PUNCT O 

, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
( - PUNCT O 
3 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Fusarium - NOUN O 
solani - NOUN O 
( - PUNCT O 
2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
were - VERB O 
found - VERB O 
. - PUNCT O 

Biochemical - ADJ O 
characterization - NOUN O 
and - CCONJ O 
stability - NOUN O 
assessment - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
lipase - VERB O 
covalently - ADV O 
immobilized - VERB O 
on - ADP O 
amino - NOUN O 
- - PUNCT O 
functionalized - ADJ O 
magnetic - ADJ O 
nanoparticles - NOUN O 
. - PUNCT O 

Production - NOUN O 
of - ADP O 
Fumaric - PROPN O 
Acid - PROPN O 
by - ADP O 
Bioconversion - PROPN O 
of - ADP O 
Corncob PROPN - B-ORG 
Hydrolytes PROPN - I-ORG 
Using VERB - I-ORG 
an - DET O 
Improved - PROPN O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
Strain PROPN - B-PERSON 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
was - VERB O 
the - DET O 
predominant - ADJ O 
species - NOUN O 
of - ADP O 
pathogen - NOUN O 
( - PUNCT O 
66.7 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Intravenous - PROPN O 
Olanzapine PROPN - B-MEDICINE 
for - ADP O 
the - DET O 
Management - PROPN O 
of - ADP O 
Agitation - PROPN O 
: - PUNCT O 
Review - NOUN O 
of - ADP O 
the - DET O 
Literature - PROPN O 
. - PUNCT O 

After - ADP O 
31st - ADJ O 
Long - PROPN O 
- - PUNCT O 
Acting - PROPN O 
Olanzapine PROPN - B-MEDICINE 
Depot - PROPN O 
Injection - PROPN O 
. - PUNCT O 

Development - PROPN O 
and - CCONJ O 
Characterization - PROPN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
Loaded - PROPN O 
Poly(lactide PROPN - B-GPE 
- - PUNCT O 
co - NOUN O 
- - ADJ O 
glycolide - ADJ O 
) - PUNCT O 
Microspheres NOUN - B-ORG 
for ADP - I-ORG 
Depot PROPN - I-ORG 
Injection PROPN - I-ORG 
: - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - ADJ O 
drug - NOUN O 
from - ADP O 
the - DET O 
thienobenzodiazepine - NOUN O 
family - NOUN O 
which - ADJ O 
displays - VERB O 
efficacy - NOUN O 
in - ADP O 
patients - NOUN O 
with - ADP O 
schizophrenia - NOUN O 
and - CCONJ O 
related - ADJ O 
psychoses - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
100 NUM - B-CARDINAL 
  - SPACE O 
uM - DET O 
) - PUNCT O 
and - CCONJ O 
clozapine - VERB O 
( - PUNCT O 
100 NUM - B-CARDINAL 
, - PUNCT O 
20 NUM - B-CARDINAL 
  - SPACE O 
uM - INTJ O 
) - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
100 NUM - B-CARDINAL 
  - SPACE O 
uM - DET O 
) - PUNCT O 
and - CCONJ O 
aripiprazole - NOUN O 
( - PUNCT O 
20 NUM - B-CARDINAL 
  - SPACE O 
uM - INTJ O 
) - PUNCT O 
increased - VERB O 
BDNF - ADJ O 
expression - NOUN O 
. - PUNCT O 

Pharmacokinetics - PROPN O 
and - CCONJ O 
Short - ADJ O 
- - PUNCT O 
term - NOUN O 
Safety PROPN - B-PRODUCT 
of ADP - I-PRODUCT 
ALKS PROPN - I-PRODUCT 
3831 NUM - I-PRODUCT 
, - PUNCT O 
a - DET O 
Fixed PROPN - B-ORG 
- - PUNCT O 
dose - NOUN O 
Combination PROPN - B-ORG 
of ADP - I-ORG 
Olanzapine PROPN - I-MEDICINE 
and - CCONJ O 
Samidorphan PROPN - B-GPE 
, - PUNCT O 
in - ADP O 
Adult PROPN - B-LOC 
Subjects PROPN - I-LOC 
with - ADP O 
Schizophrenia PROPN - B-GPE 
. - PUNCT O 

Late - ADJ O 
- - PUNCT O 
Onset - NOUN O 
Cholestatic - PROPN O 
Liver - PROPN O 
Injury - PROPN O 
During - ADP O 
Combination - PROPN O 
Treatment - PROPN O 
With - ADP O 
Chlorpromazine - PROPN O 
and - CCONJ O 
Olanzapine PROPN - B-MEDICINE 

Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
Induced - PROPN O 
Fever - PROPN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
appears - VERB O 
effective - ADJ O 
and - CCONJ O 
tolerable - ADJ O 
as - ADP O 
an - DET O 
antiemetic - NOUN O 
in - ADP O 
patients - NOUN O 
with - ADP O 
advanced - ADJ O 
cancer - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
commonly - ADV O 
used - VERB O 
for - ADP O 
the - DET O 
management - NOUN O 
of - ADP O 
psychotic - ADJ O 
symptoms - NOUN O 
as - ADV O 
well - ADV O 
as - ADP O 
for - ADP O 
the - DET O 
management - NOUN O 
of - ADP O 
behavioural - ADJ O 
and - CCONJ O 
psychological - ADJ O 
problems - NOUN O 
with - ADP O 
dementia - NOUN O 
in - ADP O 
the - DET O 
elderly - ADJ O 
. - PUNCT O 

Agranulocytosis - NOUN O 
- - PUNCT O 
Protective - ADJ O 
Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
Loaded - VERB O 
Nanostructured - PROPN O 
Lipid - PROPN O 
Carriers - PROPN O 
Engineered - VERB O 
for - ADP O 
CNS PROPN - B-ORG 
Delivery - PROPN O 
: - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
is - VERB O 
commonly - ADV O 
utilized - VERB O 
in - ADP O 
palliative - ADJ O 
care - NOUN O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
nausea - NOUN O 
, - PUNCT O 
and - CCONJ O 
a - DET O 
known - VERB O 
side - NOUN O 
effect - NOUN O 
of - ADP O 
olanzapine NOUN - B-MEDICINE 
is - VERB O 
increased - VERB O 
appetite - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
also - ADV O 
known - VERB O 
to - PART O 
cause - VERB O 
re - NOUN O 
- - NOUN O 
emergence - NOUN O 
of - ADP O 
eating - VERB O 
disorders - NOUN O 
( - PUNCT O 
EDs - NOUN O 
) - PUNCT O 
in - ADP O 
patients - NOUN O 
utilizing - VERB O 
olanzapine NOUN - B-MEDICINE 
for - ADP O 
its - ADJ O 
antipsychotic - ADJ O 
effects - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
, - PUNCT O 
an - DET O 
atypical - ADJ O 
antipsychotic - ADJ O 
drug - NOUN O 
, - PUNCT O 
has - VERB O 
therapeutic - ADJ O 
effects - NOUN O 
for - ADP O 
schizophrenia - NOUN O 
. - PUNCT O 

CONCLUSION - NOUN O 
: - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
may - VERB O 
exacerbate - VERB O 
atherosclerosis - NOUN O 
by - ADP O 
deregulating - VERB O 
hepatic - ADJ O 
lipid - NOUN O 
metabolism - NOUN O 
and - CCONJ O 
worsening - VERB O 
hyperlipidemia - ADJ O 
and - CCONJ O 
aortic - ADJ O 
inflammation - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
monotherapy - NOUN O 
increased - VERB O 
BMI NOUN - B-ORG 
and - CCONJ O 
circulating - NOUN O 
insulin - NOUN O 
, - PUNCT O 
triglyceride - NOUN O 
, - PUNCT O 
and - CCONJ O 
MIF PROPN - B-ORG 
concentrations - NOUN O 
in - ADP O 
drug - NOUN O 
- - PUNCT O 
naive - ADJ O 
schizophrenic - ADJ O 
patients - NOUN O 
with - ADP O 
normal - ADJ O 
MIF NOUN - B-ORG 
expression - NOUN O 
, - PUNCT O 
but - CCONJ O 
not - ADV O 
in - ADP O 
genotypic - ADJ O 
low - ADJ O 
MIF PROPN - B-ORG 
expressers - NOUN O 
. - PUNCT O 

Olanzapine ADJ - B-MEDICINE 
administration - NOUN O 
to - ADP O 
mice - NOUN O 
increased - VERB O 
their - ADJ O 
food - NOUN O 
intake - NOUN O 
and - CCONJ O 
hypothalamic - ADJ O 
MIF NOUN - B-ORG 
expression - NOUN O 
, - PUNCT O 
which - ADJ O 
led - VERB O 
to - ADP O 
activation - NOUN O 
of - ADP O 
the - DET O 
appetite - NOUN O 
- - PUNCT O 
related - VERB O 
AMP - PROPN O 
- - PUNCT O 
activated - VERB O 
protein - NOUN O 
kinase - NOUN O 
and - CCONJ O 
Agouti PROPN - B-ORG 
- - PUNCT O 
related - VERB O 
protein - NOUN O 
pathway - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
also - ADV O 
upregulated - VERB O 
MIF PROPN - B-ORG 
expression - NOUN O 
in - ADP O 
adipose - NOUN O 
tissue - NOUN O 
, - PUNCT O 
which - ADJ O 
reduced - VERB O 
lipolysis - NOUN O 
and - CCONJ O 
increased - VERB O 
lipogenic - NOUN O 
pathways - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
as - ADP O 
an - DET O 
antiemetic - ADJ O 
represents - VERB O 
a - DET O 
new - ADJ O 
use - NOUN O 
of - ADP O 
an - DET O 
antipsychotic - ADJ O 
drug - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
versus - ADP O 
placebo - NOUN O 
/ - SYM O 
no - INTJ O 
treatmentPrimary - PROPN O 
outcomesOlanzapine - NOUN O 
probably - ADV O 
doubles - VERB O 
the - DET O 
likelihood - NOUN O 
of - ADP O 
no - DET O 
nausea - NOUN O 
or - CCONJ O 
vomiting - NOUN O 
during - ADP O 
chemotherapy - NOUN O 
from - ADP O 
25 NUM - B-PERCENT 
% NOUN - I-PERCENT 
to ADP - I-PERCENT 
50 NUM - I-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
risk - NOUN O 
ratio - NOUN O 
( - PUNCT O 
RR PROPN - B-ORG 
) - PUNCT O 
1.98 - NUM O 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
confidence - NOUN O 
interval - NOUN O 
( - PUNCT O 
CI PROPN - B-ORG 
) - PUNCT O 
1.59 NUM - B-CARDINAL 
to - ADP O 
2.47 NUM - B-CARDINAL 
; - PUNCT O 
561 NUM - B-CARDINAL 
participants - NOUN O 
; - PUNCT O 
3 NUM - B-CARDINAL 
studies - NOUN O 
; - PUNCT O 
solid - ADJ O 
tumours - NOUN O 
; - PUNCT O 
HEC - PROPN O 
or - CCONJ O 
MEC PROPN - B-ORG 
therapy - NOUN O 
; - PUNCT O 
moderate - ADJ O 
- - PUNCT O 
quality - NOUN O 
evidence - NOUN O 
) - PUNCT O 
when - ADV O 
added - VERB O 
to - ADP O 
standard - ADJ O 
therapy - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
may - VERB O 
increase - VERB O 
other - ADJ O 
adverse - ADJ O 
events - NOUN O 
( - PUNCT O 
RR - NOUN O 
1.71 NUM - B-CARDINAL 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
0.99 NUM - B-CARDINAL 
to - ADP O 
2.96 NUM - B-CARDINAL 
; - PUNCT O 
332 NUM - B-CARDINAL 
participants - NOUN O 
; - PUNCT O 
4 NUM - B-CARDINAL 
studies - NOUN O 
; - PUNCT O 
low - ADJ O 
- - PUNCT O 
quality - NOUN O 
evidence - NOUN O 
) - PUNCT O 
and - CCONJ O 
probably - ADV O 
increases - VERB O 
somnolence - NOUN O 
and - CCONJ O 
fatigue - NOUN O 
compared - VERB O 
to - ADP O 
no - DET O 
treatment - NOUN O 
or - CCONJ O 
placebo - NOUN O 
( - PUNCT O 
RR - PROPN O 
2.33 NUM - B-MONEY 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
1.30 NUM - B-CARDINAL 
to - ADP O 
4.18 NUM - B-CARDINAL 
; - PUNCT O 
anticipated - VERB O 
absolute - ADJ O 
risk - NOUN O 
8.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
more - ADJ O 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
1.9 - NUM O 
to - ADP O 
18.8 NUM - B-CARDINAL 
; - PUNCT O 
464 NUM - B-CARDINAL 
participants - NOUN O 
; - PUNCT O 
5 NUM - B-CARDINAL 
studies - NOUN O 
; - PUNCT O 
moderate - ADJ O 
- - PUNCT O 
quality - NOUN O 
evidence - NOUN O 
) - PUNCT O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
probably - ADV O 
does - VERB O 
not - ADV O 
affect - VERB O 
all - DET O 
- - PUNCT O 
cause - NOUN O 
attrition - NOUN O 
( - PUNCT O 
RR - NOUN O 
0.99 - NUM O 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
0.57 NUM - B-CARDINAL 
to - ADP O 
1.73 NUM - B-CARDINAL 
; - PUNCT O 
943 NUM - B-CARDINAL 
participants - NOUN O 
; - PUNCT O 
8 NUM - B-CARDINAL 
studies - NOUN O 
; - PUNCT O 
I² - NOUN O 
= - SYM O 
0 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
probably - ADV O 
reduces - VERB O 
delayed - VERB O 
nausea - NOUN O 
( - PUNCT O 
RR - NOUN O 
1.71 NUM - B-CARDINAL 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
1.40 - NUM O 
to - ADP O 
2.09 NUM - B-CARDINAL 
; - PUNCT O 
585 NUM - B-CARDINAL 
participants - NOUN O 
; - PUNCT O 
3 NUM - B-CARDINAL 
studies - NOUN O 
) - PUNCT O 
and - CCONJ O 
vomiting - VERB O 
( - PUNCT O 
RR - PROPN O 
1.28 NUM - B-CARDINAL 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
1.14 NUM - B-CARDINAL 
to - ADP O 
1.42 NUM - B-CARDINAL 
; - PUNCT O 
702 NUM - B-CARDINAL 
participants - NOUN O 
; - PUNCT O 
5 NUM - B-CARDINAL 
studies).Subgroup - NUM O 
analysis - NOUN O 
: - PUNCT O 
5 NUM - B-CARDINAL 
mg - X O 
versus - ADP O 
10 NUM - B-CARDINAL 
mgPlanned - VERB O 
subgroup - NOUN O 
analyses - NOUN O 
found - VERB O 
that - ADP O 
it - PRON O 
is - VERB O 
unclear - ADJ O 
if - ADP O 
5 NUM - B-CARDINAL 
mg - PRON O 
is - VERB O 
as - ADV O 
effective - ADJ O 
an - DET O 
antiemetic - ADJ O 
as - ADP O 
10 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
can - VERB O 
lower - VERB O 
seizure - NOUN O 
threshold - NOUN O 
and - CCONJ O 
induce - VERB O 
epileptiform - NOUN O 
discharges - NOUN O 
. - PUNCT O 

However - ADV O 
in - ADP O 
patients - NOUN O 
on - ADP O 
Olanzapine PROPN - B-MEDICINE 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
a - DET O 
primary - ADJ O 
psychiatric - ADJ O 
disorder - NOUN O 
, - PUNCT O 
clinical - ADJ O 
seizure - NOUN O 
is - VERB O 
a - DET O 
rare - ADJ O 
occurrence - NOUN O 
. - PUNCT O 

We - PRON O 
report - VERB O 
the - DET O 
case - NOUN O 
of - ADP O 
a - DET O 
23-year NUM - B-CARDINAL 
- - PUNCT O 
old - ADJ O 
female - NOUN O 
with - ADP O 
mild - ADJ O 
mental - ADJ O 
retardation - NOUN O 
with - ADP O 
schizophrenia - NOUN O 
with - ADP O 
obsessive - ADJ O 
compulsive - ADJ O 
disorder - NOUN O 
who - NOUN O 
developed - VERB O 
new - ADJ O 
- - PUNCT O 
onset - NOUN O 
generalized - VERB O 
tonic - NOUN O 
- - PUNCT O 
clonic - NOUN O 
seizure - NOUN O 
probably - ADV O 
due - ADP O 
to - ADP O 
Olanzapine PROPN - B-MEDICINE 
. - PUNCT O 

The - DET O 
seizure - NOUN O 
risk - NOUN O 
associated - VERB O 
with - ADP O 
Olanzapine PROPN - B-MEDICINE 
was - VERB O 
reviewed - VERB O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
associated - VERB O 
with - ADP O 
somnolence - NOUN O 
, - PUNCT O 
and - CCONJ O 
we - PRON O 
have - VERB O 
previously - ADV O 
conducted - VERB O 
a - DET O 
randomized - VERB O 
Phase PROPN - B-PRODUCT 
II PROPN - I-PRODUCT 
study - NOUN O 
to - PART O 
evaluate - VERB O 
the - DET O 
efficacy - NOUN O 
and - CCONJ O 
safety - NOUN O 
of - ADP O 
10 NUM - B-CARDINAL 
mg - NOUN O 
and - CCONJ O 
5 NUM - B-CARDINAL 
mg - PRON O 
olanzapine ADV - B-MEDICINE 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
: - PUNCT O 
a - DET O 
full - ADJ O 
and - CCONJ O 
potent - ADJ O 
agonist - NOUN O 
at - ADP O 
the - DET O 
hM4D(Gi - NOUN O 
) - PUNCT O 
DREADD - VERB O 
amenable - ADJ O 
to - ADP O 
clinical - ADJ O 
translation - NOUN O 
of - ADP O 
chemogenetics - NOUN O 

Olanzapine NOUN - B-MEDICINE 
with - ADP O 
ondansetron - NOUN O 
and - CCONJ O 
dexamethasone - NOUN O 
for - ADP O 
the - DET O 
prevention - NOUN O 
of - ADP O 
cisplatin - NOUN O 
- - PUNCT O 
based - VERB O 
chemotherapy - NOUN O 
- - PUNCT O 
induced - VERB O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
in - ADP O 
lung - NOUN O 
cancer - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - ADJ O 
drug - NOUN O 
commonly - ADV O 
used - VERB O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
schizophrenia - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
Olz - NOUN O 
) - PUNCT O 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - NOUN O 
used - VERB O 
to - PART O 
treat - VERB O 
depression - NOUN O 
, - PUNCT O 
anxiety - NOUN O 
and - CCONJ O 
schizophrenia - NOUN O 
, - PUNCT O 
which - ADJ O 
can - VERB O 
be - VERB O 
caused - VERB O 
by - ADP O 
chronic - ADJ O 
psychosocial - ADJ O 
stress - NOUN O 
. - PUNCT O 

Intraindividual - ADJ O 
and - CCONJ O 
Interindividual ADJ - B-ORG 
Variability PROPN - I-ORG 
of ADP - I-ORG 
Olanzapine PROPN - I-MEDICINE 
Trough PROPN - I-ORG 
Concentrations PROPN - I-ORG 
in - ADP O 
Patients - NOUN O 
Treated - VERB O 
With - ADP O 
the - DET O 
Long - PROPN O 
- - PUNCT O 
Acting - PROPN O 
Injectable - PROPN O 
Formulation - PROPN O 
. - PUNCT O 

Bioequivalence - NOUN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
Given - VERB O 
in - ADP O 
Combination PROPN - B-ORG 
With - ADP O 
Samidorphan - PROPN O 
as - ADP O 
a - DET O 
Bilayer - PROPN O 
Tablet - PROPN O 
( - PUNCT O 
ALKS PROPN - B-PRODUCT 
3831 NUM - I-PRODUCT 
) - PUNCT O 

Compared - VERB O 
With - ADP O 
Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
Alone - ADJ O 
Tablets - NOUN O 
: - PUNCT O 
Results - NOUN O 
From - ADP O 
a - DET O 
Randomized - VERB O 
, - PUNCT O 
Crossover - PROPN O 
Relative - PROPN O 
Bioavailability - PROPN O 
Study - PROPN O 
. - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
the - DET O 
Efficacy - PROPN O 
and - CCONJ O 
Safety - PROPN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
for - ADP O 
Anorexia PROPN - B-PERSON 
Nervosa PROPN - I-PERSON 
in - ADP O 
Children PROPN - B-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Adolescents PROPN - B-PERSON 
; - PUNCT O 
http://clinicaltrials.gov - X O 
; - PUNCT O 
NCT01184443 PROPN - B-PERSON 
. - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
the - DET O 
Effectiveness - PROPN O 
and - CCONJ O 
Safety - PROPN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
as - ADP O 
an - DET O 
Adjunctive - PROPN O 
Treatment - PROPN O 
for - ADP O 
Anorexia - PROPN O 
Nervosa - PROPN O 
in - ADP O 
Adolescents NOUN - B-GPE 
: - PUNCT O 
An - DET O 
Open - PROPN O 
- - PUNCT O 
Label - PROPN O 
Trial - PROPN O 
. - PUNCT O 

Craving - PROPN O 
Behavior PROPN - B-PERSON 
from - ADP O 
Opioid - PROPN O 
Addiction - PROPN O 
Controlled - VERB O 
with - ADP O 
Olanzapine PROPN - B-MEDICINE 
in - ADP O 
an - DET O 
Advanced - PROPN O 
Cancer - PROPN O 
Patient - PROPN O 
: - PUNCT O 
A DET - B-WORK_OF_ART 
Case PROPN - I-WORK_OF_ART 
Report PROPN - I-WORK_OF_ART 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
is - VERB O 
more - ADV O 
commonly - ADV O 
prescribed - VERB O 
to - ADP O 
people - NOUN O 
with - ADP O 
lower - ADJ O 
weight - NOUN O 
. - PUNCT O 

Olanzapine ADV - B-MEDICINE 
, - PUNCT O 
clozapine - NOUN O 
and - CCONJ O 
risperidone - NOUN O 
showed - VERB O 
superiority - NOUN O 
for - ADP O 
symptom - NOUN O 
reduction - NOUN O 
compared - VERB O 
to - ADP O 
some - DET O 
other - ADJ O 
drugs - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
10 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
or - CCONJ O 
matching - VERB O 
placebo - NOUN O 
were - VERB O 
given - VERB O 
on - ADP O 
each DET - B-DATE 
chemotherapy NOUN - I-DATE 
day NOUN - I-DATE 
and - CCONJ O 
3 NUM - B-DATE 
days NOUN - I-DATE 
after ADV - I-DATE 
. - PUNCT O 

Versus - PROPN O 
FOND - PROPN O 
Plus - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
FOND - PROPN O 
- - PUNCT O 
O - PROPN O 
) - PUNCT O 
for - ADP O 
the - DET O 
Prevention - PROPN O 
of - ADP O 
Chemotherapy - PROPN O 
- - PUNCT O 
Induced - VERB O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 
in - ADP O 
Patients - PROPN O 
with - ADP O 
Hematologic - PROPN O 
Malignancies - PROPN O 
Receiving - VERB O 
Highly - ADV O 
Emetogenic - ADJ O 
Chemotherapy - PROPN O 
and - CCONJ O 
Hematopoietic PROPN - B-ORG 
Cell PROPN - I-ORG 

Olanzapine NOUN - B-MEDICINE 
as - ADP O 
antiemetic - ADJ O 
drug - NOUN O 
in - ADP O 
oncology - NOUN O 
: - PUNCT O 
a - DET O 
retrospective - ADJ O 
study - NOUN O 
in - ADP O 
non - ADJ O 
- - NOUN O 
responders - NOUN O 
to - ADP O 
standard - ADJ O 
antiemetic - ADJ O 
therapy - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
long - ADV O 
- - PUNCT O 
acting - VERB O 
injections - NOUN O 
( - PUNCT O 
OLAIs - NOUN O 
) - PUNCT O 
are - VERB O 
often - ADV O 
prescribed - VERB O 
to - ADP O 
patients - NOUN O 
with - ADP O 
severe - ADJ O 
schizophrenia - NOUN O 
who - NOUN O 
are - VERB O 
typically - ADV O 
excluded - VERB O 
from - ADP O 
randomized - VERB O 
clinical - ADJ O 
trials - NOUN O 
. - PUNCT O 

Metabolic PROPN - B-ORG 
Changes PROPN - I-ORG 
in - ADP O 
Patients PROPN - B-GPE 
with - ADP O 
Schizophrenia - PROPN O 
Switched - VERB O 
From - ADP O 
Olanzapine PROPN - B-MEDICINE 
to - ADP O 
Asenapine PROPN - B-GPE 
or - CCONJ O 
Clozapine PROPN - B-ORG 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
was - VERB O 
superior - ADJ O 
to - PART O 
haloperidol - VERB O 
in - ADP O 
overall - ADJ O 
symptoms - NOUN O 
, - PUNCT O 
negative - ADJ O 
symptoms - NOUN O 
and - CCONJ O 
response - NOUN O 
, - PUNCT O 
and - CCONJ O 
it - PRON O 
was - VERB O 
associated - VERB O 
with - ADP O 
fewer - ADJ O 
dropouts - NOUN O 
than - ADP O 
risperidone - NOUN O 
. - PUNCT O 

Intramuscular PROPN - B-PERSON 
Midazolam PROPN - I-PERSON 
, - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
, - PUNCT O 
Ziprasidone PROPN - B-GPE 
, - PUNCT O 
or - CCONJ O 
Haloperidol PROPN - B-ORG 
for ADP - I-ORG 
Treating PROPN - I-ORG 
Acute PROPN - I-ORG 
Agitation PROPN - I-ORG 
in ADP - I-ORG 
the DET - I-ORG 
Emergency PROPN - I-ORG 
Department PROPN - I-ORG 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
widely - ADV O 
used - VERB O 
atypical - ADJ O 
antipsychotic - ADJ O 
medication - NOUN O 
for - ADP O 
treatment - NOUN O 
of - ADP O 
schizophrenia - NOUN O 
and - CCONJ O 
is - VERB O 
often - ADV O 
associated - VERB O 
with - ADP O 
serious - ADJ O 
metabolic - NOUN O 
abnormalities - NOUN O 
including - VERB O 
weight - NOUN O 
gain - NOUN O 
and - CCONJ O 
impaired - VERB O 
glucose - NOUN O 
tolerance - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
challenge - NOUN O 
induced - VERB O 
remarkably - ADV O 
increased - VERB O 
body - NOUN O 
weight - NOUN O 
, - PUNCT O 
fasting - VERB O 
insulin - NOUN O 
, - PUNCT O 
homeostasis - NOUN O 
model - NOUN O 
assessment - NOUN O 
- - PUNCT O 
insulin - NOUN O 
resistance - NOUN O 
index - NOUN O 
, - PUNCT O 
and - CCONJ O 
TCF7L2 ADJ - B-NORP 
protein - NOUN O 
expression - NOUN O 
in - ADP O 
liver - NOUN O 
, - PUNCT O 
skeletal - ADJ O 
muscle - NOUN O 
, - PUNCT O 
and - CCONJ O 
adipose - NOUN O 
tissues - NOUN O 
. - PUNCT O 

The - DET O 
Wnt - PROPN O 
Signaling - PROPN O 
Pathway - PROPN O 
Effector - PROPN O 
TCF7L2 - VERB O 
Mediates - PROPN O 
Olanzapine PROPN - B-MEDICINE 
- - PUNCT O 
Induced - VERB O 
Weight - PROPN O 
Gain - PROPN O 
and - CCONJ O 
Insulin PROPN - B-ORG 
Resistance PROPN - I-ORG 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
was - VERB O 
used - VERB O 
in - ADP O 
five NUM - B-CARDINAL 
and - CCONJ O 
risperidone - NOUN O 
in - ADP O 
six NUM - B-CARDINAL 
experiments - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
effective - ADJ O 
antipsychotic - ADJ O 
drug - NOUN O 
but - CCONJ O 
since - ADP O 
it - PRON O 
causes - VERB O 
significant - ADJ O 
weight - NOUN O 
gain - NOUN O 
, - PUNCT O 
it - PRON O 
is - VERB O 
not - ADV O 
well - ADV O 
tolerated - VERB O 
by - ADP O 
psychosis - NOUN O 
patients - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
combined - VERB O 
with - ADP O 
palonosetron - NOUN O 
and - CCONJ O 
dexamethasone - NOUN O 
significantly - ADV O 
improved - VERB O 
QOL PROPN - B-ORG 
and - CCONJ O 
vomiting - NOUN O 
control - NOUN O 
among - ADP O 
previously - ADV O 
untreated - ADJ O 
patients - NOUN O 
receiving - VERB O 
MEC PROPN - B-ORG 
, - PUNCT O 
although - ADP O 
the - DET O 
efficacy - NOUN O 
was - VERB O 
limited - VERB O 
to - ADP O 
the - DET O 
reduction - NOUN O 
of - ADP O 
the - DET O 
frequency - NOUN O 
of - ADP O 
CINV PROPN - B-ORG 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
100 NUM - B-CARDINAL 
uM - NOUN O 
) - PUNCT O 
treatment - NOUN O 
caused - VERB O 
a - DET O 
significant - ADJ O 
increase - NOUN O 
in - ADP O 
IL-6 - PROPN O 
while - ADP O 
aripiprazole - NOUN O 
( - PUNCT O 
20 NUM - B-CARDINAL 
uM - INTJ O 
) - PUNCT O 
significantly - ADV O 
decreased - VERB O 
IL-10 - PROPN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
100 NUM - B-CARDINAL 
uM - INTJ O 
) - PUNCT O 
and - CCONJ O 
aripiprazole - NOUN O 
( - PUNCT O 
20 NUM - B-CARDINAL 
uM - INTJ O 
) - PUNCT O 
increased - VERB O 
BDNF - ADJ O 
expression - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
widely - ADV O 
prescribed - VERB O 
antipsychotic - ADJ O 
drug - NOUN O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
on - ADP O 
Clinical - PROPN O 
and - CCONJ O 
Polysomnography - PROPN O 
Profiles - PROPN O 
in - ADP O 
Patients NOUN - B-GPE 
with - ADP O 
Schizophrenia PROPN - B-GPE 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
peripheral - ADJ O 
eosinophilia - NOUN O 
and - CCONJ O 
eosinophilic - ADJ O 
pleural - ADJ O 
effusion - NOUN O 
: - PUNCT O 
A - DET O 
case - NOUN O 
report - NOUN O 
. - PUNCT O 

ResultsThe - PROPN O 
most - ADV O 
frequently - ADV O 
used - VERB O 
drugs - NOUN O 
were - VERB O 
Risperidone PROPN - B-ORG 
, - PUNCT O 
Aripiprazole PROPN - B-GPE 
, - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
in - ADP O 
the - DET O 
antipsychotic - ADJ O 
drug - NOUN O 
, - PUNCT O 
Valproate PROPN - B-ORG 
, PUNCT - I-ORG 
Lamotrigine PROPN - I-ORG 
, PUNCT - I-ORG 
Topiramate NOUN - I-ORG 
in - ADP O 
the - DET O 
anticonvulsant - ADJ O 
agents - NOUN O 
, - PUNCT O 
Escitalopram PROPN - B-ORG 
, - PUNCT O 
Sertraline PROPN - B-ORG 
, - PUNCT O 
Milnacipran PROPN - B-ORG 
in - ADP O 
antidepressants - NOUN O 
, - PUNCT O 
Lorazepam PROPN - B-PERSON 
, - PUNCT O 
Clonazepam PROPN - B-PERSON 
, - PUNCT O 
Zolpidem PROPN - B-ORG 
in - ADP O 
anxiolytics - NOUN O 
or - CCONJ O 
sedatives - NOUN O 
, - PUNCT O 
Propranolol PROPN - B-PERSON 
, - PUNCT O 
Benztropine PROPN - B-PERSON 
, - PUNCT O 
Trihexyphenidyl PROPN - B-PERSON 
in - ADP O 
antiparkinson - NOUN O 
drugs - NOUN O 
. - PUNCT O 

Aripiprazole - PROPN O 
also - ADV O 
showed - VERB O 
a - DET O 
lower - ADJ O 
incidence - NOUN O 
of - ADP O 
discontinuation - NOUN O 
except - ADP O 
for - ADP O 
Clozapine PROPN - B-ORG 
and - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
. - PUNCT O 

Within - ADP O 
this - DET O 
paper - NOUN O 
, - PUNCT O 
OTF - PROPN O 
strips - VERB O 
containing - VERB O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
were - VERB O 
prepared - VERB O 
using - VERB O 
the - DET O 
solvent - NOUN O 
casting - NOUN O 
method - NOUN O 
and - CCONJ O 
then - ADV O 
characterised - VERB O 
to - PART O 
ensure - VERB O 
the - DET O 
method - NOUN O 
could - VERB O 
conform - VERB O 
to - ADP O 
acceptable - ADJ O 
levels - NOUN O 
of - ADP O 
uniformity - NOUN O 
, - PUNCT O 
the - DET O 
mean - ADJ O 
( - PUNCT O 
SD PROPN - B-ORG 
) - PUNCT O 
diclofenac NOUN - B-MEDICINE 
sodium NOUN - I-MEDICINE 
content - NOUN O 
was - VERB O 
25.43(1.39 - NUM O 
) - PUNCT O 
mg - VERB O 
, - PUNCT O 
range - VERB O 
22.84 NUM - B-CARDINAL 
- - SYM O 
27.44 - NUM O 
mg - PRON O 
. - PUNCT O 

Development - PROPN O 
an - DET O 
LC - PROPN O 
- - PUNCT O 
MS - PROPN O 
/ - SYM O 
MS - PROPN O 
Method - PROPN O 
for - ADP O 
the DET - B-ORG 
Quantification PROPN - I-ORG 
of ADP - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
in - ADP O 
Dairy PROPN - B-GPE 
Cow PROPN - B-PERSON 
Plasma PROPN - I-PERSON 
and - CCONJ O 
its - ADJ O 
Application PROPN - B-ORG 
in ADP - I-ORG 
Pharmacokinetics PROPN - I-ORG 
Studies PROPN - I-ORG 
. - PUNCT O 

Diclofenac PROPN - B-ORG 
Sodium PROPN - I-ORG 
Treatment PROPN - I-ORG 
Ameliorates PROPN - I-ORG 
Extrapancreatic PROPN - I-ORG 
Organ PROPN - I-ORG 
Injuries PROPN - I-ORG 
in - ADP O 
a - DET O 
Murine PROPN - B-NORP 
Model PROPN - B-NORP 
of - ADP O 
Acute PROPN - B-ORG 
Pancreatitis PROPN - I-ORG 
Induced VERB - I-ORG 
by - ADP O 
Caerulein PROPN - B-GPE 
. - PUNCT O 

Oral PROPN - B-ORG 
Versus PROPN - I-ORG 
Topical PROPN - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
in - ADP O 
the DET - B-ORG 
Treatment PROPN - I-ORG 
of ADP - I-ORG 
Osteoarthritis PROPN - I-ORG 
. - PUNCT O 

A - DET O 
case - NOUN O 
study - NOUN O 
of - ADP O 
Diclofenac PROPN - B-ORG 
Sodium NOUN - I-ORG 
Extended - ADJ O 
Release - PROPN O 
Matrix - PROPN O 
Tablets - NOUN O 
. - PUNCT O 

Study - NOUN O 
on - ADP O 
the DET - B-ORG 
Visible ADJ - I-ORG 
- PUNCT - I-ORG 
Light NOUN - I-ORG 
Photocatalytic PROPN - I-ORG 
Performance PROPN - I-ORG 
and CCONJ - I-ORG 
Degradation PROPN - I-ORG 
Mechanism PROPN - I-ORG 
of ADP - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
under - ADP O 
the - DET O 
System - PROPN O 
of - ADP O 
Hetero - PROPN O 
- - PUNCT O 
Structural - PROPN O 
CuBi₂O₄/Ag₃PO₄ - PROPN O 
with - ADP O 
H₂O₂. - NOUN O 

Application - PROPN O 
of - ADP O 
Quality - PROPN O 
by - ADP O 
Design - PROPN O 
: - PUNCT O 
Development - NOUN O 
to - ADP O 
Manufacturing NOUN - B-ORG 
of ADP - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
Topical - PROPN O 
Gel - PROPN O 
. - PUNCT O 

pH - NOUN O 
- - PUNCT O 
Responsive - ADJ O 
PLGA - PROPN O 
Nanoparticle - PROPN O 
for - ADP O 
Controlled - PROPN O 
Payload - PROPN O 
Delivery - NOUN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
. - PUNCT O 

The DET - B-WORK_OF_ART 
Effectiveness PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Diclofenac PROPN - I-WORK_OF_ART 
Sodium PROPN - I-WORK_OF_ART 
in ADP - I-WORK_OF_ART 
the DET - I-WORK_OF_ART 
Treatment PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Mondor PROPN - I-WORK_OF_ART 
's PART - I-WORK_OF_ART 
Disease PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
the DET - I-WORK_OF_ART 
Breast PROPN - I-WORK_OF_ART 
: PUNCT - I-WORK_OF_ART 
The DET - I-WORK_OF_ART 
Topical PROPN - I-WORK_OF_ART 
Patch PROPN - I-WORK_OF_ART 

Design - PROPN O 
and - CCONJ O 
Evaluation - PROPN O 
of - ADP O 
Topical - PROPN O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Gel - PROPN O 
Using - VERB O 
Hot - PROPN O 
Melt - PROPN O 
Extrusion - PROPN O 
Technology - PROPN O 
as - ADP O 
a - DET O 
Continuous - PROPN O 
Manufacturing - PROPN O 
Process - PROPN O 
with - ADP O 
Kolliphor - PROPN O 
® - PUNCT O 
P407 - PROPN O 
. - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
Bromelain PROPN - B-GPE 
along - ADV O 
with - ADP O 
Trypsin PROPN - B-GPE 
, - PUNCT O 
Rutoside PROPN - B-ORG 
Trihydrate PROPN - I-ORG 
Enzymes PROPN - I-ORG 
and - CCONJ O 
Diclofenac PROPN - B-ORG 
Sodium PROPN - I-ORG 
Combination PROPN - I-ORG 
Therapy PROPN - I-ORG 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
TMJ PROPN - B-ORG 
Osteoarthritis - PROPN O 
- - PUNCT O 
A - PROPN O 
Randomised VERB - B-ORG 
Clinical PROPN - I-ORG 
Trial PROPN - I-ORG 
. - PUNCT O 

Characterization - NOUN O 
of - ADP O 
the DET - B-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Drug PROPN - I-ORG 
- PUNCT - I-ORG 
Drug NOUN - I-ORG 
Interaction PROPN - I-ORG 
on ADP - I-ORG 
Protein PROPN - I-ORG 
Binding PROPN - I-ORG 
in ADP - I-ORG 
Concurrent PROPN - I-ORG 
Administration PROPN - I-ORG 
of ADP - I-ORG 
Sulfamethoxazol PROPN - I-ORG 
and CCONJ - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 

Topical - ADJ O 
Fluorometholone - NOUN O 
Versus - PROPN O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
in - ADP O 
Cases PROPN - B-ORG 
With ADP - I-ORG 
Perennial PROPN - I-ORG 
Allergic PROPN - I-ORG 
Conjunctivitis PROPN - I-ORG 
. - PUNCT O 

Composition NOUN - B-ORG 
and CCONJ - I-ORG 
Concentration NOUN - I-ORG 
Gradient PROPN - I-ORG 
Induced VERB - I-ORG 
Structural PROPN - I-ORG 
Transition PROPN - I-ORG 
from - ADP O 
Micelles - NOUN O 
to - ADP O 
Vesicles PROPN - B-GPE 
in - ADP O 
the - DET O 
Mixed - PROPN O 
System - PROPN O 
of - ADP O 
Ionic - PROPN O 
Liquid - PROPN O 
- - PUNCT O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
on - ADP O 
BMP PROPN - B-ORG 
- PUNCT - I-ORG 
induced VERB - I-ORG 
Inflammation PROPN - I-ORG 
in - ADP O 
a - DET O 
Rodent - PROPN O 
Model PROPN - B-PRODUCT 
. - PUNCT O 

In - ADP O 
Situ - PROPN O 
Hydrogels - NOUN O 
Combined - VERB O 
With - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
- - PUNCT O 
Loaded - PROPN O 
Alginate - PROPN O 
Microspheres - PROPN O 
. - PUNCT O 

Design - PROPN O 
and - CCONJ O 
Evaluation - PROPN O 
of - ADP O 
Ocular - PROPN O 
Controlled - PROPN O 
Delivery - PROPN O 
System - PROPN O 
for - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
. - PUNCT O 

Stability - PROPN O 
of - ADP O 
Atenolol - PROPN O 
, - PUNCT O 
Clonazepam - PROPN O 
, - PUNCT O 
Dexamethasone PROPN - B-ORG 
, PUNCT - I-ORG 
Diclofenac PROPN - B-PERSON 
Sodium PROPN - I-PERSON 
, - PUNCT O 
Diltiazem PROPN - B-PERSON 
, - PUNCT O 
Enalapril PROPN - B-PERSON 
Maleate PROPN - I-PERSON 
, - PUNCT O 
Ketoprofen PROPN - B-PERSON 
, - PUNCT O 
Lamotrigine - PROPN O 
, - PUNCT O 
Penicillamine - PROPN O 
- - PUNCT O 
D - PROPN O 
, - PUNCT O 
and - CCONJ O 
Thiamine PROPN - B-NORP 
in - ADP O 
SyrSpend - PROPN O 
SF - PROPN O 
PH4 - PROPN O 
Oral - PROPN O 
Suspensions - PROPN O 
. - PUNCT O 

In - ADP O 
the - DET O 
present - ADJ O 
study - NOUN O 
, - PUNCT O 
Diclofenac PROPN - B-PERSON 
Sodium PROPN - I-PERSON 
( - PUNCT O 
DS PROPN - B-PERSON 
) - PUNCT O 
matrix - NOUN O 
tablets - NOUN O 
were - VERB O 
prepared - VERB O 
by - ADP O 
direct - ADJ O 
compression - NOUN O 
method - NOUN O 
under - ADP O 
different - ADJ O 
compression - NOUN O 
forces - NOUN O 
( - PUNCT O 
5 NUM - B-CARDINAL 
, - PUNCT O 
10 NUM - B-CARDINAL 
, - PUNCT O 
15 NUM - B-DATE 
and - CCONJ O 
20 NUM - B-CARDINAL 
KN PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
using - VERB O 
ethylcellulose - NOUN O 
as - ADP O 
matrix - NOUN O 
forming - VERB O 
material - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-ORG 
is - VERB O 
a - DET O 
frequently - ADV O 
prescribed - VERB O 
antibacterial - ADJ O 
agent - NOUN O 
with - ADP O 
Diclofenac PROPN - B-ORG 
Sodium PROPN - I-ORG 
for - ADP O 
pain - NOUN O 
management - NOUN O 
in - ADP O 
infectious - ADJ O 
conditions - NOUN O 
. - PUNCT O 

The - DET O 
objective - NOUN O 
of - ADP O 
the - DET O 
present - ADJ O 
work - NOUN O 
is - VERB O 
to - PART O 
evaluate - VERB O 
the - DET O 
level - NOUN O 
of - ADP O 
interaction - NOUN O 
between - ADP O 
Levofloxacin PROPN - B-ORG 
and - CCONJ O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
. - PUNCT O 

However - ADV O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
showed - VERB O 
adherence - NOUN O 
with - ADP O 
( - PUNCT O 
first ADJ - B-ORDINAL 
order - NOUN O 
, - PUNCT O 
Hixson PROPN - B-PERSON 
Crowell PROPN - I-PERSON 
and - CCONJ O 
Weibull PROPN - B-PERSON 
) - PUNCT O 
at - ADP O 
pH - PROPN O 
( - PUNCT O 
1.2 NUM - B-CARDINAL 
, - PUNCT O 
4.5 NUM - B-CARDINAL 
and - CCONJ O 
6.8 NUM - B-DATE 
) - PUNCT O 
but - CCONJ O 
following - VERB O 
Higuchi PROPN - B-GPE 
at - ADP O 
pH - PROPN O 
1.2 NUM - B-CARDINAL 
and - CCONJ O 
4.5 NUM - B-CARDINAL 
only - ADV O 
. - PUNCT O 

The - DET O 
studies - NOUN O 
showed - VERB O 
that - ADP O 
the - DET O 
percent - NOUN O 
availability - NOUN O 
of - ADP O 
Levofloxacin PROPN - B-ORG 
was - VERB O 
increased - VERB O 
significantly - ADV O 
in - ADP O 
FaSSIF PROPN - B-ORG 
i.e. - X O 
129.173±0.323 - NUM O 
at - ADP O 
45 NUM - B-TIME 
minutes NOUN - I-TIME 
in - ADP O 
the - DET O 
presence - NOUN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
. - PUNCT O 

[ - PUNCT O 
Catalytic - ADJ O 
Degradation - PROPN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
over - ADP O 
the DET - B-ORG 
Catalyst PROPN - I-ORG 
of ADP - I-ORG 
3D PROPN - I-ORG 
Flower PROPN - I-ORG 
- - PUNCT O 
like - PROPN O 
alpha - NOUN O 
- - PUNCT O 
FeOOH - NOUN O 
Synergized - VERB O 
with - ADP O 
H2O2 - NOUN O 
Under - ADP O 
Visible ADJ - B-PRODUCT 
Light NOUN - I-PRODUCT 
Irradiation]. PROPN - I-PRODUCT 

Antimicrobial - PROPN O 
Efficacy - NOUN O 
of - ADP O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
- - PUNCT O 
eluting - VERB O 
Polymer PROPN - B-ORG 
Nanofibers PROPN - I-ORG 
against - ADP O 
Multispecies PROPN - B-ORG 
Biofilm PROPN - I-ORG 
. - PUNCT O 

Clindamycin - PROPN O 
- - PUNCT O 
modified - VERB O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Nanofibers - PROPN O 
: - PUNCT O 
A - DET O 
Stain - NOUN O 
- - PUNCT O 
free - ADJ O 
Antimicrobial PROPN - B-ORG 
Intracanal PROPN - I-ORG 
Drug PROPN - I-ORG 
Delivery PROPN - I-ORG 
System PROPN - I-ORG 
. - PUNCT O 

Mineral - NOUN O 
Trioxide - NOUN O 
Aggregate - PROPN O 
, - PUNCT O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Paste - PROPN O 
, - PUNCT O 
and - CCONJ O 
Abscess - NOUN O 
Remedy - PROPN O 
on - ADP O 
Apical - PROPN O 
Development - PROPN O 
of - ADP O 
Vital - PROPN O 
Young - ADJ O 
Permanent - PROPN O 
Teeth - PROPN O 
. - PUNCT O 

Comparison NOUN - B-ORG 
of ADP - I-ORG 
Antimicrobial PROPN - I-ORG 
Effects PROPN - I-ORG 
of ADP - I-ORG 
Triple PROPN - I-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
and - CCONJ O 
Calcium - PROPN O 
Hydroxide - PROPN O 
Mixed - VERB O 
with - ADP O 
2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
Chlorhexidine - PROPN O 
as - ADP O 
Intracanal - ADJ O 
Medicaments - PROPN O 

Efficacy - NOUN O 
of - ADP O 
XP PROPN - B-PERSON 
- PUNCT - I-PERSON 
Endo PROPN - I-PERSON 
Finisher PROPN - I-PERSON 
in - ADP O 
the - DET O 
Removal - PROPN O 
of - ADP O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Paste - PROPN O 
from - ADP O 
Immature PROPN - B-ORG 
Root PROPN - I-ORG 
Canals PROPN - I-ORG 
. - PUNCT O 

To - PART O 
observe - VERB O 
the - DET O 
potential - NOUN O 
of - ADP O 
combinations - NOUN O 
[ - PUNCT O 
( - PUNCT O 
Amoxicillin+ PROPN - B-ORG 
Metronidazole PROPN - I-ORG 
, - PUNCT O 
Amoxicillin - PROPN O 
Clavulanic - PROPN O 
Acid - PROPN O 
+ - CCONJ O 
Metronidazole - PROPN O 
; - PUNCT O 
Amoxicillin PROPN - B-GPE 
and - CCONJ O 
Cloxacillin PROPN - B-ORG 
+ CCONJ - I-ORG 
Metronidazole PROPN - I-ORG 
) - PUNCT O 
] - PUNCT O 
over - ADP O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
. - PUNCT O 

The - DET O 
largest - ADJ O 
inhibition - NOUN O 
zones - NOUN O 
were - VERB O 
observed - VERB O 
for - ADP O 
the DET - B-ORG 
Triple PROPN - I-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
, - PUNCT O 
followed - VERB O 
by - ADP O 
Amoxicillin PROPN - B-GPE 
and - CCONJ O 
Clavulanic PROPN - B-ORG 
acid - NOUN O 
+ - CCONJ O 
Metronidazole - PROPN O 
group - NOUN O 
however - ADV O 
, - PUNCT O 
the - DET O 
clearest - ADJ O 
zones - NOUN O 
were - VERB O 
achieved - VERB O 
with - ADP O 
Amoxicillin PROPN - B-ORG 
and - CCONJ O 
Clavlunic PROPN - B-ORG 
acid - NOUN O 
+ - CCONJ O 
Metronidazole - PROPN O 
group - NOUN O 
and - CCONJ O 
the - DET O 
smallest - ADJ O 
for - ADP O 
Amoxicillin PROPN - B-ORG 
and - CCONJ O 
Metronidazole PROPN - B-PRODUCT 
group - NOUN O 
. - PUNCT O 

Key - ADJ O 
words - NOUN O 
: - PUNCT O 
Enterococcus - NOUN O 
faecalis - NOUN O 
, - PUNCT O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
, - PUNCT O 
Amoxcillin PROPN - B-GPE 
, - PUNCT O 
Clavulanic ADJ - B-ORG 
acid - NOUN O 
. - PUNCT O 

Comparative - PROPN O 
Evaluation - NOUN O 
of - ADP O 
Anti - PROPN O 
Microbial - ADJ O 
effects - NOUN O 
of - ADP O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
and - CCONJ O 
Amox PROPN - B-PERSON 
and - CCONJ O 
its - ADJ O 
derivatives - NOUN O 
against - ADP O 
E. PROPN - B-PERSON 
Faecalis PROPN - I-PERSON 
: - PUNCT O 

Effect - NOUN O 
of - ADP O 
a - DET O 
Low - PROPN O 
Surface - PROPN O 
Tension - PROPN O 
Vehicle - PROPN O 
on - ADP O 
the DET - B-EVENT 
Dentinal PROPN - I-EVENT 
Tubule PROPN - I-EVENT 
Penetration PROPN - I-EVENT 
of ADP - I-EVENT 
Calcium PROPN - I-EVENT 
Hydroxide PROPN - I-EVENT 
and - CCONJ O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
. - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
, - PUNCT O 
Moxifloxacin PROPN - B-ORG 
, - PUNCT O 
Calcium PROPN - B-PERSON 
Hydroxide PROPN - I-PERSON 
And - CCONJ O 
2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
Chlorhexidine - PROPN O 
Gel - PROPN O 

Minimum - PROPN O 
Intracanal - PROPN O 
Dressing - PROPN O 
Time - PROPN O 
of - ADP O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Paste - PROPN O 
to - PART O 
Eliminate VERB - B-ORG 
Enterococcus PROPN - I-ORG 
Faecalis PROPN - I-ORG 
( - PUNCT O 
ATCC - PROPN O 
29212 NUM - B-DATE 
) - PUNCT O 
and - CCONJ O 
Determination PROPN - B-ORG 
of ADP - I-ORG 
Minimum PROPN - I-ORG 
Inhibitory PROPN - I-ORG 
Concentration PROPN - I-ORG 
and - CCONJ O 
Minimum - PROPN O 
Bactericidal - PROPN O 
Concentration - PROPN O 
: - PUNCT O 
An - PROPN O 
Ex - PROPN O 
Vivo - PROPN O 
Study - PROPN O 
. - PUNCT O 

Triple ADJ - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Polymer - PROPN O 
Nanofibers - PROPN O 
for - ADP O 
Intracanal - ADJ O 
Drug - PROPN O 
Delivery - PROPN O 
: - PUNCT O 
Effects - NOUN O 
on - ADP O 
Dual - PROPN O 
Species - PROPN O 
Biofilm - PROPN O 
and - CCONJ O 
Cell PROPN - B-ORG 
Function PROPN - I-ORG 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Laser PROPN - B-ORG 
- PUNCT - I-ORG 
Activated PROPN - I-ORG 
Irrigation PROPN - I-ORG 
with - ADP O 
Ethylene PROPN - B-PERSON 
Diaminetetraacetic PROPN - I-PERSON 
Acid PROPN - I-PERSON 
and - CCONJ O 
Phytic - ADJ O 
Acid - NOUN O 
on - ADP O 
the - DET O 
Removal - PROPN O 
of - ADP O 
Calcium - PROPN O 
Hydroxide - PROPN O 
and - CCONJ O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
from - ADP O 
Root PROPN - B-PERSON 
Dentin PROPN - I-PERSON 
. - PUNCT O 

Antimicrobial - PROPN O 
and - CCONJ O 
Cytotoxic - PROPN O 
Activity - PROPN O 
of - ADP O 
Cinnamomum PROPN - B-ORG 
zeylanicum - NOUN O 
, - PUNCT O 
Calcium PROPN - B-PERSON 
Hydroxide PROPN - I-PERSON 
, - PUNCT O 
and - CCONJ O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
as ADP - I-ORG 
Root - PROPN O 
Canal - PROPN O 
Dressing - PROPN O 
Materials - PROPN O 
. - PUNCT O 

Revisiting - VERB O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Irrigation - PROPN O 
of - ADP O 
Breast - PROPN O 
Implant - PROPN O 
Pockets - PROPN O 
: - PUNCT O 
A - DET O 
Placebo NOUN - B-GPE 
- - PUNCT O 
controlled - VERB O 
Single - PROPN O 
Practice - PROPN O 
Cohort - PROPN O 
Study - PROPN O 
. - PUNCT O 

Calcium PROPN - B-ORG 
Chloride PROPN - I-ORG 
and - CCONJ O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
in - ADP O 
Neonatal PROPN - B-ORG 
Parenteral PROPN - I-ORG 
Nutrition PROPN - I-ORG 
Solutions PROPN - I-ORG 
with - ADP O 
Added PROPN - B-ORG 
Cysteine PROPN - I-ORG 
: - PUNCT O 

Lesions - NOUN O 
Associated - VERB O 
With - ADP O 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
Extravasation - NOUN O 
: - PUNCT O 
Presentation - NOUN O 
of - ADP O 
5 NUM - B-CARDINAL 
Clinical PROPN - B-WORK_OF_ART 
Cases PROPN - I-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Analysis PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Cases PROPN - I-WORK_OF_ART 
Published VERB - I-WORK_OF_ART 
. - PUNCT O 

Calcium PROPN - B-ORG 
Chloride PROPN - I-ORG 
and - CCONJ O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
in - ADP O 
Neonatal PROPN - B-ORG 
Parenteral PROPN - I-ORG 
Nutrition PROPN - I-ORG 
Solutions PROPN - I-ORG 
without - ADP O 
Cysteine PROPN - B-ORG 
: PUNCT - I-ORG 
Compatibility PROPN - I-ORG 
Studies PROPN - I-ORG 

The - DET O 
aluminum - NOUN O 
concentration - NOUN O 
in - ADP O 
a - DET O 
recently - ADV O 
released - VERB O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
USP PROPN - I-ORG 
was - VERB O 
approximately - ADV O 
320 - NUM O 
μg - PROPN O 
/ - SYM O 
L. - PROPN O 
Phthalates - PROPN O 
were - VERB O 
not - ADV O 
detected - VERB O 
in - ADP O 
any - DET O 
calcium NOUN - B-MEDICINE 
gluconate NOUN - I-MEDICINE 
solutions - NOUN O 
or - CCONJ O 
leachates - NOUN O 
. - PUNCT O 

Aluminum PROPN - B-ORG 
and - CCONJ O 
Phthalates PROPN - B-ORG 
in ADP - I-ORG 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
: - PUNCT O 
Contribution - NOUN O 
From - ADP O 
Glass PROPN - B-PERSON 
and - CCONJ O 
Plastic - PROPN O 
Packaging - PROPN O 
. - PUNCT O 

Injectable PROPN - B-ORG 
Alginate PROPN - I-ORG 
Hydrogel PROPN - I-ORG 
Cross PROPN - I-ORG 
- PUNCT - I-ORG 
Linked VERB - I-ORG 
by - ADP O 
Calcium PROPN - B-PERSON 
Gluconate PROPN - I-PERSON 
- PUNCT - I-PERSON 
Loaded ADJ - I-PERSON 
Porous - ADJ O 
Microspheres - NOUN O 
for - ADP O 
Cartilage - PROPN O 
Tissue - PROPN O 
Engineering - PROPN O 
. - PUNCT O 

Managed VERB - B-NORP 
With - ADP O 
Hyperinsulinemia PROPN - B-ORG 
/ SYM - I-ORG 
Euglycemia PROPN - I-ORG 
Therapy PROPN - I-ORG 
Supplemented VERB - I-ORG 
With ADP - I-ORG 
Calcium PROPN - I-ORG 
Gluconate PROPN - I-ORG 
, - PUNCT O 
Intravenous - PROPN O 
Glucagon - PROPN O 
and - CCONJ O 
Other - PROPN O 
Vasopressor - PROPN O 
Support - PROPN O 
: - PUNCT O 

Hydrofluoric - PROPN O 
Acid - NOUN O 
Burn - VERB O 
on - ADP O 
a - DET O 
Fingertip - PROPN O 
Treated - VERB O 
Successfully - ADV O 
with - ADP O 
Single - PROPN O 
Session - PROPN O 
of - ADP O 
Subcutaneous - PROPN O 
Injection - PROPN O 
of - ADP O 
6.7 NUM - B-PERCENT 
% NOUN - I-PERCENT 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
. - PUNCT O 

The - DET O 
Effects - NOUN O 
of - ADP O 
Topical - PROPN O 
Application - PROPN O 
of - ADP O 
Polycal - PROPN O 
( - PUNCT O 
a - DET O 
2:98 - NUM O 
( - PUNCT O 
g - NOUN O 
/ - SYM O 
g - NOUN O 
) - PUNCT O 
Mixture - NOUN O 
of - ADP O 
Polycan - PROPN O 
and - CCONJ O 
Calcium PROPN - B-PERSON 
Gluconate PROPN - I-PERSON 
) - PUNCT O 
on - ADP O 
Experimental PROPN - B-ORG 
Periodontitis PROPN - I-ORG 
and - CCONJ O 
Alveolar - PROPN O 
Bone - PROPN O 
Loss - PROPN O 
in - ADP O 
Rats - PROPN O 
. - PUNCT O 

The DET - B-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Thyroid PROPN - I-ORG 
Hormone PROPN - I-ORG 
, - PUNCT O 
Prostaglandin PROPN - B-ORG 
E2 PROPN - I-ORG 
, - PUNCT O 
and - CCONJ O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
on ADP - I-ORG 
Orthodontic PROPN - I-ORG 
Tooth PROPN - I-ORG 
Movement PROPN - I-ORG 
and CCONJ - I-ORG 
Root PROPN - I-ORG 
Resorption PROPN - I-ORG 
in ADP - I-ORG 
Rats PROPN - I-ORG 
. - PUNCT O 

As - ADP O 
no - DET O 
RCT - PROPN O 
had - VERB O 
ever - ADV O 
compared - VERB O 
the - DET O 
use - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
alone - ADJ O 
with - ADP O 
combined - ADJ O 
vasoconstrictors - NOUN O 
and - CCONJ O 
fluid - NOUN O 
preload - NOUN O 
, - PUNCT O 
so - CCONJ O 
, - PUNCT O 
this - DET O 
randomised - VERB O 
controlled - VERB O 
trial - NOUN O 
has - VERB O 
evaluated - VERB O 
the - DET O 
efficacy - NOUN O 
of - ADP O 
the - DET O 
use - NOUN O 
of - ADP O 
ondansetron NOUN - B-MEDICINE 
alone - ADV O 
compared - VERB O 
to - ADP O 
the - DET O 
combined - VERB O 
use - NOUN O 
of - ADP O 
fluid - ADJ O 
preload - NOUN O 
and - CCONJ O 
vasoconstrictors - NOUN O 
to - PART O 
decrease - VERB O 
the - DET O 
incidence - NOUN O 
of - ADP O 
spinal - ADJ O 
hypotension - NOUN O 
. - PUNCT O 

The - DET O 
preemptive - ADJ O 
use - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
alone - ADV O 
versus - ADP O 
combined - VERB O 
vasoconstrictors - NOUN O 
with - ADP O 
fluid - ADJ O 
preload - NOUN O 
significantly - ADV O 
reduces - VERB O 
the - DET O 
incidence - NOUN O 
of - ADP O 
post - ADJ O 
- - ADJ O 
spinal - ADJ O 
hypotension - NOUN O 
( - PUNCT O 
PSH - NOUN O 
) - PUNCT O 
with - ADP O 
no - DET O 
significant - ADJ O 
difference - NOUN O 
between - ADP O 
both - DET O 
regimens - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
Is - VERB O 
an - DET O 
Effective - ADJ O 
Alternative - NOUN O 
to - ADP O 
Decrease - PROPN O 
the DET - B-ORG 
Incidence PROPN - I-ORG 
of ADP - I-ORG 
Postspinal PROPN - I-ORG 
Hypotension PROPN - I-ORG 
in - ADP O 
Healthy - PROPN O 
Subjects - PROPN O 
Undergoing - PROPN O 
Infra PROPN - B-ORG 
- PUNCT - I-ORG 
Umbilical PROPN - I-ORG 
Surgeries PROPN - I-ORG 

Helping - VERB O 
Pregnant - PROPN O 
Women - PROPN O 
and - CCONJ O 
Clinicians PROPN - B-NORP 
Understand - VERB O 
the - DET O 
Risk - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
for - ADP O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 
During - ADP O 
Pregnancy - PROPN O 
. - PUNCT O 

Determination - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
by - ADP O 
Spectrofluorimetry - PROPN O 
: - PUNCT O 
Application - NOUN O 
to - ADP O 
Forced - PROPN O 
Degradation - PROPN O 
Study - PROPN O 
, - PUNCT O 
Pharmaceuticals - PROPN O 
and - CCONJ O 
Human - PROPN O 
Plasma - PROPN O 
. - PUNCT O 

BACKGROUND::Ondansetron NOUN - B-CARDINAL 
is - VERB O 
a - DET O 
serotonin - ADJ O 
3 NUM - B-CARDINAL 
receptor - NOUN O 
antagonist - NOUN O 
widely - ADV O 
used - VERB O 
to - PART O 
prevent - VERB O 
nausea - NOUN O 
and - CCONJ O 
vomiting - VERB O 
in - ADP O 
pregnancy - NOUN O 
and - CCONJ O 
in - ADP O 
patients - NOUN O 
receiving - VERB O 
chemotherapy - NOUN O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
with - ADP O 
dexamethasone - ADJ O 
premedication - NOUN O 
was - VERB O 
more - ADV O 
effective - ADJ O 
in - ADP O 
controlling - VERB O 
PONV - PROPN O 
after - ADP O 
orthognathic - ADJ O 
surgery - NOUN O 
compared - VERB O 
to - PART O 
clonidine - VERB O 
with - ADP O 
dexamethasone - NOUN O 
group - NOUN O 
. - PUNCT O 

Comparison - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
versus - ADP O 
Clonidine PROPN - B-ORG 
efficacy - NOUN O 
for - ADP O 
prevention - NOUN O 
of - ADP O 
postoperative - ADJ O 
pain - NOUN O 
, - PUNCT O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
after - ADP O 
orthognathic - ADJ O 
surgeries - NOUN O 
: - PUNCT O 

Gaining - VERB O 
Insight - PROPN O 
Into - ADP O 
Ondansetron PROPN - B-MEDICINE 
Safety - PROPN O 
in - ADP O 
Early - ADJ O 
Pregnancy - PROPN O 
. - PUNCT O 

Association PROPN - B-ORG 
of ADP - I-ORG 
Maternal PROPN - I-ORG 
First PROPN - I-ORG 
- PUNCT - I-ORG 
Trimester NOUN - I-ORG 
Ondansetron PROPN - B-MEDICINE 
Use - PROPN O 
With - ADP O 
Cardiac PROPN - B-ORG 
Malformations PROPN - I-ORG 
and - CCONJ O 
Oral PROPN - B-FAC 
Clefts PROPN - I-FAC 
in - ADP O 
Offspring PROPN - B-GPE 
. - PUNCT O 

Oral PROPN - B-ORG 
Ondansetron PROPN - I-MEDICINE 
Administration PROPN - I-ORG 
to ADP - I-ORG 
Nondehydrated PROPN - I-ORG 
Children NOUN - I-ORG 

Ondansetron PROPN - B-MEDICINE 
alone - ADV O 
did - VERB O 
not - ADV O 
affect - VERB O 
hippocampal - ADJ O 
network - NOUN O 
oscillations - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
( - PUNCT O 
0.3 NUM - B-MONEY 
  SPACE - I-MONEY 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
, - PUNCT O 
i.v - PROPN O 
. - PUNCT O 
) - PUNCT O 
potentiated - VERB O 
theta - NOUN O 
and - CCONJ O 
gamma - NOUN O 
responses - NOUN O 
to - ADP O 
0.2 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
donepezil - VERB O 
and - CCONJ O 
prolonged - VERB O 
theta - NOUN O 
and - CCONJ O 
gamma - NOUN O 
responses - NOUN O 
to - ADP O 
0.3 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
donepezil - NOUN O 
. - PUNCT O 

Assessment - NOUN O 
and - CCONJ O 
comparison - NOUN O 
of - ADP O 
the - DET O 
effectiveness - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
and - CCONJ O 
Promethazine PROPN - B-GPE 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
acute - ADJ O 
peripheral - ADJ O 
vertigo - NOUN O 
. - PUNCT O 

A - DET O 
total - NOUN O 
of - ADP O 
170 NUM - B-CARDINAL 
eligible - ADJ O 
patients - NOUN O 
were - VERB O 
randomly - ADV O 
allocated - VERB O 
to - ADP O 
groups - NOUN O 
A - NOUN O 
: - PUNCT O 
received - VERB O 
intramuscular - ADJ O 
( - PUNCT O 
IM PROPN - B-ORG 
) - PUNCT O 
promethazine - NOUN O 
; - PUNCT O 
and - CCONJ O 
B - NOUN O 
: - PUNCT O 
received - VERB O 
intravenous - ADJ O 
( - PUNCT O 
IV PROPN - B-ORG 
) - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
using - VERB O 
quadripartite - ADJ O 
blocks - NOUN O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
and - CCONJ O 
teratogenicity - NOUN O 
in - ADP O 
rats - NOUN O 

Ondansetron PROPN - B-MEDICINE 
offers - VERB O 
symptomatic - ADJ O 
relief - NOUN O 
in - ADP O 
the - DET O 
majority - NOUN O 
of - ADP O 
patients - NOUN O 
. - PUNCT O 

Medical - PROPN O 
and - CCONJ O 
Nursing - PROPN O 
Staff - PROPN O 
Education - PROPN O 
Reduces - PROPN O 
Use - PROPN O 
of - ADP O 
Prophylactic - PROPN O 
Ondansetron PROPN - B-MEDICINE 
With - ADP O 
Opioids PROPN - B-GPE 
in - ADP O 
the DET - B-ORG 
Emergency PROPN - I-ORG 
Department PROPN - I-ORG 
. - PUNCT O 

CONCLUSIONS - NOUN O 
: - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
0.05 - NUM O 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
or - CCONJ O 
0.1 NUM - B-MONEY 
  SPACE - I-MONEY 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 

Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
potent - ADJ O 
and - CCONJ O 
highly - ADV O 
sensitive - ADJ O 
5-hydroxytryptamine - NUM O 
type - NOUN O 
3 NUM - B-CARDINAL 
( - PUNCT O 
5-HT3 - PROPN O 
) - PUNCT O 
receptor - NOUN O 
antagonist - NOUN O 
, - PUNCT O 
has - VERB O 
been - VERB O 
used - VERB O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
chemotherapy- - NOUN O 
and - CCONJ O 
radiotherapy - NOUN O 
- - PUNCT O 
induced - VERB O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
for - ADP O 
Treatment - PROPN O 
of - ADP O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 
of - ADP O 
Pregnancy - PROPN O 
and - CCONJ O 
the DET - B-ORG 
Risk PROPN - I-ORG 
of ADP - I-ORG 
Specific PROPN - I-ORG 
Birth PROPN - I-ORG 
Defects PROPN - I-ORG 
. - PUNCT O 

A - DET O 
total - NOUN O 
of - ADP O 
102 NUM - B-CARDINAL 
patients - NOUN O 
who - NOUN O 
underwent - VERB O 
laparoscopic - ADJ O 
cholecystectomy - NOUN O 
under - ADP O 
general - ADJ O 
anesthesia - NOUN O 
, - PUNCT O 
out - ADP O 
of - ADP O 
which - ADJ O 
patients - NOUN O 
who - NOUN O 
received - VERB O 
Palonosetron PROPN - B-ORG 
were - VERB O 
in - ADP O 
Group PROPN - B-ORG 
A PROPN - I-ORG 
( - PUNCT O 
n=34 - NOUN O 
) - PUNCT O 
, - PUNCT O 
patients - NOUN O 
who - NOUN O 
received - VERB O 
Ondansetron PROPN - B-MEDICINE 
were - VERB O 
in - ADP O 
group - NOUN O 
B - PROPN O 
( - PUNCT O 
n=34 - NOUN O 
) - PUNCT O 
and - CCONJ O 
patients - NOUN O 
who - NOUN O 
received - VERB O 
Granisetron PROPN - B-PERSON 
were - VERB O 
in - ADP O 
group - NOUN O 
C - NOUN O 
( - PUNCT O 
n=34 - PROPN O 
) - PUNCT O 
and - CCONJ O 
also - ADV O 
the - DET O 
patients - NOUN O 
were - VERB O 
selected - VERB O 
randomly - ADV O 
by - ADP O 
lottery - NOUN O 
method - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
was - VERB O 
unable - ADJ O 
to - PART O 
rescue - VERB O 
the - DET O 
reduction - NOUN O 
in - ADP O 
duration - NOUN O 
of - ADP O 
anesthesia - NOUN O 
induced - VERB O 
by - ADP O 
either - DET O 
rolipram - NOUN O 
or - CCONJ O 
yohimbine - NOUN O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
and - CCONJ O 
dexamethasone - NOUN O 
were - VERB O 
continued - VERB O 
for - ADP O 
48 NUM - B-TIME 
hours NOUN - I-TIME 
after - ADP O 
completion - NOUN O 
of - ADP O 
chemotherapy - NOUN O 
. - PUNCT O 

Ondansetron INTJ - B-MEDICINE 
, - PUNCT O 
a - DET O 
selective - ADJ O 
5-HT3 - ADJ O 
receptor - NOUN O 
antagonist - NOUN O 
; - PUNCT O 
L PROPN - B-ORG 
- PUNCT - I-ORG 
NAME PROPN - I-ORG 
, - PUNCT O 
a - DET O 
NOS PROPN - B-ORG 
inhibitor - NOUN O 
; - PUNCT O 
and - CCONJ O 
naloxone - NOUN O 
, - PUNCT O 
an - DET O 
opioid - ADJ O 
antagonist - NOUN O 
were - VERB O 
injected - VERB O 
to - PART O 
determine - VERB O 
the - DET O 
mechanisms - NOUN O 
of - ADP O 
antinociception - NOUN O 
and - CCONJ O 
anti - ADJ O 
- - ADJ O 
inflammation - ADJ O 
. - PUNCT O 

Ondansetron INTJ - B-MEDICINE 
, - PUNCT O 
not - ADV O 
approved - VERB O 
for - ADP O 
use - NOUN O 
in - ADP O 
pregnancy - NOUN O 
, - PUNCT O 
is - VERB O 
increasingly - ADV O 
being - VERB O 
prescribed - VERB O 
for - ADP O 
nausea - NOUN O 
and - CCONJ O 
vomiting - VERB O 
in - ADP O 
pregnancy - NOUN O 
and - CCONJ O 
hyperemesis - NOUN O 
gravidarum - NOUN O 
. - PUNCT O 

Plus - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
Infusion - PROPN O 

Ondansetron PROPN - B-MEDICINE 
use - NOUN O 
increased - VERB O 
from - ADP O 
36 NUM - B-PERCENT 
% NOUN - I-PERCENT 
to - PART O 
75 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
P - NOUN O 
< - X O 
0.001 NUM - B-CARDINAL 
) - PUNCT O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
at - ADP O 
nanomolar - ADJ O 
concentrations - NOUN O 
inhibited - VERB O 
WT PROPN - B-ORG 
and - CCONJ O 
p - NOUN O 
. - PUNCT O 

Ondansetron ADV - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
IKAS - PROPN O 
inhibition - NOUN O 
was - VERB O 
also - ADV O 
demonstrated - VERB O 
in - ADP O 
Langendorff PROPN - B-GPE 
- - PUNCT O 
perfused - VERB O 
murine - NOUN O 
hearts - NOUN O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
at - ADP O 
therapeutic - ADJ O 
( - PUNCT O 
i.e. - X O 
, - PUNCT O 
nanomolar - ADJ O 
) - PUNCT O 
concentrations - NOUN O 
is - VERB O 
a - DET O 
potent - ADJ O 
IKAS - PROPN O 
blocker - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
may - VERB O 
be - VERB O 
useful - ADJ O 
in - ADP O 
controlling - VERB O 
arrhythmias - NOUN O 
in - ADP O 
which - ADJ O 
increased - VERB O 
SK PROPN - B-GPE 
current - NOUN O 

Ondansetron PROPN - B-MEDICINE 
was - VERB O 
discontinued - VERB O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
improves - VERB O 
the - DET O 
success - NOUN O 
of - ADP O 
oral - ADJ O 
rehydration - NOUN O 
in - ADP O 
children - NOUN O 
with - ADP O 
gastroenteritis - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
does - VERB O 
not - ADV O 
affect - VERB O 
the - DET O 
QTc - NOUN O 
of - ADP O 
pediatric - ADJ O 
patients - NOUN O 
receiving - VERB O 
the - DET O 
medication - NOUN O 
for - ADP O 
nausea - NOUN O 
, - PUNCT O 
vomiting - NOUN O 
, - PUNCT O 
or - CCONJ O 
inability - NOUN O 
to - PART O 
take - VERB O 
fluids - NOUN O 
in - ADP O 
the - DET O 
emergency - NOUN O 
department - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
aimed - VERB O 
to - PART O 
formulate - VERB O 
suitable - ADJ O 
nanovesicles - NOUN O 
( - PUNCT O 
NVs - NOUN O 
) - PUNCT O 
for - ADP O 
transdermal - ADJ O 
delivery - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
. - PUNCT O 

A - DET O 
23 NUM - B-CARDINAL 
full - ADJ O 
factorial - ADJ O 
design - NOUN O 
was - VERB O 
used - VERB O 
to - PART O 
enable - VERB O 
testing - VERB O 
transfersomes - NOUN O 
, - PUNCT O 
ethosomes - NOUN O 
, - PUNCT O 
and - CCONJ O 
transethosomes - VERB O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
simultaneously - ADV O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
has - VERB O 
been - VERB O 
shown - VERB O 
to - PART O 
decrease - VERB O 
admission - NOUN O 
rates - NOUN O 
and - CCONJ O 
the - DET O 
need - NOUN O 
for - ADP O 
intravenous - ADJ O 
fluids - NOUN O 
among - ADP O 
pediatric - ADJ O 
emergency - NOUN O 
department - NOUN O 
( - PUNCT O 
ED PROPN - B-ORG 
) - PUNCT O 
patients - NOUN O 
with - ADP O 
acute - ADJ O 
gastroenteritis - NOUN O 
, - PUNCT O 
but - CCONJ O 
there - ADV O 
is - VERB O 
limited - ADJ O 
evidence - NOUN O 
regarding - VERB O 
its - ADJ O 
use - NOUN O 
after - ADP O 
ED PROPN - B-ORG 
discharge - NOUN O 
. - PUNCT O 

The DET - B-ORG 
All PROPN - I-ORG 
Ondansetron PROPN - I-MEDICINE 
Group PROPN - I-ORG 
included - VERB O 
any - DET O 
child - NOUN O 
prescribed - VERB O 
ondansetron NOUN - B-MEDICINE 
at - ADP O 
discharge - NOUN O 
. - PUNCT O 

Discharge - ADJ O 
diagnosis - NOUN O 
was - VERB O 
evaluated - VERB O 
for - ADP O 
the - DET O 
any - DET O 
Ondansetron PROPN - B-MEDICINE 
Group PROPN - I-ORG 
. - PUNCT O 

Randomized - VERB O 
, - PUNCT O 
Placebo - PROPN O 
- - PUNCT O 
Controlled - PROPN O 
, - PUNCT O 
Phase - PROPN O 
III - PROPN O 
Trial - PROPN O 
of - ADP O 
Fosaprepitant PROPN - B-GPE 
, - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
Dexamethasone PROPN - B-GPE 
( - PUNCT O 
FOND PROPN - B-ORG 
) - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
hydrochloride - NOUN O 
OR=7.12 - PROPN O 
( - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
, - PUNCT O 
1.59 NUM - B-CARDINAL 
– - NOUN O 
31.9 NUM - B-CARDINAL 
) - PUNCT O 
resulted - VERB O 
in - ADP O 
the - DET O 
highest - ADJ O 
odds - NOUN O 
of - ADP O 
pneumothorax - NOUN O 
. - PUNCT O 

Ondansetron ADJ - B-MEDICINE 
treatment - NOUN O 
reduces - VERB O 
rotavirus - NOUN O 
symptoms - NOUN O 
- - PUNCT O 
A - NOUN O 
randomized - VERB O 
double - ADJ O 
- - PUNCT O 
blinded - ADJ O 
placebo - NOUN O 
- - PUNCT O 
controlled - VERB O 
trial - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
use - VERB O 
during - ADP O 
an - DET O 
initial - ADJ O 
emergency - NOUN O 
department - NOUN O 
visit - NOUN O 
for - ADP O 
head - NOUN O 
trauma - NOUN O 
in - ADP O 
children - NOUN O 
not - ADV O 
requiring - VERB O 
neuroimaging - NOUN O 
is - VERB O 
associated - VERB O 
with - ADP O 
a - DET O 
higher - ADJ O 
likelihood - NOUN O 
of - ADP O 
return - NOUN O 
within - ADP O 
72 NUM - B-TIME 
hours NOUN - I-TIME 
and - CCONJ O 
subsequent - ADJ O 
admission - NOUN O 
. - PUNCT O 

Use - PROPN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
for - ADP O 
Vomiting - NOUN O 
After - ADP O 
Head - PROPN O 
Trauma - PROPN O 
: - PUNCT O 

Ondansetron ADV - B-MEDICINE 
, - PUNCT O 
a - DET O 
5-hydroxytryptamine - NUM O 
type - NOUN O 
3 NUM - B-CARDINAL 
receptor - NOUN O 
antagonist - NOUN O 
antiemetic - NOUN O 
, - PUNCT O 
is - VERB O 
one NUM - B-CARDINAL 
such - ADJ O 
drug - NOUN O 
. - PUNCT O 

Torsades NOUN - B-ORG 
de PROPN - I-ORG 
Pointes PROPN - I-ORG 
after - ADP O 
Ondansetron PROPN - B-MEDICINE 
Infusion PROPN - I-ORG 
in - ADP O 
2 NUM - B-CARDINAL 
Patients - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
is - VERB O 
the - DET O 
agent - NOUN O 
typically - ADV O 
administered - VERB O 
to - PART O 
prevent - VERB O 
postoperative - ADJ O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
. - PUNCT O 

Methamphetamine - NOUN O 
- - PUNCT O 
Induced - VERB O 
Neurotoxicity - PROPN O 
: - PUNCT O 
Neuroprotective - PROPN O 
Effects - PROPN O 
of - ADP O 
Nanowired - PROPN O 
Delivery - PROPN O 
of - ADP O 
5-HT3-Receptor - NUM O 
Antagonist - PROPN O 
Ondansetron PROPN - B-MEDICINE 
. - PUNCT O 

Comparison PROPN - B-ORG 
of ADP - I-ORG 
Dexamethasone PROPN - I-ORG 
- PUNCT - I-ORG 
Dimenhydrinate PROPN - I-ORG 
and - CCONJ O 
Dexamethasone - PROPN O 
- - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
in - ADP O 
Prevention - PROPN O 
of - ADP O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 
in - ADP O 
Postoperative - PROPN O 
Patients - PROPN O 
. - PUNCT O 

A - DET O 
Rare - PROPN O 
Case - PROPN O 
of - ADP O 
Fixed - PROPN O 
Drug - PROPN O 
Eruption - PROPN O 
due - ADP O 
to - ADP O 
Ondansetron PROPN - B-MEDICINE 
. - PUNCT O 

, - PUNCT O 
respectively]. - NOUN O 
Conclusion PROPN - B-PERSON 
Ondansetron PROPN - I-MEDICINE 
effectively - ADV O 
reduces - VERB O 
the - DET O 
incidences - NOUN O 
of - ADP O 
nausea - NOUN O 
/ - SYM O 
vomiting - NOUN O 
and - CCONJ O 
bradycardia - NOUN O 
under - ADP O 
spinal - ADJ O 
anesthesia - NOUN O 
during - ADP O 
cesarean - ADJ O 
section - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
randomized - VERB O 
controlled - VERB O 
study - NOUN O 
, - PUNCT O 
120 NUM - B-CARDINAL 
patients - NOUN O 
aged - VERB O 
18 NUM - B-DATE 
- SYM - I-DATE 
65 NUM - I-DATE 
years NOUN - I-DATE 
of - ADP O 
American PROPN - B-ORG 
Society PROPN - I-ORG 
of ADP - I-ORG 
Anesthesiologist PROPN - I-ORG 
( - PUNCT O 
ASA PROPN - B-ORG 
) - PUNCT O 
physical - ADJ O 
status - NOUN O 
I - PRON O 
and - CCONJ O 
II PROPN - B-ORG 
undergoing - VERB O 
various - ADJ O 
surgical - ADJ O 
procedures - NOUN O 
were - VERB O 
included - VERB O 
and - CCONJ O 
allocated - VERB O 
alternately - ADV O 
to - ADP O 
one NUM - B-CARDINAL 
of - ADP O 
the - DET O 
4 NUM - B-CARDINAL 
groups - NOUN O 
; - PUNCT O 
Normal ADJ - B-ORG 
saline - NOUN O 
( - PUNCT O 
Group1 PROPN - B-PERSON 
) - PUNCT O 
, - PUNCT O 
Ondansetron NOUN - B-MEDICINE 
4 NUM - B-QUANTITY 
mg VERB - I-QUANTITY 
( - PUNCT O 
Group2 - PROPN O 
) - PUNCT O 
, - PUNCT O 
Ketamine PROPN - B-PERSON 
0.25mg NUM - I-PERSON 
/ - SYM O 
kg - NOUN O 
( - PUNCT O 
Group3 PROPN - B-ORG 
) - PUNCT O 
and - CCONJ O 
Tramadol PROPN - B-PRODUCT 
0.5mg PROPN - I-PRODUCT 
/ SYM - I-PRODUCT 
kg NOUN - I-PRODUCT 
( - PUNCT O 
Group4 PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

The DET - B-ORG 
Effect NOUN - I-ORG 
of ADP - I-ORG 
Ondansetron PROPN - I-MEDICINE 
on ADP - I-ORG 
Acute PROPN - I-ORG 
Opioid PROPN - I-ORG 
Tolerance PROPN - I-ORG 
in ADP - I-ORG 
Patients PROPN - I-ORG 
Receiving VERB - I-ORG 
Intrathecal PROPN - I-ORG 
Opioids PROPN - I-ORG 

Ondansetron NOUN - B-MEDICINE 
and - CCONJ O 
trazodone - NOUN O 
were - VERB O 
prescribed - VERB O 
as - ADP O 
needed - VERB O 
for - ADP O 
symptom - NOUN O 
control - NOUN O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
and - CCONJ O 
trazodone - NOUN O 
have - VERB O 
both - DET O 
been - VERB O 
associated - VERB O 
with - ADP O 

574 NUM - B-CARDINAL 
] - PUNCT O 
mg - PRON O 
in - ADP O 
the - DET O 
placebo - NOUN O 
group - NOUN O 
, - PUNCT O 
P=0.95.Ondansetron - PROPN O 
significantly - ADV O 
decreased - VERB O 
the - DET O 
analgesic - ADJ O 
effect - NOUN O 
of - ADP O 
acetaminophen - NOUN O 
during - ADP O 
the - DET O 
initial - ADJ O 
postoperative - ADJ O 
period - NOUN O 
. - PUNCT O 

We - PRON O 
present - VERB O 
the - DET O 
case - NOUN O 
of - ADP O 
a - DET O 
26-year NUM - B-CARDINAL 
- - PUNCT O 
old - ADJ O 
woman - NOUN O 
who - NOUN O 
suffered - VERB O 
from - ADP O 
suspected - ADJ O 
AFE - PROPN O 
and - CCONJ O 
was - VERB O 
successfully - ADV O 
treated - VERB O 
with - ADP O 
the - DET O 
novel - ADJ O 
regimen - NOUN O 
of - ADP O 
Atropine PROPN - B-GPE 
, - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
and - CCONJ O 
Ketorolac PROPN - B-PERSON 
( - PUNCT O 
A - PROPN O 
- - PUNCT O 
OK - INTJ O 
) - PUNCT O 
. - PUNCT O 

We - PRON O 
hope - VERB O 
this - DET O 
case - NOUN O 
report - NOUN O 
will - VERB O 
prompt - VERB O 
further - ADJ O 
research - NOUN O 
into - ADP O 
this - DET O 
novel - ADJ O 
approach - NOUN O 
to - ADP O 
treating - VERB O 
AFE - PROPN O 
with - ADP O 
Atropine PROPN - B-ORG 
, - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
and - CCONJ O 
Ketorolac PROPN - B-PERSON 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
reliable - ADJ O 
and - CCONJ O 
safe - ADJ O 
drug - NOUN O 
and - CCONJ O 
it - PRON O 
is - VERB O 
currently - ADV O 
used - VERB O 
in - ADP O 
the - DET O 
prevention - NOUN O 
of - ADP O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
and - CCONJ O 
has - VERB O 
no - DET O 
side - NOUN O 
effects - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
has - VERB O 
been - VERB O 
used - VERB O 
to - PART O 
deal - VERB O 
with - ADP O 
the - DET O 
problem - NOUN O 
of - ADP O 
neuraxial - ADJ O 
morphine - NOUN O 
- - PUNCT O 
induced - VERB O 
pruritus - NOUN O 
( - PUNCT O 
NMIP PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
on - ADP O 
Attenuating - PROPN O 
Spinal - PROPN O 

Ondansetron PROPN - B-MEDICINE 
hydrochloride - NOUN O 
OR=7.12 - PROPN O 
( - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
, - PUNCT O 
1.59 NUM - B-CARDINAL 
- - SYM O 
31.9 - NUM O 
) - PUNCT O 
resulted - VERB O 
in - ADP O 
the - DET O 
highest - ADJ O 
odds - NOUN O 
of - ADP O 
pneumothorax - NOUN O 
. - PUNCT O 

Raw - ADJ O 
Material - PROPN O 
Specification - PROPN O 
, - PUNCT O 
Heparin PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Injection - PROPN O 
, - PUNCT O 
USP PROPN - B-ORG 
. - PUNCT O 

Emodin - PROPN O 
- - PUNCT O 
Loaded - ADJ O 
PLGA - NOUN O 
- - PUNCT O 
TPGS - NOUN O 
Nanoparticles - NOUN O 
Combined - VERB O 
with - ADP O 
Heparin PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
- - PUNCT O 
Loaded - PROPN O 
PLGA - NOUN O 
- - PUNCT O 
TPGS - VERB O 
Nanoparticles - NOUN O 
to - ADP O 
Enhance - VERB O 
Chemotherapeutic - PROPN O 
Efficacy - PROPN O 
Against - PROPN O 
Liver - PROPN O 
Cancer - PROPN O 
. - PUNCT O 

Study - VERB O 
on - ADP O 
Technology - PROPN O 
for - ADP O 
Purification - PROPN O 
of - ADP O 
Heparin PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 

The - DET O 
invention - NOUN O 
discloses - VERB O 
a - DET O 
process - NOUN O 
for - ADP O 
the - DET O 
coproduction - NOUN O 
of - ADP O 
Aprotinin PROPN - B-PERSON 
and - CCONJ O 
Heparin PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
through - ADP O 
extracting - VERB O 
from - ADP O 
cow - NOUN O 
's - PART O 
lungs - NOUN O 
, - PUNCT O 
the - DET O 
Aprotinin PROPN - B-PERSON 
activity - NOUN O 
can - VERB O 
reach - VERB O 
5400 NUM - B-CARDINAL 
KIU - PROPN O 
/ - SYM O 
mg - PROPN O 
, - PUNCT O 
the - DET O 
Heparin PROPN - B-ORG 
Sodium PROPN - I-ORG 
potency - NOUN O 
can - VERB O 
reach - VERB O 
70 NUM - B-CARDINAL 
IU NOUN - B-ORG 
/ SYM - I-ORG 
mg PRON - I-ORG 
. - PUNCT O 

CORRELATION - NOUN O 
FACTORS - NOUN O 
OF - ADP O 
ABNORMAL - NOUN O 
MENSES - VERB O 
IN - ADP O 
SCHIZOPHRENIA - PROPN O 
TREATMENT - NOUN O 
WITH - ADP O 
RISPERIDONE NOUN - B-MEDICINE 
. - PUNCT O 

TRPA1 - PROPN O 
Antagonists - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Practical - ADJ O 
tips - NOUN O 
for - ADP O 
IUD PROPN - B-ORG 
Counselling PROPN - I-ORG 
, PUNCT - I-ORG 
Insertion PROPN - I-ORG 
, - PUNCT O 
and - CCONJ O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Adolescents - NOUN O 
: - PUNCT O 
An - DET O 
Update - PROPN O 
. - PUNCT O 

Cochrane - PROPN O 
Review - PROPN O 
Summary - NOUN O 
: - PUNCT O 
Epidural - ADJ O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
Versus - PROPN O 
Systemic - PROPN O 
Opioid - PROPN O 
- - PUNCT O 
Based - VERB O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
for - ADP O 
Abdominal - PROPN O 
Aortic - PROPN O 
Surgery - PROPN O 
. - PUNCT O 

Pharmacological - ADJ O 
and - CCONJ O 
Non ADJ - B-ORG 
- ADJ - I-ORG 
Pharmacological ADJ - I-ORG 
Methods PROPN - I-ORG 
of ADP - I-ORG 
Labour - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
- - PUNCT O 
Establishment - PROPN O 
of - ADP O 
Effectiveness - PROPN O 
and - CCONJ O 
Comparison - PROPN O 
. - PUNCT O 

The DET - B-ORG 
Lancet PROPN - I-ORG 
Commission PROPN - I-ORG 
on - ADP O 
Global - PROPN O 
Access - PROPN O 
to - ADP O 
Palliative - PROPN O 
Care - PROPN O 
and - CCONJ O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
developed - VERB O 
a - DET O 
framework - NOUN O 
to - PART O 
measure - VERB O 
the - DET O 
global - ADJ O 
burden - NOUN O 
of - ADP O 
serious - ADJ O 
health - NOUN O 
- - PUNCT O 
related - VERB O 
suffering - NOUN O 
and - CCONJ O 
generated - VERB O 
the - DET O 
evidence - NOUN O 
base - NOUN O 
to - PART O 
address - VERB O 
this - DET O 
burden - NOUN O 
. - PUNCT O 

We - PRON O 
present - VERB O 
the - DET O 
inequities - NOUN O 
in - ADP O 
access - NOUN O 
to - ADP O 
pain NOUN - B-MEDICINE 
relief NOUN - I-MEDICINE 
and - CCONJ O 
highlight - VERB O 
key - ADJ O 
points - NOUN O 
from - ADP O 
country - NOUN O 
responses - NOUN O 
, - PUNCT O 
drawing - VERB O 
from - ADP O 
and - CCONJ O 
building - VERB O 
on - ADP O 
recommendations - NOUN O 
of - ADP O 
the - DET O 
Lancet PROPN - B-ORG 
Commission PROPN - I-ORG 
report - NOUN O 
" - PUNCT O 
Alleviating VERB - B-WORK_OF_ART 
the DET - I-WORK_OF_ART 
Access PROPN - I-WORK_OF_ART 
Abyss PROPN - I-WORK_OF_ART 
in ADP - I-WORK_OF_ART 
Palliative PROPN - I-WORK_OF_ART 
Care PROPN - I-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Pain PROPN - I-WORK_OF_ART 
Relief PROPN - I-WORK_OF_ART 
- PUNCT - I-WORK_OF_ART 
An DET - I-WORK_OF_ART 
Imperative PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Universal PROPN - I-WORK_OF_ART 
Health PROPN - I-WORK_OF_ART 
Coverage PROPN - I-WORK_OF_ART 
" - PUNCT O 
to - PART O 
close - VERB O 
the - DET O 
access - NOUN O 
abyss - NOUN O 
in - ADP O 
relief - NOUN O 
of - ADP O 
pain - NOUN O 
and - CCONJ O 
other - ADJ O 
types - NOUN O 
of - ADP O 
serious - ADJ O 
health - NOUN O 
- - PUNCT O 
related - VERB O 
suffering - NOUN O 
. - PUNCT O 

Pain ADJ - B-MEDICINE 
Relief PROPN - I-MEDICINE 
by - ADP O 
Parecoxib - PROPN O 
for - ADP O 
Laparoscopic - PROPN O 
Cholecystectomy - PROPN O 
: - PUNCT O 
A - PROPN O 
Meta - PROPN O 
- - PUNCT O 
Analysis - PROPN O 
of - ADP O 
Randomized - PROPN O 
Controlled - PROPN O 
Trials - PROPN O 
. - PUNCT O 

Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
as - ADP O 
an - DET O 
Integral - PROPN O 
Part - PROPN O 
of - ADP O 
the - DET O 
Palliative - PROPN O 
Care - PROPN O 
. - PUNCT O 

Does - VERB O 
Immediate - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
After - ADP O 
an - DET O 
Injection - NOUN O 
into - ADP O 
the - DET O 
Sacroiliac - PROPN O 
Joint - PROPN O 
with - ADP O 
Anesthetic - PROPN O 
and - CCONJ O 
Corticosteroid - PROPN O 
Predict - PROPN O 
Subsequent - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
? - PUNCT O 

Pleasant - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Inhibitory - PROPN O 
Conditioned - VERB O 
Pain - PROPN O 
Modulation - PROPN O 
: - PUNCT O 
A - DET O 
Psychophysical - PROPN O 
Study - PROPN O 
. - PUNCT O 

The - DET O 
Effect - PROPN O 
of - ADP O 
Normal - PROPN O 
Physiologic - PROPN O 
Childbirth - PROPN O 
on - ADP O 
Labor - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
: - PUNCT O 
an - DET O 
Interventional - PROPN O 
Study - PROPN O 
in - ADP O 
Mother - PROPN O 
- - PUNCT O 
Friendly - PROPN O 
Hospitals - PROPN O 
. - PUNCT O 

Plant PROPN - B-ORG 
- PUNCT - I-ORG 
Chemical PROPN - I-ORG 
Shows PROPN - I-ORG 
Promise PROPN - I-ORG 
for ADP - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
. - PUNCT O 

Minimal ADJ - B-PERSON 
Use PROPN - I-PERSON 
of - ADP O 
Opioids PROPN - B-GPE 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
an - DET O 
Internal - PROPN O 
Medicine - PROPN O 
Department - PROPN O 
. - PUNCT O 

Fluoroscopically ADV - B-ORG 
Guided VERB - I-ORG 
Facet PROPN - I-ORG 
Injections PROPN - I-ORG 
: - PUNCT O 
Comparison PROPN - B-ORG 
of ADP - I-ORG 
Intra PROPN - I-ORG 
- PUNCT - I-ORG 
Articular PROPN - I-ORG 
and - CCONJ O 
Periarticular PROPN - B-ORG 
Steroid PROPN - I-ORG 
and CCONJ - I-ORG 
Anesthetic PROPN - I-ORG 
Injection PROPN - I-ORG 
on ADP - I-ORG 
Immediate PROPN - I-ORG 
and CCONJ - I-ORG 
Short PROPN - I-ORG 
- PUNCT - I-ORG 
Term PROPN - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
. - PUNCT O 

Acupuncture - VERB O 
and - CCONJ O 
Sham - PROPN O 
Acupuncture - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Physical - PROPN O 
- - PUNCT O 
Agent - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
Modalities - PROPN O 
for - ADP O 
Fibromyalgia - PROPN O 
Patients - PROPN O 
: - PUNCT O 
A - PROPN O 
Systematic - PROPN O 
Review - PROPN O 
and - CCONJ O 
Meta PROPN - B-ORG 
- PUNCT - I-ORG 
Analysis PROPN - I-ORG 
of ADP - I-ORG 
Randomized PROPN - I-ORG 
Controlled PROPN - I-ORG 
Trials PROPN - I-ORG 
. - PUNCT O 

Oral - PROPN O 
Sucrose - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
During - ADP O 
Clubfoot - PROPN O 
Casting - PROPN O 
: - PUNCT O 
A - DET O 
Double - ADJ O 
- - PUNCT O 
Blinded - PROPN O 
Randomized - PROPN O 
Controlled - PROPN O 
Trial - PROPN O 
. - PUNCT O 

A - DET O 
Randomized - VERB O 
Controlled - PROPN O 
Trial - PROPN O 
on - ADP O 
Efficacy - PROPN O 
and - CCONJ O 
Safety - PROPN O 
of - ADP O 
Trocar - PROPN O 
- - PUNCT O 
Site - NOUN O 
Infiltration - NOUN O 
with - ADP O 
Lidocaine - PROPN O 
for - ADP O 
Postoperative - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
after - ADP O 
Diagnostic PROPN - B-PERSON 
Laparoscopy PROPN - I-PERSON 
. - PUNCT O 

Transcutaneous - ADJ O 
Electrical - PROPN O 
Nerve - NOUN O 
Stimulation - NOUN O 
( - PUNCT O 
TENS - NOUN O 
) - PUNCT O 
in - ADP O 
the DET - B-ORG 
Emergency PROPN - I-ORG 
Department PROPN - I-ORG 
for ADP - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
: PUNCT - I-ORG 
A DET - I-ORG 
Preliminary PROPN - I-ORG 
Study PROPN - I-ORG 
of ADP - I-ORG 
Feasibility PROPN - I-ORG 
and CCONJ - I-ORG 
Efficacy PROPN - I-ORG 
. - PUNCT O 

Impact - NOUN O 
of - ADP O 
Empathy - PROPN O 
in - ADP O 
the - DET O 
Patient - PROPN O 
- - PUNCT O 
Doctor - PROPN O 
Relationship - PROPN O 
on - ADP O 
Chronic - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Quality - PROPN O 
of - ADP O 
Life - PROPN O 
: - PUNCT O 
A - DET O 
Prospective - ADJ O 
Study - PROPN O 
in - ADP O 
Spanish PROPN - B-NORP 
Pain - PROPN O 
Clinics - PROPN O 
. - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Different - PROPN O 
Postherpetic - PROPN O 
Neuralgia - PROPN O 
Therapies - PROPN O 
: - PUNCT O 
A - DET O 
Network - PROPN O 
Meta - PROPN O 
- - PUNCT O 
Analysis - PROPN O 
. - PUNCT O 

Comparison - PROPN O 
the - DET O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
of - ADP O 
Amitriptyline - ADJ O 
Mouthwash - PROPN O 
with - ADP O 
Benzydamine - PROPN O 
in - ADP O 
Oral PROPN - B-FAC 
Mucositis PROPN - I-FAC 
. - PUNCT O 

Identification - NOUN O 
of - ADP O 
the - DET O 
First - PROPN O 
Synthetic - PROPN O 
Allosteric - PROPN O 
Modulator - PROPN O 
of - ADP O 
the - DET O 
CB2 - PROPN O 
Receptors - PROPN O 
and - CCONJ O 
Evidence - PROPN O 
of - ADP O 
Its - ADJ O 
Efficacy - NOUN O 
for - ADP O 
Neuropathic - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Osteopathic - PROPN O 
Manipulative - PROPN O 
Treatment - PROPN O 
Effect - PROPN O 
on - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Quality - PROPN O 
of - ADP O 
Life - PROPN O 
in - ADP O 
Oncology - PROPN O 

The DET - B-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Flat PROPN - I-ORG 
Dual PROPN - I-ORG 
- PUNCT - I-ORG 
Cure NOUN - I-ORG 
Stabilizer NOUN - I-ORG 
Occlusal PROPN - I-ORG 
Splint PROPN - I-ORG 
in ADP - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
of ADP - I-ORG 
Individuals PROPN - I-ORG 
Suffering PROPN - I-ORG 
from - ADP O 
Migraine PROPN - B-GPE 
Headaches NOUN - I-GPE 
. - PUNCT O 

In - ADP O 
Postoperative - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Autologous - ADJ O 
Chondrocyte - PROPN O 
Implantation - PROPN O 
and - CCONJ O 
Tibial - PROPN O 
Tubercle - PROPN O 
Osteotomy - PROPN O 
for - ADP O 
Patellofemoral - PROPN O 
Chondral - PROPN O 
Defects - PROPN O 
: - PUNCT O 
Improved - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Occupational - PROPN O 
Outcomes - PROPN O 
Among - ADP O 
US - PROPN O 
Army - PROPN O 
Servicemembers - PROPN O 
. - PUNCT O 

Comparison NOUN - B-ORG 
of ADP - I-ORG 
Postoperative PROPN - I-ORG 
Quality PROPN - I-ORG 
of ADP - I-ORG 
Recovery PROPN - I-ORG 
and CCONJ - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
with ADP - I-ORG 
Preoperative ADJ - I-ORG 
Single PROPN - I-ORG 
- PUNCT - I-ORG 
Dose PROPN - I-ORG 
Dexamethasone PROPN - I-ORG 
and - CCONJ O 
Lignocaine PROPN - B-GPE 
after - ADP O 
Laparoscopic PROPN - B-ORG 
Cholecystectomy PROPN - I-ORG 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Different - ADJ O 
Volumes - PROPN O 
on - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Patient - PROPN O 
Receiving - VERB O 
Fluoroscopic - PROPN O 
Guided - VERB O 
Interlaminar - PROPN O 
Lumbar - PROPN O 
Epidural - PROPN O 
Steroid - PROPN O 
Injection - PROPN O 
. - PUNCT O 

Serratus - PROPN O 
Anterior - PROPN O 
Plane - PROPN O 
Block - PROPN O 
Versus - PROPN O 
Thoracic - PROPN O 
Epidural - PROPN O 
Analgesia - PROPN O 
for - ADP O 
Post PROPN - B-ORG 
- PROPN - I-ORG 
Thoracotomy PROPN - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
. - PUNCT O 

The - DET O 
Effects - NOUN O 
of - ADP O 
Cold - PROPN O 
Application - PROPN O 
to - ADP O 
the - DET O 
Perineum - PROPN O 
on - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 

Progress - NOUN O 
on - ADP O 
Botulinum - PROPN O 
Toxin - PROPN O 
Type - PROPN O 
A - PROPN O 
- - PUNCT O 
Induced - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
the - DET O 
Field - PROPN O 
of - ADP O 
Plastics - PROPN O 
. - PUNCT O 

The DET - B-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
on ADP - I-ORG 
Daily PROPN - I-ORG 
Physical PROPN - I-ORG 
Activity PROPN - I-ORG 
: - PUNCT O 
In - ADP O 
- - PUNCT O 
Home - NOUN O 
Objective - PROPN O 
Physical - PROPN O 
Activity - PROPN O 
Assessment - PROPN O 
in - ADP O 
Chronic - PROPN O 
Low - PROPN O 
Back - PROPN O 
Pain - NOUN O 
Patients - PROPN O 
after - ADP O 
Paravertebral PROPN - B-ORG 
Spinal PROPN - I-ORG 
Block PROPN - I-ORG 
. - PUNCT O 

Clinical - ADJ O 
and - CCONJ O 
Radiographic - ADJ O 
Results - PROPN O 
of - ADP O 
39 NUM - B-CARDINAL 
Retrospectives - PROPN O 
Cases - PROPN O 
- - PUNCT O 
Is - VERB O 
the - DET O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
Enough - PROPN O 
? - PUNCT O 

Nerve - PROPN O 
Safety - PROPN O 
, - PUNCT O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
, - PUNCT O 
and - CCONJ O 
Patient - PROPN O 
Satisfaction - PROPN O 
. - PUNCT O 

Two NUM - B-CARDINAL 
- - PUNCT O 
Point - PROPN O 
Discrimination - PROPN O 
Predicts - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
after - ADP O 
Lower - PROPN O 
Limb - PROPN O 
Nerve - PROPN O 
Decompression - PROPN O 
for - ADP O 
Painful - ADJ O 
Diabetic - PROPN O 
Peripheral - PROPN O 
Neuropathy - PROPN O 
. - PUNCT O 

Comparison NOUN - B-ORG 
of ADP - I-ORG 
Epidural PROPN - I-ORG 
Bupivacaine PROPN - I-ORG 
and - CCONJ O 
Dexmedetomidine - PROPN O 
with - ADP O 
Bupivacaine PROPN - B-GPE 
and - CCONJ O 
Fentanyl PROPN - B-GPE 
for - ADP O 
Postoperative - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Lower - PROPN O 
Limb - PROPN O 
Orthopedic - PROPN O 
Surgery - PROPN O 
. - PUNCT O 

Neural - PROPN O 
Targeting - PROPN O 
Shows - VERB O 
Superior - ADJ O 
Chronic - PROPN O 
Axial - NOUN O 
Low - ADJ O 
Back - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 

Nerve - PROPN O 
Decompression - PROPN O 
Improves - VERB O 
Spinal - ADJ O 
Synaptic - PROPN O 
Plasticity - PROPN O 
of - ADP O 
Opioid - PROPN O 
Receptors - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Ibuprofen PROPN - B-ORG 
and - CCONJ O 
Morphine PROPN - B-ORG 
Provide PROPN - I-ORG 
Similar PROPN - I-ORG 
Post PROPN - I-ORG 
- PUNCT - I-ORG 
op NOUN - I-ORG 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Kids PROPN - B-PERSON 
; - PUNCT O 
Ibuprofen PROPN - B-PERSON 
Has VERB - I-PERSON 
Fewer ADJ - B-PERSON 
Harms PROPN - I-PERSON 
. - PUNCT O 

Carbon - NOUN O 
acquisition - NOUN O 
and - CCONJ O 
water - NOUN O 
use - NOUN O 
in - ADP O 
a - DET O 
Northern - PROPN O 
Utah - PROPN O 
Juniperus - PROPN O 
osteosperma - ADV O 
( - PUNCT O 
Utah PROPN - B-GPE 
juniper - NOUN O 
) - PUNCT O 
population - NOUN O 
. - PUNCT O 

Initial - ADJ O 
colonization - NOUN O 
occurred - VERB O 
by - ADP O 
AD - NOUN O 
1246 - NUM O 
, - PUNCT O 
but - CCONJ O 
expansion - NOUN O 
was - VERB O 
forestalled - VERB O 
by - ADP O 
catastrophic - ADJ O 
drought - NOUN O 
( - PUNCT O 
1250 NUM - B-DATE 
- SYM - I-DATE 
1288 NUM - I-DATE 
) - PUNCT O 
, - PUNCT O 
which - ADJ O 
we - PRON O 
speculate - VERB O 
produced - VERB O 
extensive - ADJ O 
mortality - NOUN O 
of - ADP O 
Utah PROPN - B-ORG 
Juniper PROPN - I-ORG 
( - PUNCT O 
Juniperus PROPN - B-FAC 
osteosperma - ADV O 
( - PUNCT O 
Torr - ADJ O 
. - PUNCT O 
) - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
Ciprofloxacin PROPN - B-ORG 
and - CCONJ O 
Levofloxacin PROPN - B-MEDICINE 
Disk - PROPN O 
Diffusion - PROPN O 
and - CCONJ O 
Etest PROPN - B-ORG 
Using VERB - I-ORG 
the - DET O 
2019 NUM - B-DATE 
Enterobacteriaceae PROPN - B-FAC 
CLSI PROPN - I-FAC 
Breakpoints NOUN - I-FAC 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
is - VERB O 
used - VERB O 
to - PART O 
treat - VERB O 
and - CCONJ O 
prevent - VERB O 
drug - NOUN O 
- - PUNCT O 
resistant - ADJ O 
tuberculosis - NOUN O 
in - ADP O 
children - NOUN O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
dosing - VERB O 
recommendations - NOUN O 
may - VERB O 
require - VERB O 
reevaluation - NOUN O 
. - PUNCT O 

Therapeutic ADJ - B-ORG 
Effect NOUN - I-ORG 
of ADP - I-ORG 
the DET - I-ORG 
Quinolone PROPN - I-ORG 
Levofloxacin PROPN - I-MEDICINE 
on ADP - I-ORG 
Inflammatory PROPN - I-ORG 
Fibroblast PROPN - I-ORG 
- PUNCT - I-ORG 
like ADJ - I-ORG 
Synoviocytes PROPN - I-ORG 
. - PUNCT O 

Impact - NOUN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
for - ADP O 
the DET - B-ORG 
Prophylaxis PROPN - I-ORG 
of ADP - I-ORG 
Bloodstream PROPN - I-ORG 
Infection PROPN - I-ORG 
on - ADP O 
the - DET O 
Gut - PROPN O 
Microbiome - PROPN O 
in - ADP O 
Patients - PROPN O 
with - ADP O 
Hematologic - PROPN O 
Malignancy - PROPN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
0.5 NUM - B-MONEY 
  SPACE - I-MONEY 
g - NOUN O 
/ - SYM O 
day - NOUN O 
) - PUNCT O 
was - VERB O 
used - VERB O 
for - ADP O 
20 NUM - B-DATE 
days NOUN - I-DATE 
; - PUNCT O 
however - ADV O 
, - PUNCT O 
L. PROPN - B-PERSON 
lactis - NOUN O 
subsp - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
was - VERB O 
administered - VERB O 
from - ADP O 
autologous - ADJ O 
SCT PROPN - B-GPE 
( - PUNCT O 
day NOUN - B-DATE 
0 NUM - I-DATE 
) - PUNCT O 
until - ADP O 
day NOUN - B-DATE 
13 NUM - I-DATE 
, - PUNCT O 
absolute - ADJ O 
neutrophil - NOUN O 
count - NOUN O 
> - X O 
500/mm3 NUM - B-CARDINAL 
, - PUNCT O 
or - CCONJ O 
neutropenic - ADJ O 
fever - NOUN O 
, - PUNCT O 
whichever - ADJ O 
occurred - VERB O 
first - ADV O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
prophylaxis - NOUN O 
was - VERB O 
effective - ADJ O 
in - ADP O 
reducing - VERB O 
CLABSIs - NOUN O 
and - CCONJ O 
neutropenic - ADJ O 
fever - NOUN O 
in - ADP O 
patients - NOUN O 
undergoing - VERB O 
autologous - ADJ O 
SCT PROPN - B-ORG 
. - PUNCT O 

In - ADP O 
Vitro - PROPN O 
Study - PROPN O 
of - ADP O 
the - DET O 
Modulatory - PROPN O 
Effects - PROPN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
and - CCONJ O 
BCG - PROPN O 
on - ADP O 
Secretion - NOUN O 
of - ADP O 
Proinflammatory - PROPN O 
Cytokines - PROPN O 
in - ADP O 
Infiltrative - PROPN O 
Pulmonary - PROPN O 
Tuberculosis - PROPN O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
and - CCONJ O 
amiodarone - NOUN O 
are - VERB O 
both - DET O 
known - VERB O 
to - PART O 
prolong - VERB O 
the - DET O 
QT PROPN - B-ORG 
interval - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
is - VERB O 
used - VERB O 
for - ADP O 
the - DET O 
treatment - NOUN O 
and - CCONJ O 
prevention - NOUN O 
of - ADP O 
multidrug - NOUN O 
- - PUNCT O 
resistant - ADJ O 
tuberculosis - NOUN O 
in - ADP O 
children - NOUN O 
, - PUNCT O 
but - CCONJ O 
current - ADJ O 
adult - NOUN O 
formulations - NOUN O 
are - VERB O 
poorly - ADV O 
palatable - ADJ O 
. - PUNCT O 

Acceptability - NOUN O 
of - ADP O 
a - DET O 
Novel - PROPN O 
Levofloxacin PROPN - B-MEDICINE 
Dispersible - PROPN O 
Tablet - PROPN O 
Formulation - NOUN O 
in - ADP O 
Young - ADJ O 
Children - NOUN O 
Exposed - VERB O 
to - ADP O 
Multidrug - PROPN O 
- - PUNCT O 
Resistant - PROPN O 
Tuberculosis - PROPN O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
versus - ADP O 
placebo - NOUN O 
for - ADP O 
the - DET O 
prevention - NOUN O 
of - ADP O 
tuberculosis - NOUN O 
disease - NOUN O 
in - ADP O 
child - NOUN O 
contacts - NOUN O 
of - ADP O 
multidrug - NOUN O 
- - PUNCT O 
resistant - ADJ O 
tuberculosis - NOUN O 
: - PUNCT O 
study - VERB O 
protocol - NOUN O 
for - ADP O 
a - DET O 
phase - NOUN O 
III NUM - B-ORG 
cluster - NOUN O 
randomised - VERB O 
controlled - VERB O 
trial - NOUN O 
( - PUNCT O 
TB - PROPN O 
- - PUNCT O 
CHAMP - PROPN O 
) - PUNCT O 
. - PUNCT O 

( - PUNCT O 
67%)16 - NUM O 
( - PUNCT O 
10%)35 - NUM O 
( - PUNCT O 
23%)Levofloxacin114 NUM - B-DATE 
( - PUNCT O 
74%)6 NUM - B-CARDINAL 
( - PUNCT O 
4%)35 - NUM O 
( - PUNCT O 
23%)BMD ADJ - B-CARDINAL 
readings - NOUN O 
were - VERB O 
often - ADV O 
complicated - VERB O 
by - ADP O 
noticeably - ADV O 
poor - ADJ O 
growth - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
antituberculosis - NOUN O 
drug - NOUN O 
with - ADP O 
substantial - ADJ O 
interindividual - ADJ O 
pharmacokinetic - ADJ O 
variability - NOUN O 
; - PUNCT O 
therapeutic - ADJ O 
drug - NOUN O 
monitoring - NOUN O 
( - PUNCT O 
TDM PROPN - B-ORG 
) - PUNCT O 
could - VERB O 
therefore - ADV O 
be - VERB O 
helpful - ADJ O 
to - PART O 
improve - VERB O 
treatment - NOUN O 
results - NOUN O 
. - PUNCT O 

Population PROPN - B-ORG 
Pharmacokinetic PROPN - I-ORG 
Model PROPN - I-ORG 
and - CCONJ O 
Limited PROPN - B-ORG 
Sampling PROPN - I-ORG 
Strategies PROPN - I-ORG 
for ADP - I-ORG 
Personalized PROPN - I-ORG 
Dosing PROPN - I-ORG 
of ADP - I-ORG 
Levofloxacin PROPN - I-MEDICINE 
in ADP - I-ORG 
Tuberculosis PROPN - I-ORG 
Patients PROPN - I-ORG 
. - PUNCT O 

Clinical - ADJ O 
and - CCONJ O 
Cardiac - PROPN O 
Safety - PROPN O 
of - ADP O 
Long - ADJ O 
- - PUNCT O 
term - NOUN O 
Levofloxacin PROPN - B-MEDICINE 
in - ADP O 
Children PROPN - B-WORK_OF_ART 
Treated VERB - I-WORK_OF_ART 
for ADP - I-WORK_OF_ART 
Multidrug PROPN - I-WORK_OF_ART 
- - PUNCT O 
resistant - ADJ O 
Tuberculosis NOUN - B-ORG 
. - PUNCT O 

Impact - NOUN O 
of - ADP O 
USCAST - PROPN O 
Proposed - VERB O 
Breakpoint - PROPN O 
Changes - NOUN O 
to - ADP O 
Aminoglycosides - PROPN O 
, - PUNCT O 
Cyclines - PROPN O 
, - PUNCT O 
and - CCONJ O 
Levofloxacin PROPN - B-MEDICINE 
on - ADP O 
Carbapenem PROPN - B-ORG 
- PUNCT - I-ORG 
Resistant PROPN - I-ORG 
Enterobacteriaceae PROPN - I-ORG 
at - ADP O 
a - DET O 
US PROPN - B-GPE 
Tertiary PROPN - B-ORG 
Referral PROPN - I-ORG 
Academic PROPN - I-ORG 
Medical PROPN - I-ORG 
Center PROPN - I-ORG 
. - PUNCT O 

Mesoporous - ADJ O 
Bioactive - NOUN O 
Glasses - PROPN O 
Equipped - VERB O 
with - ADP O 
Stimuli PROPN - B-ORG 
- PUNCT - I-ORG 
Responsive PROPN - I-ORG 
Molecular PROPN - I-ORG 
Gates PROPN - I-ORG 
for - ADP O 
Controlled - PROPN O 
Delivery - PROPN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
against - ADP O 
Bacteria PROPN - B-GPE 
. - PUNCT O 

Population PROPN - B-ORG 
Pharmacokinetics PROPN - I-ORG 
and CCONJ - I-ORG 
Pharmacodynamics PROPN - B-ORG 
Modeling PROPN - I-ORG 
of ADP - I-ORG 
Oral PROPN - I-ORG 
Levofloxacin PROPN - I-MEDICINE 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
LVX PROPN - B-ORG 
) - PUNCT O 
inhaled - VERB O 
solution - NOUN O 
is - VERB O 
already - ADV O 
an - DET O 
effective - ADJ O 
option - NOUN O 
. - PUNCT O 

Acute PROPN - B-PERSON 
Delirium PROPN - I-PERSON 
Associated - VERB O 
With - ADP O 
Levofloxacin PROPN - B-MEDICINE 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
pharmacokinetics - NOUN O 
and - CCONJ O 
pharmacodynamics - NOUN O 
and - CCONJ O 
outcome - NOUN O 
in - ADP O 
MDR - PROPN O 
- - PUNCT O 
TB - PROPN O 
patients - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
based - VERB O 
alternate - ADJ O 
therapy - NOUN O 
is - VERB O 
safer - ADJ O 
to - ADP O 
the - DET O 
patients - NOUN O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
and - CCONJ O 
posaconzole - NOUN O 
emerged - VERB O 
as - ADP O 
the - DET O 
most - ADV O 
likely - ADJ O 
culprit - NOUN O 
drugs - NOUN O 
, - PUNCT O 
neither - DET O 
of - ADP O 
which - ADJ O 
have - VERB O 
a - DET O 
strong - ADJ O 
history - NOUN O 
in - ADP O 
the - DET O 
literature - NOUN O 
of - ADP O 
being - VERB O 
associated - VERB O 
with - ADP O 
photosensitive - ADJ O 
hyperpigmentation - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
was - VERB O 
determined - ADJ O 
to - PART O 
be - VERB O 
the - DET O 
culprit - NOUN O 
drug - NOUN O 
when - ADV O 
the - DET O 
hyperpigmentation - NOUN O 
gradually - ADV O 
resolved - VERB O 
several ADJ - B-DATE 
weeks NOUN - I-DATE 
after - ADP O 
discontinuation - NOUN O 
of - ADP O 
levofloxacin NOUN - B-MEDICINE 
, - PUNCT O 
with - ADP O 
continuation - NOUN O 
of - ADP O 
posaconazole - NOUN O 
and - CCONJ O 
all - DET O 
other - ADJ O 
long - ADJ O 
- - PUNCT O 
term - NOUN O 
medications - NOUN O 
. - PUNCT O 

Increased - PROPN O 
Doses - VERB O 
Lead - VERB O 
to - ADP O 
Higher - PROPN O 
Drug - PROPN O 
Exposures - PROPN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
for - ADP O 
Treatment - PROPN O 
of - ADP O 
Tuberculosis - PROPN O 
. - PUNCT O 

Response - VERB O 
to - ADP O 
" - PUNCT O 
Levofloxacin PROPN - B-MEDICINE 
- - PUNCT O 
containing - VERB O 
versus - ADP O 
Clarithromycin - PROPN O 
- - PUNCT O 
containing - VERB O 
Therapy - PROPN O 
for - ADP O 
Helicobacter - PROPN O 
pylori - NOUN O 
Eradication - NOUN O 
: - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
LV - PROPN O 
) - PUNCT O 
given - VERB O 
once - ADV O 
neutropenia - NOUN O 
develops - VERB O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
Achilles PROPN - B-PERSON 
Tendon PROPN - I-PERSON 
Rupture PROPN - I-PERSON 
. - PUNCT O 

Risk NOUN - B-ORG 
Factors NOUN - I-ORG 
for ADP - I-ORG 
Community PROPN - I-ORG 
- PUNCT - I-ORG 
Onset PROPN - I-ORG 
Pneumonia PROPN - I-ORG 
Caused - VERB O 
by - ADP O 
Levofloxacin PROPN - B-MEDICINE 
- PUNCT - I-ORG 
Nonsusceptible PROPN - I-ORG 
Streptococcus PROPN - I-ORG 
pneumoniae - VERB O 
. - PUNCT O 

Formal PROPN - B-PERSON 
Synthesis PROPN - I-PERSON 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
which - ADJ O 
was - VERB O 
not - ADV O 
among - ADP O 
the - DET O 
suspected - VERB O 
drugs - NOUN O 
, - PUNCT O 
was - VERB O 
administered - VERB O 
with - ADP O 
ethambutol - NOUN O 
in - ADP O 
order - NOUN O 
to - PART O 
avoid - VERB O 
drug - NOUN O 
resistance - NOUN O 
resulting - VERB O 
from - ADP O 
the - DET O 
administration - NOUN O 
of - ADP O 
a - DET O 
single - ADJ O 
drug - NOUN O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
- - PUNCT O 
Loaded - VERB O 
Nanoparticles PROPN - B-ORG 
Decrease PROPN - I-ORG 
Emergence PROPN - I-ORG 
of - ADP O 
Fluoroquinolone - PROPN O 
Resistance - PROPN O 
in - ADP O 
Escherichia PROPN - B-GPE 
coli - NOUN O 
. - PUNCT O 

Compared - VERB O 
with - ADP O 
Levofloxacin PROPN - B-MEDICINE 
in - ADP O 
the - DET O 
Treatment - PROPN O 
of - ADP O 
Complicated - PROPN O 
Urinary - PROPN O 
Tract - PROPN O 
Infection - PROPN O 
and - CCONJ O 
Acute - PROPN O 
Pyelonephritis - PROPN O 
. - PUNCT O 

Bilosomes - NOUN O 
were - VERB O 
developed - VERB O 
in - ADP O 
order - NOUN O 
to - PART O 
investigate - VERB O 
their - ADJ O 
efficacy - NOUN O 
as - ADP O 
nanocarriers - NOUN O 
for - ADP O 
transdermal - ADJ O 
delivery - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
HCl - NOUN O 
( - PUNCT O 
TZN PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
a - DET O 
skeletal - ADJ O 
muscle - NOUN O 
relaxant - NOUN O 
with - ADP O 
low - ADJ O 
oral - ADJ O 
bioavailability - NOUN O 
. - PUNCT O 

Tizanidine VERB - B-MEDICINE 
, - PUNCT O 
a - DET O 
widely - ADV O 
used - VERB O 
muscle - NOUN O 
relaxant - NOUN O 
that - ADJ O 
can - VERB O 
lower - VERB O 
blood - NOUN O 
pressure - NOUN O 
, - PUNCT O 
is - VERB O 
metabolized - VERB O 
by - ADP O 
the - DET O 
cytochrome - ADJ O 
P450 - PROPN O 
1A2 - NUM O 
( - PUNCT O 
CYP1A2 - NOUN O 
) - PUNCT O 
. - PUNCT O 

Analysis - PROPN O 
of - ADP O 
Drug - PROPN O 
- - PUNCT O 
Drug - PROPN O 
Interactions - PROPN O 
in - ADP O 
Swiss PROPN - B-ORG 
Claims PROPN - I-ORG 
Data PROPN - I-ORG 
Using VERB - I-ORG 
Tizanidine PROPN - I-MEDICINE 
and - CCONJ O 
Ciprofloxacin PROPN - B-ORG 
as - ADP O 
a - DET O 
Prototypical - PROPN O 
Contraindicated - PROPN O 
Combination - PROPN O 
. - PUNCT O 

Test - NOUN O 
compounds - NOUN O 
included - VERB O 
Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
TIZ PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
a - DET O 
noradrenergic - ADJ O 
α2 - NOUN O 
agonist - NOUN O 
and - CCONJ O 
imidazoline - ADJ O 
ligand - NOUN O 
selected - VERB O 
for - ADP O 
its - ADJ O 
ability - NOUN O 
to - PART O 
reduce - VERB O 
descending - VERB O 
noradrenergic - ADJ O 
drive - NOUN O 
, - PUNCT O 
and - CCONJ O 
Isradipine PROPN - B-ORG 
, - PUNCT O 
a - DET O 
dihyropyridine - ADJ O 
calcium - NOUN O 
- - PUNCT O 
channel - NOUN O 
antagonist - NOUN O 
selected - VERB O 
for - ADP O 
its - ADJ O 
ability - NOUN O 
to - PART O 
post - VERB O 
- - ADJ O 
synaptically - ADV O 
mitigate - VERB O 
a - DET O 
portion - NOUN O 
of - ADP O 
the - DET O 
excitatory - ADJ O 
effects - NOUN O 
of - ADP O 
monoamines - NOUN O 
on - ADP O 
motoneurons - NOUN O 
. - PUNCT O 

We - PRON O 
found - VERB O 
that - ADP O 
Tizanidine PROPN - B-MEDICINE 
significantly - ADV O 
reduced - VERB O 
expression - NOUN O 
of - ADP O 
the - DET O 
flexion - NOUN O 
synergy - NOUN O 
. - PUNCT O 

A - DET O 
predominantly - ADV O 
spinal - ADJ O 
action - NOUN O 
for - ADP O 
this - DET O 
effect - NOUN O 
is - VERB O 
unlikely - ADJ O 
because - ADP O 
Tizanidine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
agonist - NOUN O 
acting - VERB O 
on - ADP O 
a - DET O 
baseline - NOUN O 
of - ADP O 
spinal - ADJ O 
noradrenergic - ADJ O 
drive - NOUN O 
that - ADJ O 
is - VERB O 
likely - ADJ O 
to - PART O 
be - VERB O 
pathologically - ADV O 
enhanced - VERB O 
post - ADJ O 
- - ADJ O 
stroke - NOUN O 
due - ADJ O 
to - ADP O 
increased - VERB O 
reliance - NOUN O 
on - ADP O 
cortico - NOUN O 
- - PUNCT O 
reticulospinal - NOUN O 
motor - NOUN O 
pathways - NOUN O 
. - PUNCT O 

Although - ADP O 
spinal - ADJ O 
actions - NOUN O 
of - ADP O 
TIZ PROPN - B-ORG 
can - VERB O 
not - ADV O 
be - VERB O 
excluded - VERB O 
, - PUNCT O 
particularly - ADV O 
from - ADP O 
Group PROPN - B-ORG 
II PROPN - I-ORG 
pathways - NOUN O 
, - PUNCT O 
our - ADJ O 
finding - NOUN O 
is - VERB O 
consistent - ADJ O 
with - ADP O 
a - DET O 
supraspinal - ADJ O 
action - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
to - PART O 
reduce - VERB O 
descending - VERB O 
noradrenergic - ADJ O 
drive - NOUN O 
and - CCONJ O 
disfacilitate - VERB O 
motoneurons - NOUN O 
. - PUNCT O 

Development - PROPN O 
and - CCONJ O 
Validation - PROPN O 
of - ADP O 
a - DET O 
Versatile - PROPN O 
UPLC - PROPN O 
- - PUNCT O 
PDA - PROPN O 
Method - PROPN O 
for - ADP O 
Simultaneous - PROPN O 
Determination - PROPN O 
of - ADP O 
Paracetamol - PROPN O 
, - PUNCT O 
Tizanidine PROPN - B-MEDICINE 
, - PUNCT O 
Aceclofenac PROPN - B-GPE 
, - PUNCT O 
and - CCONJ O 
Nimesulide NOUN - B-ORG 
in - ADP O 
Their - ADJ O 
New - PROPN O 
Combinations - PROPN O 
. - PUNCT O 

Importance - NOUN O 
of - ADP O 
Medication - PROPN O 
Reconciliation - PROPN O 
: - PUNCT O 
Tizanidine NOUN - B-MEDICINE 
- - PUNCT O 
Induced - PROPN O 
Hepatitis - PROPN O 
. - PUNCT O 

Synthesized - ADJ O 
TAX - PROPN O 
was - VERB O 
utilized - VERB O 
to - PART O 
prepare - VERB O 
Tizanidine ADJ - B-MEDICINE 
HCl - NOUN O 
( - PUNCT O 
TZN - PROPN O 
HCl - NOUN O 
) - PUNCT O 
loaded - VERB O 
sustained - ADJ O 
release - NOUN O 
( - PUNCT O 
SR - NOUN O 
) - PUNCT O 
mucoadhesive - ADJ O 
buccal - ADJ O 
films - NOUN O 
using - VERB O 
a - DET O 
solvent - NOUN O 
casting - NOUN O 
technique - NOUN O 
. - PUNCT O 

Corrigendum - VERB O 
to - ADP O 
" - PUNCT O 
Spinal PROPN - B-WORK_OF_ART 
Antinociceptive PROPN - I-WORK_OF_ART 
Action PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Amiloride PROPN - I-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Its ADJ - I-WORK_OF_ART 
Interaction NOUN - I-WORK_OF_ART 
with ADP - I-WORK_OF_ART 
Tizanidine PROPN - I-MEDICINE 
in ADP - I-WORK_OF_ART 
the DET - I-WORK_OF_ART 
Rat PROPN - I-WORK_OF_ART 
Formalin PROPN - I-WORK_OF_ART 
Test PROPN - I-WORK_OF_ART 
" - PUNCT O 
. - PUNCT O 

Poster - NOUN O 
257 NUM - B-CARDINAL 
Tizanidine PROPN - B-MEDICINE 
Reduces - PROPN O 
Night - PROPN O 
Sweats - PROPN O 
due - ADP O 
to - ADP O 
Dysautonomia PROPN - B-GPE 
in - ADP O 
Syringomyelia PROPN - B-GPE 
: - PUNCT O 
A - DET O 
Case - PROPN O 
Report - PROPN O 
. - PUNCT O 

A - DET O 
UHPLC NOUN - B-ORG 
- - PUNCT O 
UV - NOUN O 
Method - PROPN O 
to - ADP O 
Quantify PROPN - B-ORG 
Skin PROPN - I-ORG 
Deposition PROPN - I-ORG 
and CCONJ - I-ORG 
Transdermal PROPN - I-ORG 
Permeation PROPN - I-ORG 
of ADP - I-ORG 
Tizanidine PROPN - I-MEDICINE 
Hydrochloride PROPN - I-ORG 
. - PUNCT O 

Magnetic - ADJ O 
molecularly - ADJ O 
imprinted - VERB O 
polymer - NOUN O 
nanoparticles - NOUN O 
for - ADP O 
selective - ADJ O 
solid - ADJ O 
phase - NOUN O 
extraction - NOUN O 
and - CCONJ O 
pre - ADJ O 
- - ADJ O 
concentration - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
in - ADP O 
human - ADJ O 
urine - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
hydrochloride - NOUN O 
, - PUNCT O 
α2-receptor - NOUN O 
stimulant - NOUN O 
, - PUNCT O 
is - VERB O 
a - DET O 
central - ADJ O 
muscle - NOUN O 
relaxant - NOUN O 
. - PUNCT O 

Comparison - PROPN O 
of - ADP O 
Efficacy - PROPN O 
and - CCONJ O 
Side - PROPN O 
Effects - PROPN O 
of - ADP O 
Oral - PROPN O 
Baclofen - PROPN O 
Versus - PROPN O 
Tizanidine PROPN - B-MEDICINE 
Therapy - NOUN O 
with - ADP O 
Adjuvant - PROPN O 
Botulinum - PROPN O 
Toxin - PROPN O 
Type - PROPN O 
A - PROPN O 
in - ADP O 
Children PROPN - B-ORG 
With ADP - I-ORG 
Cerebral PROPN - I-ORG 
Palsy PROPN - I-ORG 
and - CCONJ O 
Spastic - PROPN O 
Equinus - PROPN O 
Foot - PROPN O 
Deformity - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
, - PUNCT O 
fentanyl - X O 
, - PUNCT O 
alfentanil - VERB O 
, - PUNCT O 
gabapentin - NOUN O 
and - CCONJ O 
baclofen - NOUN O 
produced - VERB O 
no - DET O 
flare - NOUN O 
. - PUNCT O 

A - DET O 
severe - ADJ O 
interaction - NOUN O 
between - ADP O 
Tizanidine PROPN - B-MEDICINE 
and - CCONJ O 
Ciprofloxacin PROPN - B-ORG 
. - PUNCT O 

The - DET O 
objective - NOUN O 
of - ADP O 
this - DET O 
study - NOUN O 
was - VERB O 
to - PART O 
investigate - VERB O 
whether - ADP O 
an - DET O 
anti - ADJ O 
- - ADJ O 
spasticity - ADJ O 
medication - NOUN O 
can - VERB O 
facilitate - VERB O 
the - DET O 
effects - NOUN O 
of - ADP O 
robotic - ADJ O 
locomotor - NOUN O 
treadmill - NOUN O 
training - NOUN O 
( - PUNCT O 
LTT PROPN - B-ORG 
) - PUNCT O 
to - PART O 
improve - VERB O 
gait - ADJ O 
function - NOUN O 
in - ADP O 
people - NOUN O 
with - ADP O 
incomplete - ADJ O 
spinal - ADJ O 
cord - NOUN O 
injury - NOUN O 
( - PUNCT O 
SCI).Individuals - NOUN O 
with - ADP O 
chronic - ADJ O 
incomplete - ADJ O 
SCI PROPN - B-ORG 
were - VERB O 
recruited - VERB O 
and - CCONJ O 
carried - VERB O 
out - PART O 
a - DET O 
4 NUM - B-CARDINAL 
  - SPACE O 
week - NOUN O 
intervention - NOUN O 
of - ADP O 
either - DET O 
locomotor - NOUN O 
treadmill - NOUN O 
training - NOUN O 
( - PUNCT O 
LTT NOUN - B-ORG 
) - PUNCT O 
alone - ADV O 
( - PUNCT O 
n - CCONJ O 
  - SPACE O 
= - SYM O 
  - SPACE O 
26 NUM - B-CARDINAL 
) - PUNCT O 
or - CCONJ O 
LTT PROPN - B-ORG 
combined - VERB O 
with - ADP O 
Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
TizLTT NOUN - B-ORG 
) - PUNCT O 
, - PUNCT O 
an - DET O 
anti - ADJ O 
- - ADJ O 
spasticity - ADJ O 
medication - NOUN O 
( - PUNCT O 
n - NOUN O 
  - SPACE O 
= - PUNCT O 
  - SPACE O 
22 NUM - B-CARDINAL 
) - PUNCT O 
. - PUNCT O 

0.40 NUM - B-CARDINAL 
; - PUNCT O 
P - NOUN O 
  - SPACE O 
< - X O 
  - SPACE O 
0.05).Tizanidine - NUM O 
appears - VERB O 
to - PART O 
facilitate - VERB O 
the - DET O 
effects - NOUN O 
of - ADP O 
LTT PROPN - B-ORG 
on - ADP O 
gait - ADJ O 
function - NOUN O 
in - ADP O 
individuals - NOUN O 
with - ADP O 
chronic - ADJ O 
SCI PROPN - B-ORG 
that - ADJ O 
are - VERB O 
higher - ADJ O 
functioning - VERB O 
at - ADP O 
baseline - NOUN O 
. - PUNCT O 

We - PRON O 
speculate - VERB O 
that - ADP O 
this - DET O 
may - VERB O 
be - VERB O 
due - ADP O 
to - ADP O 
restoration - NOUN O 
of - ADP O 
inhibitory - ADJ O 
mechanisms - NOUN O 
by - ADP O 
Tizanidine PROPN - B-MEDICINE 
, - PUNCT O 
resulting - VERB O 
in - ADP O 
greater - ADJ O 
stretch - NOUN O 
in - ADP O 
the - DET O 
planterflexor - ADJ O 
muscles - NOUN O 
during - ADP O 
the - DET O 
LTT PROPN - B-ORG 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
should - VERB O 
be - VERB O 
used - VERB O 
cautiously - ADV O 
in - ADP O 
elderly - ADJ O 
population - NOUN O 
and - CCONJ O 
drug - NOUN O 
interactions - NOUN O 
screening - VERB O 
should - VERB O 
be - VERB O 
performed - VERB O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
EC50 - PROPN O 
  - SPACE O 
= - SYM O 
  - SPACE O 

Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
2 NUM - B-CARDINAL 
mg - NOUN O 
) - PUNCT O 
was - VERB O 
administered - VERB O 
( - PUNCT O 
4\day NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
for - ADP O 
4 NUM - B-DATE 
weeks NOUN - I-DATE 
. - PUNCT O 

The - DET O 
spectroscopic - ADJ O 
techniques - NOUN O 
and - CCONJ O 
semi - ADJ O 
- - ADJ O 
empirical - ADJ O 
molecular - ADJ O 
calculations - NOUN O 
have - VERB O 
been - VERB O 
utilized - VERB O 
to - PART O 
analyze - VERB O 
the - DET O 
drug - NOUN O 
Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
5CDIBTA - PROPN O 
) - PUNCT O 
. - PUNCT O 

Normal - ADJ O 
co - NOUN O 
- - ADJ O 
ordinate - ADJ O 
analysis - NOUN O 
, - PUNCT O 
molecular - ADJ O 
structural - ADJ O 
, - PUNCT O 
non - ADJ O 
- - ADJ O 
linear - ADJ O 
optical - ADJ O 
, - PUNCT O 
second ADJ - B-ORDINAL 
order - NOUN O 
perturbation - NOUN O 
studies - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
by - ADP O 
density - NOUN O 
functional - ADJ O 
theory - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
was - VERB O 
conducted - VERB O 
to - PART O 
assess - VERB O 
the - DET O 
effects - NOUN O 
of - ADP O 
various - ADJ O 
excipients - NOUN O 
in - ADP O 
10 NUM - B-CARDINAL 
different - ADJ O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
tablet - NOUN O 
dosage - NOUN O 
forms - NOUN O 
that - ADJ O 
were - VERB O 
prepared - VERB O 
by - ADP O 
direct - ADJ O 
compression - NOUN O 
method - NOUN O 
( - PUNCT O 
DC - PROPN O 
) - PUNCT O 
. - PUNCT O 

It - PRON O 
was - VERB O 
observed - VERB O 
that - ADP O 
Formulations PROPN - B-ORG 
B PROPN - I-ORG 
, - PUNCT O 
D - PROPN O 
and - CCONJ O 
H - PROPN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
gave - VERB O 
best - ADJ O 
results - NOUN O 
within - ADP O 
USP PROPN - B-ORG 
specified - VERB O 
limits - NOUN O 
for - ADP O 
the - DET O 
tests - NOUN O 
employed - VERB O 
among - ADP O 
all - ADJ O 
the - DET O 
formulations - NOUN O 
whereas - ADP O 
Formulations PROPN - B-ORG 
F PROPN - I-ORG 
and - CCONJ O 
G - PROPN O 
showed - VERB O 
poor - ADJ O 
friability - NOUN O 
, - PUNCT O 
disintegration - NOUN O 
and - CCONJ O 
dissolution - NOUN O 
profiles - NOUN O 
rendering - VERB O 
starch - NOUN O 
in - ADP O 
combination - NOUN O 
of - ADP O 
talc - NOUN O 
and - CCONJ O 
sodium - VERB O 
carboxy - NOUN O 
- - PUNCT O 
methyl - NOUN O 
cellulose - NOUN O 
unsuitable - ADJ O 
for - ADP O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
tablet - NOUN O 
formulations - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
plasma - NOUN O 
concentrations - NOUN O 
were - VERB O 
determined - VERB O 
by - ADP O 
liquid - ADJ O 
chromatography - NOUN O 
/ - SYM O 
mass - NOUN O 
spectrometry - NOUN O 
. - PUNCT O 

Among - ADP O 
others - NOUN O 
, - PUNCT O 
two NUM - B-CARDINAL 
substances - NOUN O 
that - ADJ O 
never - ADV O 
had - VERB O 
been - VERB O 
detected - VERB O 
before - ADV O 
in - ADP O 
this - DET O 
river - NOUN O 
, - PUNCT O 
namely - ADV O 
, - PUNCT O 
the - DET O 
muscle - NOUN O 
relaxant - NOUN O 
Tizanidine PROPN - B-MEDICINE 
and - CCONJ O 
the - DET O 
solvent - NOUN O 
1,3-Dimethyl-2-imidazolidinone - NUM O 
( - PUNCT O 
DMI PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
were - VERB O 
identified - VERB O 
and - CCONJ O 
confirmed - VERB O 
, - PUNCT O 
and - CCONJ O 
their - ADJ O 
loads - NOUN O 
were - VERB O 
roughly - ADV O 
estimated - VERB O 
along - ADP O 
the - DET O 
river - NOUN O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
is - VERB O 
α2-receptor - NOUN O 
agonists - NOUN O 
that - ADJ O 
suppresses - VERB O 
central - ADJ O 
sympathetic - ADJ O 
system - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
evaluates - VERB O 
the - DET O 
effects - NOUN O 
of - ADP O 
oral - ADJ O 
Tizanidine PROPN - B-MEDICINE 
on - ADP O 
hemodynamic - ADJ O 
responses - NOUN O 
during - ADP O 
operations - NOUN O 
and - CCONJ O 
aims - VERB O 
to - PART O 
determine - VERB O 
the - DET O 
appropriate - ADJ O 
Propofol ADJ - B-PERSON 
dosage - NOUN O 
to - PART O 
maintain - VERB O 
anesthesia - NOUN O 
under - ADP O 
BIS PROPN - B-ORG 
monitoring - NOUN O 
. - PUNCT O 

35 NUM - B-CARDINAL 
randomly - ADV O 
selected - VERB O 
patients - NOUN O 
( - PUNCT O 
the - DET O 
case - NOUN O 
group - NOUN O 
) - PUNCT O 
were - VERB O 
given - VERB O 
4 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
of - ADP O 
oral - ADJ O 
Tizanidine PROPN - B-MEDICINE 
90 NUM - I-TIME 
minutes NOUN - I-TIME 
before - ADP O 
the - DET O 
induction - NOUN O 
of - ADP O 
anesthesia - NOUN O 
whereas - ADP O 
the - DET O 
remaining - VERB O 
subjects - NOUN O 
( - PUNCT O 
the - DET O 
control - NOUN O 
group - NOUN O 
) - PUNCT O 
were - VERB O 
given - VERB O 
placebo - NOUN O 
. - PUNCT O 

Data - NOUN O 
analysis - NOUN O 
was - VERB O 
done - VERB O 
with - ADP O 
T - NOUN O 
- - PUNCT O 
test - NOUN O 
and - CCONJ O 
Chi PROPN - B-PERSON 
- - PUNCT O 
squared - ADJ O 
test - NOUN O 
, - PUNCT O 
using - VERB O 
SPSS - NOUN O 
software - NOUN O 
version - NOUN O 
16.Variations - NOUN O 
of - ADP O 
blood - NOUN O 
pressure - NOUN O 
and - CCONJ O 
heart - NOUN O 
rate - NOUN O 
after - ADP O 
anesthesia - NOUN O 
induction - NOUN O 
, - PUNCT O 
intubation - NOUN O 
and - CCONJ O 
extubation - NOUN O 
were - VERB O 
less - ADJ O 
in - ADP O 
Tizanidine PROPN - B-MEDICINE 
group - NOUN O 
generally - ADV O 
. - PUNCT O 

Using - VERB O 
oral - ADJ O 
Tizanidine PROPN - B-MEDICINE 
as - ADP O 
a - DET O 
premedication - NOUN O 
, - PUNCT O 
yielded - VERB O 
stability - NOUN O 
in - ADP O 
blood - NOUN O 
pressure - NOUN O 
and - CCONJ O 
heart - NOUN O 
rate - NOUN O 
during - ADP O 
surgery - NOUN O 
and - CCONJ O 
decreased - VERB O 
required - VERB O 
Propofol PROPN - B-PERSON 
. - PUNCT O 

Considering - VERB O 
its - ADJ O 
short - ADJ O 
duration - NOUN O 
of - ADP O 
action - NOUN O 
, - PUNCT O 
Tizanidine PROPN - B-MEDICINE 
use - NOUN O 
as - ADP O 
a - DET O 
premedication - NOUN O 
is - VERB O 
recommended - VERB O 
for - ADP O 
sedation - NOUN O 
and - CCONJ O 
stabilization - NOUN O 
of - ADP O 
hemodynamic - ADJ O 
responses - NOUN O 
during - ADP O 
the - DET O 
operations - NOUN O 
. - PUNCT O 

To - PART O 
assess - VERB O 
the - DET O 
bioequivalence - NOUN O 
of - ADP O 
two NUM - B-CARDINAL 
Tizanidine PROPN - B-MEDICINE 
4 - NUM O 
mg - NOUN O 
tablet - NOUN O 
formulations - NOUN O 
( - PUNCT O 
Tizanidine ADJ - B-MEDICINE 
® - NOUN O 
of - ADP O 
the - DET O 
Pharma PROPN - B-ORG 
International PROPN - I-ORG 
company - NOUN O 
, - PUNCT O 
as - ADP O 
test - NOUN O 
product - NOUN O 
, - PUNCT O 
and - CCONJ O 
Sirdalud PROPN - B-PERSON 
® NOUN - I-PERSON 
of - ADP O 
Novartis PROPN - B-PRODUCT 
as - ADP O 
a - DET O 
reference - NOUN O 
product - NOUN O 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
to - PART O 
investigate - VERB O 
possible - ADJ O 
effects - NOUN O 
of - ADP O 
smoking - NOUN O 
on - ADP O 
pharmacokinetics - NOUN O 
of - ADP O 
tizanidine NOUN - B-MEDICINE 
. - PUNCT O 

ng - NOUN O 
/ - SYM O 
ml - PROPN O 
and - CCONJ O 
1.28 NUM - B-CARDINAL 
± - NUM O 
1.11 NUM - B-CARDINAL 
ng - NOUN O 
/ - SYM O 
ml - PROPN O 
for - ADP O 
Tizanidine PROPN - B-MEDICINE 
PIC - PROPN O 
® - NOUN O 
and - CCONJ O 
Sirdalud PROPN - B-PERSON 
® NOUN - I-PERSON 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

The - DET O 
area - NOUN O 
under - ADP O 
the - DET O 
plasma - NOUN O 
concentration - NOUN O 
- - PUNCT O 
time - NOUN O 
profiles - NOUN O 
AUC0→last - PROPN O 
were - VERB O 
2.53 NUM - B-CARDINAL 
± - NUM O 
2.10 NUM - B-CARDINAL 
ng×h - PROPN O 
/ - SYM O 
ml - NOUN O 
and - CCONJ O 
2.46 NUM - B-CARDINAL 
± - X O 
2.23 NUM - B-CARDINAL 
ng×h/ - PROPN O 
ml - INTJ O 
, - PUNCT O 
whereas - ADP O 
the - DET O 
AUC0→∞were - PROPN O 
2.81 NUM - B-CARDINAL 
± - PUNCT O 
2.27 NUM - B-CARDINAL 
ng×h - NOUN O 
/ - SYM O 
ml - PROPN O 
and - CCONJ O 
2.75 NUM - B-CARDINAL 
± - NUM O 
2.37 NUM - B-CARDINAL 
ng×h - NOUN O 
/ - SYM O 
ml - PROPN O 
for - ADP O 
Tizanidine PROPN - B-MEDICINE 
PIC - PROPN O 
® - NOUN O 
and - CCONJ O 
Sirdalud PROPN - B-PERSON 
® NOUN - I-PERSON 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

Based - VERB O 
on - ADP O 
the - DET O 
pharmacokinetic - ADJ O 
and - CCONJ O 
statistical - ADJ O 
results - NOUN O 
, - PUNCT O 
it - PRON O 
was - VERB O 
concluded - VERB O 
that - ADP O 
; - PUNCT O 
Tizanidine VERB - B-MEDICINE 
PIC - NOUN O 
® - NOUN O 

Tizanidine NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
adverse - ADJ O 
effects - NOUN O 
were - VERB O 
examined - VERB O 
in - ADP O 
100 NUM - B-CARDINAL 
patients - NOUN O 
treated - VERB O 
with - ADP O 
coadministration - NOUN O 
of - ADP O 
tizanidine NOUN - B-MEDICINE 
and - CCONJ O 
8 NUM - B-CARDINAL 
CYP1A2 - NOUN O 
inhibitors - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
crystallizes - NOUN O 
with - ADP O 
two NUM - B-CARDINAL 
almost - ADV O 
identical - ADJ O 
molecules - NOUN O 
in - ADP O 
the - DET O 
asymmetric - ADJ O 
unit - NOUN O 
( - PUNCT O 
r.m.s - VERB O 
. - PUNCT O 
deviation - NOUN O 
= - SYM O 
0.179 NUM - B-CARDINAL 
Å - NOUN O 
for - ADP O 
all - DET O 
non - ADJ O 
- - ADJ O 
H - ADJ O 
atoms - NOUN O 
) - PUNCT O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
does - VERB O 
not - ADV O 
crystallize - VERB O 
as - ADP O 
the - DET O 
usually - ADV O 
drawn - VERB O 
2-amino - NUM O 
- - PUNCT O 
imidazoline - NOUN O 
tautomer - NOUN O 
, - PUNCT O 
but - CCONJ O 
as - ADP O 
the - DET O 
2-imino NUM - B-NORP 
- - PUNCT O 
imidazolidine - NOUN O 
tautomer - NOUN O 
. - PUNCT O 

Tizanidine VERB - B-MEDICINE 
and - CCONJ O 
tizanidine VERB - B-MEDICINE 
hydrochloride - NOUN O 
: - PUNCT O 
on - ADP O 
the - DET O 
correct - ADJ O 
tautomeric - ADJ O 
form - NOUN O 
of - ADP O 
tizanidine NOUN - B-MEDICINE 
. - PUNCT O 

We - PRON O 
investigated - VERB O 
whether - ADP O 
a - DET O 
pharmacological - ADJ O 
intervention - NOUN O 
using - VERB O 
Tizanidine PROPN - B-MEDICINE 
, - PUNCT O 
an - DET O 
anti - ADJ O 
- - ADJ O 
spastic - ADJ O 
medication - NOUN O 
acting - VERB O 
as - ADP O 
an - DET O 
α2-adrenergic - NOUN O 
agonist - NOUN O 
, - PUNCT O 
could - VERB O 
lead - VERB O 
to - ADP O 
improvements - NOUN O 
in - ADP O 
walking - VERB O 
endurance - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
could - VERB O 
be - VERB O 
a - DET O 
safe - ADJ O 
and - CCONJ O 
effective - ADJ O 
treatment - NOUN O 
of - ADP O 
children - NOUN O 
with - ADP O 
dysfunctional - ADJ O 
voiding - NOUN O 
due - ADP O 
to - ADP O 
pelvic - ADJ O 
floor - NOUN O 
/ - SYM O 
skeletal - ADJ O 
sphincter - NOUN O 
dysfunction - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
hydrochloride - NOUN O 
( - PUNCT O 
TIZ PROPN - B-ORG 
) - PUNCT O 
was - VERB O 
used - VERB O 
as - ADP O 
a - DET O 
model - NOUN O 
drug - NOUN O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
Zanaflex PROPN - B-PERSON 
) - PUNCT O 
is - VERB O 
a - DET O 
centrally - ADV O 
acting - VERB O 
imidazoline - ADJ O 
muscle - NOUN O 
relaxant - NOUN O 
that - ADJ O 
is - VERB O 
structurally - ADV O 
similar - ADJ O 
to - ADP O 
clonidine - VERB O 
( - PUNCT O 
α(2)-adrenergic - ADJ O 
agonist - NOUN O 
) - PUNCT O 
but - CCONJ O 
not - ADV O 
to - ADP O 
other - ADJ O 
myorelaxants - NOUN O 
such - ADJ O 
as - ADP O 
baclofen - NOUN O 
or - CCONJ O 
benzodiazepines - NOUN O 
. - PUNCT O 

( - PUNCT O 
3 PUNCT - B-CARDINAL 
) - PUNCT O 
Tizanidine VERB - B-MEDICINE 
0.25 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
/ SYM - I-QUANTITY 
kg NOUN - I-QUANTITY 
ip - NOUN O 
caused - VERB O 
a - DET O 
maximal - ADJ O 
11.93 NUM - B-CARDINAL 
± - PUNCT O 
1.49 NUM - B-QUANTITY 
ms DET - I-QUANTITY 
prolongation - NOUN O 
of - ADP O 
corrected - VERB O 
QT PROPN - B-ORG 
interval - NOUN O 
( - PUNCT O 
QTc - PROPN O 
) - PUNCT O 
, - PUNCT O 
90 NUM - B-TIME 
minutes NOUN - I-TIME 
after - ADP O 
injection - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
prolongs - NOUN O 
the - DET O 
QT PROPN - B-ORG 
interval - NOUN O 
by - ADP O 
blocking - VERB O 
I(Kr - PROPN O 
) - PUNCT O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
( - PUNCT O 
Zanaflex PROPN - B-PERSON 
) - PUNCT O 
: - PUNCT O 
a - DET O 
muscle - NOUN O 
relaxant - NOUN O 
that - ADJ O 
may - VERB O 
prolong - VERB O 
the - DET O 
QT PROPN - B-ORG 
interval - NOUN O 
by - ADP O 
blocking - VERB O 
IKr - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
can - VERB O 
play - VERB O 
a - DET O 
role - NOUN O 
in - ADP O 
alcohol - NOUN O 
withdrawal - NOUN O 
since - ADP O 
it - PRON O 
interferes - VERB O 
with - ADP O 
the - DET O 
noradrenergic - ADJ O 
system - NOUN O 
neurotransmission - NOUN O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
α2-adrenoreceptor - NOUN O 
agonist - NOUN O 
that - ADJ O 
inhibits - VERB O 
noradrenaline - ADJ O 
release - NOUN O 
and - CCONJ O 
binds - VERB O 
to - PART O 
imidazoline - ADJ O 
receptors - NOUN O 
. - PUNCT O 

Although - ADP O 
Tizanidine PROPN - B-MEDICINE 
has - VERB O 
been - VERB O 
tested - VERB O 
as - ADP O 
a - DET O 
treatment - NOUN O 
for - ADP O 
opioid - ADJ O 
withdrawal - NOUN O 
it - PRON O 
has - VERB O 
not - ADV O 
been - VERB O 
tried - VERB O 
in - ADP O 
alcohol - NOUN O 
withdrawal - NOUN O 
yet - ADV O 
. - PUNCT O 

Tizanidine VERB - B-MEDICINE 
for - ADP O 
alcohol - NOUN O 
withdrawal - NOUN O 
treatment - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
HCl - NOUN O 
is - VERB O 
a - DET O 
centrally - ADV O 
acting - VERB O 
α-2 - VERB O 
adrenergic - ADJ O 
agonist - NOUN O 
muscle - NOUN O 
relaxant - NOUN O 
with - ADP O 
a - DET O 
slightly - ADV O 
bitter - ADJ O 
taste - NOUN O 
having - VERB O 
short - ADJ O 
half ADJ - B-CARDINAL 
- - PUNCT O 
life - NOUN O 
of - ADP O 
2.5 NUM - B-CARDINAL 
h. - NOUN O 

Tizanidine NOUN - B-MEDICINE 
may - VERB O 
be - VERB O 
administered - VERB O 
in - ADP O 
the - DET O 
form - NOUN O 
of - ADP O 
an - DET O 
immediate - ADJ O 
release - NOUN O 
multiparticulate - VERB O 
composition - NOUN O 
at - ADP O 
or - CCONJ O 
around - ADP O 
the - DET O 
time - NOUN O 
food - NOUN O 
is - VERB O 
consumed - VERB O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
ligand - NOUN O 
of - ADP O 
TAS2R10 PROPN - B-ORG 
, - PUNCT O 
but - CCONJ O 
its - ADJ O 
relaxant - ADJ O 
profile - NOUN O 
is - VERB O 
unknown - ADJ O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
significantly - ADV O 
relieved - VERB O 
airway - ADJ O 
hyperreactivity - NOUN O 
in - ADP O 
asthma - NOUN O 
model - NOUN O 
mice - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
relaxed - ADJ O 
mouse - NOUN O 
tracheal - NOUN O 
segments - NOUN O 
precontracted - VERB O 
with - ADP O 
carbachol - NOUN O 
, - PUNCT O 
KCl - NOUN O 
, - PUNCT O 
5-hydroxytryptamine NUM - B-ORG 
and - CCONJ O 
U46619 - PROPN O 
, - PUNCT O 
and - CCONJ O 
further - ADV O 
dilated - VERB O 
the - DET O 
tracheal - NOUN O 
rings - NOUN O 
relaxed - VERB O 
by - ADP O 
isoprenaline - NOUN O 
or - CCONJ O 
atropine - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
did - VERB O 
n't - ADV O 
elevate - VERB O 
cAMP - NOUN O 
level - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
had - VERB O 
marked - VERB O 
bronchodilatory - NOUN O 
effect - NOUN O 
. - PUNCT O 

Precursor - PROPN O 
Supply - PROPN O 
for - ADP O 
Erythromycin PROPN - B-MEDICINE 
Biosynthesis - PROPN O 
: - PUNCT O 
Engineering - PROPN O 
of - ADP O 
Propionate - PROPN O 
Assimilation - PROPN O 
Pathway - PROPN O 

Erythromycin NOUN - B-MEDICINE 
and - CCONJ O 
florfenicol - ADJ O 
treatment - NOUN O 
of - ADP O 
rainbow - NOUN O 
trout - NOUN O 

BACKGROUND PROPN - B-ORG 
Erythromycin PROPN - I-MEDICINE 
and - CCONJ O 
its - ADJ O 
derivatives - NOUN O 
have - VERB O 
been - VERB O 
used - VERB O 
to - PART O 
treat - VERB O 
nasal - NOUN O 
polyposis - NOUN O 
and - CCONJ O 
reduce - VERB O 
inflammation - NOUN O 
, - PUNCT O 
but - CCONJ O 
the - DET O 
mechanism - NOUN O 
of - ADP O 
action - NOUN O 
remains - VERB O 
unclear - ADJ O 
. - PUNCT O 

Erythromycin NOUN - B-MEDICINE 
treatment - NOUN O 
significantly - ADV O 
decreased - VERB O 
cell - NOUN O 
proliferation - NOUN O 
and - CCONJ O 
the - DET O 
expression - NOUN O 
of - ADP O 
p NOUN - B-ORG 
- PUNCT - I-ORG 
MEK1 NOUN - I-ORG 
and - CCONJ O 
p - PUNCT O 
- - PUNCT O 
ERK1 - PROPN O 
, - PUNCT O 
and - CCONJ O 
increased - VERB O 
apoptosis - NOUN O 
in - ADP O 
nasal - ADJ O 
polyp - NOUN O 
- - PUNCT O 
derived - VERB O 
cells - NOUN O 
compared - VERB O 
with - ADP O 
control - NOUN O 
cells - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
is - VERB O 
non - ADJ O 
- - ADJ O 
inferior - ADJ O 
to - PART O 
metoclopramide - VERB O 
in - ADP O 
facilitating - VERB O 
post - ADJ O 
- - ADJ O 
pyloric - ADJ O 
placement - NOUN O 
of - ADP O 
spiral - ADJ O 
NETs - NOUN O 
in - ADP O 
critically - ADV O 
ill - ADJ O 
patients - NOUN O 
. - PUNCT O 

Cost - NOUN O 
- - PUNCT O 
effectiveness - NOUN O 
Analysis - PROPN O 
and - CCONJ O 
Safety - PROPN O 
of - ADP O 
Erythromycin PROPN - B-MEDICINE 
4%Gel - NUM O 
and - CCONJ O 
4 NUM - B-PERCENT 
% NOUN - I-PERCENT 
Chlorhexidine - PROPN O 
Scrub - PROPN O 
for - ADP O 
Pitted PROPN - B-ORG 
Keratolysis PROPN - I-ORG 
Treatment PROPN - I-ORG 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
has - VERB O 
been - VERB O 
recorded - VERB O 
in - ADP O 
coastal - ADJ O 
waters - NOUN O 
and - CCONJ O 
could - VERB O 
pose - VERB O 
a - DET O 
severe - ADJ O 
threat - NOUN O 
to - ADP O 
marine - ADJ O 
microbial - ADJ O 
life - NOUN O 
. - PUNCT O 

Benzyl NOUN - B-PERSON 
penicillin - NOUN O 
, - PUNCT O 
Ampicillin PROPN - B-PERSON 
, - PUNCT O 
Cefotaxime - PROPN O 
, - PUNCT O 
Ceftriaxone - PROPN O 
, - PUNCT O 
Levofloxacin PROPN - B-ORG 
, - PUNCT O 
Erythromycin PROPN - B-MEDICINE 
, - PUNCT O 
Clindamycin PROPN - B-ORG 
, PUNCT - I-ORG 
Linezolid PROPN - I-ORG 
, - PUNCT O 
Vancomycin PROPN - B-ORG 
, - PUNCT O 
Tetracycline PROPN - B-PERSON 
and - CCONJ O 
Cotrimoxazole PROPN - B-GPE 
, - PUNCT O 
Olea PROPN - B-GPE 
europaea - NOUN O 
leaf - NOUN O 
extracts - NOUN O 
and - CCONJ O 
essential - ADJ O 
oil - NOUN O 
were - VERB O 
tested - VERB O 
against - ADP O 
GBS - PROPN O 
isolates - NOUN O 
from - ADP O 
South PROPN - B-GPE 
Africa PROPN - I-GPE 
and - CCONJ O 
Namibia PROPN - B-GPE 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
the - DET O 
antibacterial - ADJ O 
activities - NOUN O 
of - ADP O 
nine NUM - B-CARDINAL 
compounds - NOUN O 
from - ADP O 
Buddleja PROPN - B-GPE 
  SPACE - I-GPE 
albiflora - NOUN O 
were - VERB O 
evaluated - VERB O 
against - ADP O 
Listeria PROPN - B-GPE 
monocytogenes - NOUN O 
, - PUNCT O 
Staphyloccocus PROPN - B-PERSON 
aureus - NOUN O 
, - PUNCT O 
Escherichia PROPN - B-PERSON 
coli - NOUN O 
and - CCONJ O 
Pseudomonas PROPN - B-ORG 
aeruginosa - NOUN O 
, - PUNCT O 
either - CCONJ O 
alone - ADV O 
or - CCONJ O 
in - ADP O 
combination - NOUN O 
with - ADP O 
Erythromycin PROPN - B-MEDICINE 
( - PUNCT O 
Ery - PROPN O 
) - PUNCT O 
, - PUNCT O 
Gentamicin PROPN - B-ORG 
( PUNCT - I-ORG 
Gen PROPN - I-ORG 
) - PUNCT O 
and - CCONJ O 
Ampicillin PROPN - B-PERSON 
( - PUNCT O 
Amp - PROPN O 
) - PUNCT O 
. - PUNCT O 

Infiltration - NOUN O 
Into - ADP O 
Erythromycin PROPN - B-MEDICINE 
- - PUNCT O 
Resistant - PROPN O 
Campylobacter - PROPN O 
coli - NOUN O 
and - CCONJ O 
Campylobacter PROPN - B-PERSON 
jejuni - ADV O 
from - ADP O 
Commercial PROPN - B-ORG 
Turkey PROPN - I-ORG 
Production PROPN - I-ORG 
in - ADP O 
Eastern PROPN - B-GPE 
North PROPN - I-GPE 
Carolina PROPN - I-GPE 
: - PUNCT O 

Serial - ADJ O 
Gastric - PROPN O 
Ultrasound - PROPN O 
to - ADP O 
Evaluate VERB - B-ORG 
Gastric PROPN - I-ORG 
Emptying PROPN - I-ORG 
After ADP - I-ORG 
Prokinetic - PROPN O 
Therapy - PROPN O 
With - ADP O 
Domperidone - PROPN O 
and - CCONJ O 
Erythromycin PROPN - B-MEDICINE 
in - ADP O 
a - DET O 
Surgical - PROPN O 
Patient - PROPN O 
With - ADP O 
a - DET O 
Full - ADJ O 
Stomach - NOUN O 
: - PUNCT O 
A - DET O 
Case - PROPN O 
Report - PROPN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
resistance - NOUN O 
was - VERB O 
42 NUM - B-PERCENT 
% NOUN - I-PERCENT 
in - ADP O 
735 NUM - B-CARDINAL 
isolates - NOUN O 
reported - VERB O 
, - PUNCT O 
0.1 NUM - B-PERCENT 
% NOUN - I-PERCENT 
penicillin - NOUN O 
of - ADP O 
1,916 NUM - B-CARDINAL 
isolates - NOUN O 
reported - VERB O 
, - PUNCT O 
and - CCONJ O 
1.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
TMP PROPN - B-ORG 
/ SYM - I-ORG 
SMX PROPN - I-ORG 
of - ADP O 
= - PUNCT O 
135 NUM - B-CARDINAL 
isolates - NOUN O 
reported - VERB O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
( - PUNCT O 
12.5 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
four NUM - B-CARDINAL 
times - NOUN O 
daily - ADV O 
for - ADP O 
3 NUM - B-CARDINAL 
  - SPACE O 
days NOUN - B-DATE 
) - PUNCT O 
exhibits - VERB O 
similar - ADJ O 
bacteriological - ADJ O 
and - CCONJ O 
clinical - ADJ O 
success - NOUN O 
and - CCONJ O 
should - VERB O 
be - VERB O 
listed - VERB O 
as - ADP O 
a - DET O 
second ADJ - B-ORDINAL 
- - PUNCT O 
line - NOUN O 
therapy - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
is - VERB O 
one - NUM O 
of - ADP O 
the - DET O 
most - ADV O 
widely - ADV O 
used - VERB O 
macrolide - NOUN O 
antibiotics - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
resistance - NOUN O 
correlated - VERB O 
very - ADV O 
well - ADV O 
with - ADP O 
the - DET O 
presence - NOUN O 
of - ADP O 
ermD. - PROPN O 

However - ADV O 
, - PUNCT O 
Erythromycin PROPN - B-MEDICINE 
- - PUNCT O 
the - DET O 
very - ADV O 
closely - ADV O 
- - PUNCT O 
related - VERB O 
parent - NOUN O 
compound - NOUN O 
- - PUNCT O 
did - VERB O 
not - ADV O 
show - VERB O 
any - DET O 
senolytic - ADJ O 
activity - NOUN O 
, - PUNCT O 
highlighting - VERB O 
the - DET O 
dramatic - ADJ O 
specificity - NOUN O 
of - ADP O 
these - DET O 
interactions - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
could - VERB O 
elevate - VERB O 
the - DET O 
success - NOUN O 
rate - NOUN O 
of - ADP O 
tube - NOUN O 
insertion - NOUN O 
, - PUNCT O 
but - CCONJ O 
its - ADJ O 
clinical - ADJ O 
efficiency - NOUN O 
still - ADV O 
remains - VERB O 
controversial - ADJ O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
significantly - ADV O 
increases - VERB O 
the - DET O 
success - NOUN O 
rate - NOUN O 
of - ADP O 
postpyloric - ADJ O 
feeding - NOUN O 
tube - NOUN O 
placement - NOUN O 
. - PUNCT O 

Methylase - PROPN O 
Genes - PROPN O 
Confers - PROPN O 
Erythromycin PROPN - B-MEDICINE 
and - CCONJ O 
Clindamycin PROPN - B-ORG 
Resistance PROPN - I-ORG 
in ADP - I-ORG 
Bifidobacterium PROPN - I-ORG 
breve - VERB O 
. - PUNCT O 

OBJECTIVE - NOUN O 
: - PUNCT O 
Erythromycin PROPN - B-MEDICINE 
( - PUNCT O 
ERY PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
used - VERB O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
gastroparesis - NOUN O 
; - PUNCT O 
however - ADV O 
, - PUNCT O 
this - DET O 
medication - NOUN O 
is - VERB O 
associated - VERB O 
with - ADP O 
serious - ADJ O 
side - NOUN O 
effects - NOUN O 
, - PUNCT O 
such - ADJ O 
as - ADP O 
cardiac - ADJ O 
arrhythmias - NOUN O 
and - CCONJ O 
consequent - ADJ O 
cardiorespiratory - ADJ O 
arrest - NOUN O 
. - PUNCT O 

The - DET O 
evaluation - NOUN O 
of - ADP O 
the - DET O 
modulatory - ADJ O 
activity - NOUN O 
of - ADP O 
fluoxetine - NOUN O 
was - VERB O 
performed - VERB O 
by - ADP O 
combining - VERB O 
this - DET O 
drug - NOUN O 
with - ADP O 
the - DET O 
following - ADJ O 
antibiotics - NOUN O 
: - PUNCT O 
Erythromycin PROPN - B-MEDICINE 
, - PUNCT O 
Gentamicin PROPN - B-ORG 
, - PUNCT O 
Imipenem PROPN - B-ORG 
, - PUNCT O 
Norfloxacin PROPN - B-ORG 
and - CCONJ O 
Tetracycline PROPN - B-PERSON 
at - ADP O 
subinhibitory - ADJ O 
concentrations - NOUN O 
( - PUNCT O 
MIC/8 PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

Erythromycin NOUN - B-MEDICINE 
esterase - NOUN O 
, - PUNCT O 
encoded - VERB O 
by - ADP O 
S. PROPN - B-ORG 
  SPACE - I-ORG 
erythraea - NOUN O 
SACE_1765 PROPN - B-ORG 
, - PUNCT O 
inactivates - VERB O 
erythromycin NOUN - B-MEDICINE 
by - ADP O 
hydrolyzing - VERB O 
the - DET O 
macrolactone - NOUN O 
ring - NOUN O 
. - PUNCT O 

Erythromycin NOUN - B-MEDICINE 
, - PUNCT O 
clindamycin - NOUN O 
, - PUNCT O 
tetracycline - ADJ O 
, - PUNCT O 
trimethoprim - NOUN O 
- - PUNCT O 
sulfamethoxazole - NOUN O 
, - PUNCT O 
and - CCONJ O 
levofloxacin - ADJ O 
resistant - ADJ O 
rates - NOUN O 
were - VERB O 
30.4 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
15.6 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
16.3 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
16.3 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
and - CCONJ O 
1.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
effective - ADJ O 
and - CCONJ O 
safe - ADJ O 
sclerosing - VERB O 
agent - NOUN O 
for - ADP O 
pleurodesis - NOUN O 
in - ADP O 
management - NOUN O 
of - ADP O 
RSP PROPN - B-ORG 
. - PUNCT O 

Mechanism - PROPN O 
of - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Hydration - PROPN O 
Based - VERB O 
on - ADP O 
the DET - B-ORG 
Multi PROPN - I-ORG 
- PUNCT - I-ORG 
Rate PROPN - I-ORG 
Model PROPN - I-ORG 
. - PUNCT O 

Doxorubicin - PROPN O 
Loaded - VERB O 
Magnesium NOUN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoflakes - VERB O 
as - ADP O 
pH - PROPN O 
Dependent - PROPN O 
Carriers - PROPN O 
for - ADP O 
Simultaneous - PROPN O 
Treatment - PROPN O 
of - ADP O 
Cancer - PROPN O 
and - CCONJ O 
Hypomagnesemia PROPN - B-GPE 
. - PUNCT O 

Physically - ADV O 
Transient - ADJ O 
Threshold - PROPN O 
Switching - NOUN O 
Device - NOUN O 
Based - VERB O 
on - ADP O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
for ADP - I-ORG 
Security PROPN - I-ORG 
Application PROPN - I-ORG 
. - PUNCT O 

Antimicrobial PROPN - B-ORG 
Activities PROPN - I-ORG 
and - CCONJ O 
Mechanisms - PROPN O 
of - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoparticles - PROPN O 
( - PUNCT O 
nMgO - ADV O 
) - PUNCT O 
against - ADP O 
Pathogenic PROPN - B-PERSON 
Bacteria PROPN - I-PERSON 
, - PUNCT O 
Yeasts PROPN - B-NORP 
, - PUNCT O 
and - CCONJ O 
Biofilms PROPN - B-PERSON 
. - PUNCT O 

Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoparticles - PROPN O 
: - PUNCT O 

Porous - PROPN O 
Aluminum - PROPN O 
Oxide - PROPN O 
and - CCONJ O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Films - PROPN O 

Effect - NOUN O 
of - ADP O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
Supplementation PROPN - I-ORG 
on - ADP O 
Nocturnal - PROPN O 
Leg PROPN - B-PERSON 
Cramps PROPN - I-PERSON 
: - PUNCT O 

[ - PUNCT O 
Influence - NOUN O 
of - ADP O 
Storage - PROPN O 
Conditions - PROPN O 
after - ADP O 
One NUM - B-CARDINAL 
- - PUNCT O 
dose - NOUN O 
Packaging - NOUN O 
on - ADP O 
Stability - PROPN O 
of - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Tablets]. - PROPN O 

Pharmacokinetic - PROPN O 
Studies - PROPN O 
of - ADP O 
Orally - ADV O 
Administered - PROPN O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
in - ADP O 
Rats - PROPN O 
. - PUNCT O 

Catalytic - ADJ O 
Partial - ADJ O 
Oxidation - PROPN O 
of - ADP O 
Cyclohexane - PROPN O 
by - ADP O 
Bimetallic PROPN - B-ORG 
Ag PROPN - I-ORG 
/ SYM - I-ORG 
Pd PROPN - I-ORG 
Nanoparticles PROPN - I-ORG 
on - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
. - PUNCT O 

Determination - NOUN O 
of - ADP O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
Content PROPN - I-ORG 
in - ADP O 
Mineral - PROPN O 
Medicine - PROPN O 
Talcum - PROPN O 
Using - VERB O 
Near - PROPN O 
- - PUNCT O 
Infrared - PROPN O 
Spectroscopy - PROPN O 
Integrated - VERB O 
with - ADP O 
Support - PROPN O 
Vector - PROPN O 
Machine - PROPN O 
. - PUNCT O 

Magnesium NOUN - B-ORG 
Oxide NOUN - I-ORG 
Embedded VERB - I-ORG 
Nitrogen PROPN - I-ORG 
Self PROPN - I-ORG 
- PUNCT - I-ORG 
Doped PROPN - I-ORG 
Biochar PROPN - I-ORG 
Composites PROPN - I-ORG 
: - PUNCT O 

Magnesium NOUN - B-ORG 
Oxide PROPN - I-ORG 
( - PUNCT O 
MgO PROPN - B-ORG 
) - PUNCT O 
pH - NOUN O 
- - PUNCT O 
sensitive - ADJ O 
Sensing PROPN - B-PERSON 
Membrane PROPN - I-PERSON 
in - ADP O 
Electrolyte PROPN - B-ORG 
- PUNCT - I-ORG 
Insulator PROPN - I-ORG 
- PUNCT - I-ORG 
Semiconductor PROPN - I-ORG 
Structures PROPN - I-ORG 
with - ADP O 
CF4 PROPN - B-ORG 
Plasma PROPN - I-ORG 
Treatment PROPN - I-ORG 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Food - PROPN O 
Thickener - PROPN O 
on - ADP O 
Dissolution - PROPN O 
and - CCONJ O 
Laxative - PROPN O 
Activity - PROPN O 
of - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Tablets - PROPN O 
in - ADP O 
Mice NOUN - B-GPE 
. - PUNCT O 

Mechanochemically ADV - B-PERSON 
Activated PROPN - I-PERSON 
, - PUNCT O 
Calcium PROPN - B-PERSON 
Oxide PROPN - I-PERSON 
- PUNCT - I-PERSON 
Based PROPN - I-PERSON 
, - PUNCT O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
- PUNCT - I-ORG 
Stabilized VERB - I-ORG 
Carbon PROPN - I-ORG 
Dioxide NOUN - I-ORG 
Sorbents PROPN - I-ORG 
. - PUNCT O 

Synthesis - PROPN O 
of - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Hierarchical - PROPN O 
Microspheres - VERB O 
: - PUNCT O 
A - DET O 
Dual - PROPN O 
- - PUNCT O 
Functional - PROPN O 
Material - PROPN O 
for - ADP O 
Water - PROPN O 
Remediation - PROPN O 
. - PUNCT O 

Functional - ADJ O 
Improvement - NOUN O 
in - ADP O 
Rats - PROPN O 
' - PART O 
Pancreatic - ADJ O 
Islets - PROPN O 
Using - VERB O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoparticles - PROPN O 
Through - ADP O 
Antiapoptotic - PROPN O 
and - CCONJ O 
Antioxidant PROPN - B-PERSON 
Pathways PROPN - I-PERSON 
. - PUNCT O 

In - ADP O 
Vitro PROPN - B-ORG 
Toxicological PROPN - I-ORG 
Assessment PROPN - I-ORG 
of ADP - I-ORG 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoparticle - PROPN O 
Exposure - NOUN O 
in - ADP O 
Several - ADJ O 
Mammalian PROPN - B-NORP 
Cell - PROPN O 
Types - PROPN O 
. - PUNCT O 

Magnesium NOUN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Supported - VERB O 
Nanoscale - PROPN O 
Zero - PROPN O 
- - PUNCT O 
Valent - PROPN O 
Iron - PROPN O 
. - PUNCT O 

Improvement - NOUN O 
of - ADP O 
Cycling - PROPN O 
Performance - PROPN O 
of - ADP O 
Lithium - PROPN O 
- - PUNCT O 
Sulfur - PROPN O 
Batteries - NOUN O 
by - ADP O 
Using - VERB O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
as - ADP O 
a - DET O 
Functional - PROPN O 
Additive - PROPN O 
for - ADP O 
Trapping - VERB O 
Lithium - PROPN O 
Polysulfide - PROPN O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Oral - PROPN O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Supplementation - PROPN O 
on - ADP O 
Cisplatin PROPN - B-ORG 
- PUNCT - I-ORG 
Induced PROPN - I-ORG 
Hypomagnesemia PROPN - I-ORG 
in ADP - I-ORG 
Cancer PROPN - I-ORG 
Patients PROPN - I-ORG 
: - PUNCT O 
A - DET O 
Randomized - VERB O 
Controlled - PROPN O 
Trial - PROPN O 
. - PUNCT O 

Nano - PROPN O 
- - PUNCT O 
Structured - VERB O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Coated - PROPN O 
Iron - PROPN O 
Ore - PROPN O 
: - PUNCT O 

Enhancing - VERB O 
the - DET O 
Heat - PROPN O 
Transfer - PROPN O 
Efficiency - PROPN O 
in - ADP O 
Graphene PROPN - B-ORG 
- PUNCT - I-ORG 
Epoxy PROPN - I-ORG 
Nanocomposites PROPN - I-ORG 
Using VERB - I-ORG 
a DET - I-ORG 
Magnesium PROPN - I-ORG 
Oxide PROPN - I-ORG 
- PUNCT - I-ORG 
Graphene PROPN - I-ORG 
Hybrid PROPN - I-ORG 
Structure PROPN - I-ORG 
. - PUNCT O 

Activation - PROPN O 
of - ADP O 
Methane - PROPN O 
and - CCONJ O 
Carbon - PROPN O 
Dioxide - PROPN O 
Mediated - VERB O 
by - ADP O 
Transition PROPN - B-ORG 
- PUNCT - I-ORG 
Metal PROPN - I-ORG 
Doped PROPN - I-ORG 
Magnesium PROPN - I-ORG 
Oxide PROPN - I-ORG 
Clusters PROPN - I-ORG 
[ - PUNCT O 
MMgO](+/0/- - PROPN O 
) - PUNCT O 

A - DET O 
Polycarbonate - PROPN O 
/ - SYM O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanocomposite - PROPN O 
with - ADP O 
High - PROPN O 
Flame - PROPN O 
Retardancy - PROPN O 
. - PUNCT O 

A - DET O 
Method - PROPN O 
for - ADP O 
Efficient - PROPN O 
Loading - PROPN O 
of - ADP O 
Ciprofloxacin PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
in - ADP O 
Cationic - PROPN O 
Solid - PROPN O 
Lipid - PROPN O 
Nanoparticles - PROPN O 
: - PUNCT O 
Formulation - PROPN O 
and - CCONJ O 
Microbiological - PROPN O 
Evaluation - PROPN O 
. - PUNCT O 

The - DET O 
Correlation - PROPN O 
of - ADP O 
Adsorption - PROPN O 
Behavior - PROPN O 
between - ADP O 
Ciprofloxacin PROPN - B-PERSON 
Hydrochloride PROPN - I-PERSON 
and - CCONJ O 
the - DET O 
Active - PROPN O 
Sites - PROPN O 
of - ADP O 
Fe - PROPN O 
- - PUNCT O 
doped - ADJ O 
MCM-41 PROPN - B-PERSON 
. - PUNCT O 

[ - PUNCT O 
Photodegradation - NOUN O 
of - ADP O 
Ciprofloxacin PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
in - ADP O 
the - DET O 
Aqueous - PROPN O 
Solution - NOUN O 

